k141_29954_12	SARG|AF155139.2.gene5.p01	31.7	120	182	206	3.38e-10	55.8
k141_19066_23	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	31.0	116	120	228	2.32e-16	70.9
k141_19066_23	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.3	113	120	204	6.98e-13	61.2
k141_19066_23	CARD|gb|AAD51348.1|ARO:3003066|smeR	30.2	116	120	229	2.53e-12	60.1
k141_19066_23	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	30.1	103	120	225	1.25e-11	58.2
k141_19066_23	CARD|gb|AAC73788.1|ARO:3003841|kdpE	30.1	103	120	225	1.25e-11	58.2
k141_86_7	CARD|gb|ATC67679.1|ARO:3000838|arlR	28.1	128	507	219	1.48e-07	51.2
k141_127843_10	SARG|gb|AAC75089.1|ARO:3003577|ugd	57.9	95	113	388	1.39e-29	108
k141_127843_21	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	31.7	436	422	444	5.95e-53	182
k141_73564_3	SARG|gb|WP_188331861.1|ARO:3005345|DfrA43_TMP	33.9	177	164	195	6.45e-18	75.9
k141_73564_3	SARG|gb|AAK64581.1|ARO:3004568|dfrA18	29.9	137	164	184	1.14e-07	48.1
k141_73564_10	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	31.2	218	232	293	1.10e-34	124
k141_73564_10	SARG|gi|445996710|ref|WP_000074565.1|	31.3	230	232	309	1.48e-28	108
k141_73564_10	SARG|gi|445996719|ref|WP_000074574.1|	31.7	230	232	309	2.88e-28	107
k141_73564_10	SARG|gi|895736250|emb|COF64653.1|	31.3	230	232	309	4.02e-28	107
k141_73564_10	SARG|gi|446110087|ref|WP_000187942.1|	31.3	230	232	309	4.02e-28	107
k141_73564_10	SARG|gi|445996714|ref|WP_000074569.1|	31.3	230	232	309	4.02e-28	107
k141_73564_10	SARG|gi|895808656|emb|COR83787.1|	31.3	230	232	309	4.02e-28	107
k141_73564_10	SARG|gi|445996709|ref|WP_000074564.1|	30.9	230	232	309	5.60e-28	107
k141_73564_10	SARG|gi|445996723|ref|WP_000074578.1|	31.7	230	232	309	7.82e-28	106
k141_73564_10	SARG|gi|445996722|ref|WP_000074577.1|	31.3	230	232	309	1.09e-27	106
k141_73564_10	SARG|gi|1043490477|ref|WP_065382463.1|	31.3	230	232	309	1.52e-27	105
k141_73564_10	SARG|gi|445996726|ref|WP_000074581.1|	31.3	230	232	309	1.52e-27	105
k141_73564_10	SARG|gi|507054395|ref|WP_016125339.1|	31.3	230	232	309	1.52e-27	105
k141_73564_10	SARG|gi|445996724|ref|WP_000074579.1|	30.9	230	232	309	2.12e-27	105
k141_73564_10	SARG|gi|445996729|ref|WP_000074584.1|	31.3	230	232	309	2.12e-27	105
k141_73564_10	SARG|gi|884875933|emb|CKG93789.1|	30.9	230	232	309	2.12e-27	105
k141_73564_10	SARG|gi|507055561|ref|WP_016126482.1|	30.3	231	232	309	5.75e-27	104
k141_73564_10	SARG|gi|446026113|ref|WP_000103968.1|	31.8	223	232	306	7.62e-27	103
k141_73564_10	SARG|gi|814314593|emb|CKF49145.1|	30.4	230	232	309	8.02e-27	103
k141_73564_10	SARG|gi|488042066|ref|WP_002113463.1|	31.3	230	232	309	1.56e-26	103
k141_73564_10	SARG|gi|447057510|ref|WP_001134766.1|	31.3	230	232	309	1.56e-26	103
k141_73564_10	SARG|gi|488068784|ref|WP_002140181.1|	31.3	230	232	309	2.17e-26	102
k141_73564_10	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	32.2	227	232	307	2.92e-26	102
k141_73564_10	SARG|gi|445996708|ref|WP_000074563.1|	30.9	230	232	309	3.02e-26	102
k141_73564_10	SARG|gi|488130770|ref|WP_002201978.1|	30.3	231	232	309	3.02e-26	102
k141_73564_18	SARG|gi|696368937|ref|WP_032943949.1|	39.3	239	255	648	2.30e-43	154
k141_73564_18	SARG|gi|851913025|ref|WP_048215946.1|	39.3	239	255	648	2.30e-43	154
k141_73564_18	SARG|gi|489930965|ref|WP_003834285.1|	39.3	239	255	648	2.30e-43	154
k141_73564_18	SARG|gi|851922185|ref|WP_048218206.1|	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|YP_002850060	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|gi|696375069|ref|WP_032949617.1|	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|gi|696361545|ref|WP_032936694.1|	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|gi|489936909|ref|WP_003840216.1|	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|gi|489127020|ref|WP_003036815.1|	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|gi|507079862|ref|WP_016150620.1|	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|gi|949791377|ref|WP_057104572.1|	39.3	239	255	648	3.18e-43	154
k141_73564_18	SARG|gi|936194420|ref|WP_054528571.1|	39.3	239	255	648	4.38e-43	153
k141_73564_18	SARG|gi|491270241|ref|WP_005128370.1|	38.9	239	255	648	1.15e-42	152
k141_73564_18	SARG|gi|949718947|ref|WP_057063453.1|	39.9	233	255	648	1.15e-42	152
k141_73564_18	SARG|gi|851902043|ref|WP_048212057.1|	38.9	239	255	648	1.15e-42	152
k141_73564_18	SARG|gi|992380339|ref|WP_061067665.1|	38.9	239	255	648	1.15e-42	152
k141_73564_18	SARG|gi|740856590|ref|WP_038641842.1|	39.1	238	255	648	3.01e-42	151
k141_73564_18	SARG|gi|754951242|ref|WP_042307417.1|	39.1	238	255	648	4.15e-42	150
k141_73564_18	SARG|gi|493734654|ref|WP_006683876.1|	39.1	238	255	648	4.15e-42	150
k141_73564_18	SARG|gi|757799695|ref|WP_043016897.1|	39.5	233	255	648	7.88e-42	150
k141_73564_18	SARG|gi|1045891604|ref|WP_065554100.1|	39.5	233	255	648	7.88e-42	150
k141_73564_18	SARG|gi|507082903|ref|WP_016153652.1|	39.5	233	255	648	7.88e-42	150
k141_73564_18	SARG|gi|507086196|ref|WP_016156937.1|	39.5	233	255	648	7.88e-42	150
k141_73564_18	SARG|gi|835233765|ref|WP_047410073.1|	39.5	233	255	648	1.09e-41	149
k141_73564_18	SARG|gi|922960663|ref|WP_053388845.1|	39.5	233	255	648	1.09e-41	149
k141_73564_24	CARD|gb|CAA79966.1|ARO:3003665|NmcR	31.7	120	302	295	1.80e-09	56.6
k141_49050_21	SARG|gb|WP_011094382.1|ARO:3006903|CAR-1	35.7	98	221	342	8.72e-12	62.4
k141_49050_21	SARG|EU408347.1.gene9.p01	29.8	114	221	302	1.78e-06	46.6
k141_32707_1	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.1	550	643	655	4.13e-123	378
k141_32707_1	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.9	550	643	655	5.81e-123	378
k141_32707_1	SARG|gb|AKA86814|ARO:3003746|optrA	38.9	550	643	655	5.81e-123	378
k141_32707_1	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	39.1	550	643	655	1.15e-122	377
k141_32707_1	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.9	550	643	655	4.53e-122	375
k141_32707_1	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.9	550	643	655	4.53e-122	375
k141_32707_1	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.9	550	643	655	4.53e-122	375
k141_32707_1	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.9	550	643	655	6.38e-122	375
k141_32707_1	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.9	550	643	655	6.38e-122	375
k141_32707_1	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.9	550	643	655	8.98e-122	375
k141_32707_1	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	8.98e-122	375
k141_32707_1	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	3.53e-121	373
k141_32707_1	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	4.97e-121	373
k141_32707_1	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	4.97e-121	373
k141_32707_1	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	4.97e-121	373
k141_32707_1	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	4.97e-121	373
k141_32707_1	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	4.97e-121	373
k141_32707_1	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	38.7	550	643	655	4.97e-121	373
k141_32707_1	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	40.0	505	643	655	9.84e-121	372
k141_32707_1	SARG|gb|APB03219.1|ARO:3003986|TaeA	31.7	654	643	648	9.73e-91	293
k141_32707_1	SARG|gb|AVI44920.1|ARO:3004470|poxtA	33.3	541	643	542	5.18e-85	275
k141_32707_1	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	33.4	536	643	544	1.07e-84	275
k141_32707_1	SARG|M80346.gene.p01	31.3	552	643	551	1.40e-74	248
k141_32707_1	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	31.3	552	643	551	1.40e-74	248
k141_32707_1	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	31.8	556	643	568	4.15e-73	244
k141_32707_5	SARG|gb|ABA71733.1|ARO:3002972|vanTG	35.4	378	399	712	3.97e-69	230
k141_32707_5	NCBI|WP_063856752.1|1|1|vanT-G|vanT-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-G|AMR|glycopeptide	33.6	378	399	711	2.03e-57	198
k141_32707_5	NCBI|CZR78671.1|1|1|vanT-Cd|vanT-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|membrane-bound_serine_racemase_VanT-Cd|AMR|glycopeptide	32.5	381	399	712	1.80e-53	187
k141_32707_5	SARG|gb|ABX54690.1|ARO:3002974|vanTrL	29.9	371	399	366	1.97e-48	167
k141_32707_5	SARG|JF802084.2.gene3.p01	29.0	362	399	700	2.48e-35	136
k141_32707_5	megares|MEG_7535|Drugs|Glycopeptide|VanN-type_resistance_protein|VANTN_1	30.0	290	399	656	1.65e-27	113
k141_32707_9	SARG|gb|AAC75314.1|ARO:3003578|pmrF	26.6	320	314	322	6.93e-28	109
k141_32707_20	megares|MEG_6058|Drugs|MLS|23S_rRNA_methyltransferases|RLMH_1	55.7	158	160	159	6.90e-57	174
k141_32707_51	SARG|gb|AAC74000.1|ARO:3003950|msbA	31.1	528	612	582	2.19e-70	237
k141_32707_51	SARG|gi|827013130|ref|WP_047175495.1|	32.2	528	612	603	6.70e-69	233
k141_32707_51	SARG|gi|695887424|ref|WP_032788534.1|	30.9	521	612	605	6.99e-69	233
k141_32707_51	SARG|gi|664180077|ref|WP_030714054.1|	31.7	523	612	605	9.72e-69	233
k141_32707_51	SARG|gi|764446018|ref|WP_044369325.1|	31.8	528	612	605	5.06e-68	231
k141_32707_51	SARG|gi|695865802|ref|WP_032778631.1|	31.3	527	612	605	9.78e-68	230
k141_32707_51	SARG|gi|501350226|ref|WP_012381861.1|	31.8	528	612	603	1.31e-67	230
k141_32707_51	SARG|gi|517787730|ref|WP_018957938.1|	31.8	528	612	610	1.50e-67	230
k141_32707_51	SARG|gi|664170108|ref|WP_030704355.1|	31.8	528	612	603	1.82e-67	229
k141_32707_51	SARG|gi|490068471|ref|WP_003970646.1|	31.8	528	612	603	1.82e-67	229
k141_32707_51	SARG|gi|695891735|ref|WP_032792824.1|	31.6	528	612	603	2.52e-67	229
k141_32707_51	SARG|gi|1045390184|ref|WP_065479071.1|	31.2	523	612	605	2.63e-67	229
k141_32707_51	SARG|gi|913055317|ref|WP_050357634.1|	31.6	528	612	603	3.51e-67	229
k141_32707_51	SARG|gi|497748188|ref|WP_010062372.1|	31.3	527	612	605	3.65e-67	229
k141_32707_51	SARG|gi|926376632|ref|WP_053705806.1|	31.2	522	612	620	4.92e-67	229
k141_32707_51	SARG|gi|662129758|ref|WP_030081404.1|	31.0	523	612	605	5.08e-67	228
k141_32707_51	SARG|gi|951183771|ref|WP_057661487.1|	31.6	528	612	603	6.78e-67	228
k141_32707_51	SARG|gi|948040364|ref|WP_056699531.1|	30.8	522	612	603	6.78e-67	228
k141_32707_51	SARG|gi|664085850|ref|WP_030624018.1|	31.0	523	612	605	7.06e-67	228
k141_32707_51	SARG|gi|664556405|ref|WP_031071225.1|	30.5	545	612	602	1.28e-66	227
k141_32707_51	SARG|gi|663330365|ref|WP_030329892.1|	31.6	528	612	607	1.42e-66	227
k141_32707_51	SARG|gi|928900436|ref|WP_053931243.1|	31.1	486	612	600	1.71e-66	227
k141_32707_51	SARG|gi|664579989|ref|WP_031094015.1|	31.1	486	612	601	1.75e-66	227
k141_32707_51	SARG|gi|505420018|ref|WP_015607120.1|	31.7	524	612	603	1.82e-66	227
k141_32707_51	SARG|gi|662175949|ref|WP_030118884.1|	30.8	522	612	605	1.89e-66	227
k141_32707_57	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	24.7	454	499	633	4.69e-21	95.5
k141_32713_8	CARD|gb|BAB36671.1|ARO:3000832|evgA	36.2	69	532	204	5.86e-07	49.3
k141_27368_4	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.9	110	254	228	1.65e-11	61.2
k141_27368_4	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.7	90	254	232	4.48e-09	54.3
k141_27368_4	CARD|gb|ATC67679.1|ARO:3000838|arlR	27.7	112	254	219	1.35e-08	52.8
k141_214_7	SARG|gi|446573707|ref|WP_000651053.1|	26.1	444	454	451	1.60e-44	160
k141_214_7	SARG|gi|446573715|ref|WP_000651061.1|	25.9	444	454	451	5.93e-44	159
k141_214_7	SARG|gi|537465183|ref|WP_020976941.1|	25.5	444	454	451	8.22e-44	158
k141_214_7	SARG|gi|565830932|ref|WP_023914633.1|	25.9	444	454	451	1.58e-43	157
k141_214_7	SARG|Q2G140	25.7	444	454	451	2.19e-43	157
k141_214_7	SARG|gi|487138435|ref|WP_001629863.1|	25.9	444	454	451	2.19e-43	157
k141_214_7	SARG|gi|686396521|ref|WP_031908504.1|	25.7	444	454	451	3.03e-43	157
k141_214_7	SARG|gi|763462741|ref|WP_044292157.1|	25.7	444	454	451	3.03e-43	157
k141_214_7	SARG|gi|686390606|ref|WP_031905637.1|	25.7	444	454	451	3.03e-43	157
k141_214_7	SARG|gi|727749287|ref|WP_033861814.1|	25.7	444	454	451	3.03e-43	157
k141_214_7	SARG|gi|486215009|ref|WP_001556470.1|	25.7	444	454	451	3.03e-43	157
k141_214_7	SARG|gi|686367913|ref|WP_031894914.1|	25.7	444	454	451	4.21e-43	156
k141_214_7	SARG|gi|486285962|ref|WP_001572033.1|	25.7	444	454	451	4.21e-43	156
k141_214_7	SARG|gi|686309068|ref|WP_031870147.1|	25.7	444	454	451	4.21e-43	156
k141_214_7	SARG|Q99WP2	25.7	444	454	451	5.83e-43	156
k141_214_7	SARG|gi|686294396|ref|WP_031862836.1|	25.5	444	454	451	5.83e-43	156
k141_214_7	SARG|gi|686302738|ref|WP_031866896.1|	25.7	444	454	451	5.83e-43	156
k141_214_7	SARG|gi|686320684|ref|WP_031875798.1|	25.7	444	454	451	5.83e-43	156
k141_214_7	SARG|gi|686355454|ref|WP_031890196.1|	25.7	444	454	451	8.07e-43	155
k141_214_7	SARG|gi|516415429|ref|WP_017804827.1|	25.7	444	454	451	8.07e-43	155
k141_214_7	SARG|gi|446573693|ref|WP_000651039.1|	25.5	444	454	451	8.07e-43	155
k141_214_7	SARG|gi|446573692|ref|WP_000651038.1|	25.5	444	454	451	8.07e-43	155
k141_214_7	SARG|gi|686329335|ref|WP_031878923.1|	25.7	444	454	451	8.07e-43	155
k141_214_7	SARG|gi|686408548|ref|WP_031913080.1|	25.2	444	454	451	1.12e-42	155
k141_214_7	SARG|gi|757671144|ref|WP_042903632.1|	25.5	444	454	451	1.12e-42	155
k141_79039_23	SARG|gb|AAC75314.1|ARO:3003578|pmrF	32.3	316	313	322	9.25e-46	156
k141_79039_29	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	33.8	228	584	574	2.82e-33	133
k141_79039_29	SARG|gb|WP_104671188.1|ARO:3003948|efrA	33.5	239	584	575	2.48e-31	127
k141_79039_29	SARG|gb|AAK76136.1|ARO:3000025|patB	34.2	228	584	588	3.85e-30	124
k141_79039_29	SARG|gb|CDO61516.1|ARO:3003949|efrB	34.5	203	584	362	6.24e-30	120
k141_79039_29	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	26.8	388	584	578	1.17e-29	122
k141_79039_29	SARG|gb|AYV52072.1|ARO:3002882|lmrD	32.0	228	584	664	1.00e-27	117
k141_79039_29	SARG|gb|AAK76137.1|ARO:3000024|patA	31.6	234	584	564	3.74e-27	114
k141_79039_29	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.1	211	584	550	1.04e-09	60.1
k141_79039_29	SARG|gb|AGN74946|ARO:3003749|salA	25.2	206	584	541	7.17e-09	57.4
k141_79039_29	SARG|gb|QQA64075.1|ARO:3007043|msr(I)	26.2	195	584	485	6.14e-08	54.3
k141_79039_30	SARG|gb|AAC75314.1|ARO:3003578|pmrF	31.7	126	343	322	3.80e-07	50.1
k141_79039_39	SARG|gb|AAC75314.1|ARO:3003578|pmrF	28.8	309	322	322	1.01e-36	133
k141_79039_54	SARG|gi|445996719|ref|WP_000074574.1|	28.0	214	446	309	1.13e-17	82.4
k141_79039_54	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	27.2	202	446	307	2.71e-17	81.3
k141_79039_54	SARG|P42332	28.0	207	446	306	4.88e-17	80.5
k141_79039_54	SARG|gi|446026113|ref|WP_000103968.1|	27.2	228	446	306	4.88e-17	80.5
k141_79039_54	SARG|gi|507044560|ref|WP_016115614.1|	27.6	228	446	306	4.88e-17	80.5
k141_79039_54	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	28.0	207	446	306	4.88e-17	80.5
k141_79039_54	SARG|gi|445996710|ref|WP_000074565.1|	28.9	211	446	309	5.06e-17	80.5
k141_79039_54	SARG|gi|510143239|gb|AGN36970.1|	28.0	207	446	313	5.30e-17	80.5
k141_79039_54	SARG|ABB80128	28.0	207	446	306	8.90e-17	79.7
k141_79039_54	SARG|gi|500448961|gb|EOP61695.1|	27.6	228	446	306	2.19e-16	78.6
k141_79039_54	SARG|gi|500465078|gb|EOP76697.1|	27.6	228	446	306	2.19e-16	78.6
k141_79039_54	SARG|AAD21213	27.5	207	446	306	2.95e-16	78.2
k141_79039_54	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.8	194	446	655	3.22e-11	64.3
k141_79039_54	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.8	194	446	655	3.22e-11	64.3
k141_79039_54	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	25.9	197	446	655	1.31e-10	62.4
k141_79039_54	SARG|gi|1008988570|ref|WP_061884457.1|	31.9	160	446	492	1.43e-10	62.0
k141_79039_54	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	SARG|gb|AKA86814|ARO:3003746|optrA	26.3	194	446	655	3.03e-10	61.2
k141_79039_54	SARG|gi|765018624|ref|WP_044584737.1|	30.6	160	446	492	4.41e-10	60.5
k141_87193_8	CARD|gb|ABD30512.1|ARO:3000839|arlS	29.2	243	436	451	1.54e-31	124
k141_87193_8	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.2	248	436	381	6.77e-21	92.8
k141_87193_8	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.2	248	436	381	6.77e-21	92.8
k141_87193_8	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.2	255	436	381	9.15e-21	92.4
k141_87193_8	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.2	255	436	381	9.15e-21	92.4
k141_87193_8	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	31.7	221	436	364	3.49e-20	90.5
k141_87193_8	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	31.7	221	436	364	3.49e-20	90.5
k141_87193_8	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.4	211	436	381	4.12e-20	90.5
k141_87193_8	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.4	211	436	381	4.12e-20	90.5
k141_87193_8	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.9	211	436	381	3.34e-19	87.8
k141_87193_8	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.9	211	436	381	3.34e-19	87.8
k141_87193_8	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	28.1	224	436	392	4.93e-19	87.4
k141_87193_8	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	27.7	231	436	370	5.52e-19	87.0
k141_87193_8	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	29.2	260	436	364	3.13e-18	84.7
k141_87193_8	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	29.2	260	436	364	3.13e-18	84.7
k141_87193_8	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	25.5	220	436	365	1.22e-14	73.9
k141_87193_9	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	39.7	229	228	232	2.27e-45	150
k141_87193_9	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	39.7	229	228	232	2.27e-45	150
k141_87193_9	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.9	226	228	231	4.40e-45	149
k141_87193_9	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	226	228	231	4.40e-45	149
k141_87193_9	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	38.3	230	228	232	9.02e-45	148
k141_87193_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.4	229	228	231	3.49e-44	147
k141_87193_9	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.2	226	228	231	3.90e-43	144
k141_87193_9	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	226	228	231	7.78e-43	143
k141_87193_9	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	226	228	231	1.55e-42	142
k141_87193_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	39.1	230	228	235	3.44e-42	142
k141_87193_9	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.9	232	228	230	1.68e-41	140
k141_87193_9	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	34.8	230	228	239	6.69e-40	136
k141_87193_9	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	228	231	1.52e-39	135
k141_87193_9	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.9	229	228	231	3.02e-39	134
k141_87193_9	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.4	229	228	231	3.02e-39	134
k141_87193_9	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	37.3	228	228	231	3.02e-39	134
k141_87193_9	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.4	229	228	231	4.26e-39	134
k141_87193_9	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.0	228	228	233	6.33e-39	133
k141_87193_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.5	230	228	229	1.60e-38	132
k141_87193_9	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.4	228	228	232	6.82e-38	130
k141_87193_9	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.6	227	228	235	2.91e-37	129
k141_87193_9	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.8	228	228	232	5.35e-37	128
k141_87193_9	CARD|gb|AAD51348.1|ARO:3003066|smeR	36.7	221	228	229	9.83e-37	127
k141_87193_9	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.4	228	228	232	1.06e-36	127
k141_87193_9	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.0	228	228	232	2.11e-36	127
k141_62703_5	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.6	580	586	582	2.12e-92	294
k141_62703_5	SARG|gi|860594225|ref|WP_048475168.1|	29.8	571	586	620	3.84e-87	281
k141_62703_5	SARG|gi|664100597|ref|WP_030638327.1|	29.9	571	586	601	6.67e-87	280
k141_62703_5	SARG|gi|662754041|ref|WP_030125200.1|	29.9	571	586	601	9.34e-87	280
k141_62703_5	SARG|gi|503923650|ref|WP_014157644.1|	29.8	571	586	601	1.83e-86	279
k141_62703_5	SARG|gi|505389066|ref|WP_015576168.1|	29.8	571	586	601	2.57e-86	279
k141_62703_5	SARG|gi|926351744|ref|WP_053683383.1|	29.8	571	586	648	3.98e-86	280
k141_62703_5	SARG|gi|928900436|ref|WP_053931243.1|	30.3	575	586	600	4.92e-86	278
k141_62703_5	SARG|gi|664579989|ref|WP_031094015.1|	30.3	575	586	601	5.05e-86	278
k141_62703_5	SARG|gi|497748188|ref|WP_010062372.1|	30.1	571	586	605	1.09e-85	277
k141_62703_5	SARG|gi|664352659|ref|WP_030880307.1|	29.8	571	586	601	1.39e-85	277
k141_62703_5	SARG|gi|648667297|ref|WP_026359044.1|	30.6	575	586	605	1.53e-85	277
k141_62703_5	SARG|gi|917203192|ref|WP_051809904.1|	30.4	575	586	620	1.56e-85	277
k141_62703_5	SARG|gi|919568551|ref|WP_052871170.1|	30.1	575	586	620	1.56e-85	277
k141_62703_5	SARG|gi|695887424|ref|WP_032788534.1|	30.1	571	586	605	3.00e-85	276
k141_62703_5	SARG|gi|917155568|ref|WP_051762280.1|	31.0	575	586	620	3.06e-85	276
k141_62703_5	SARG|gi|1045390184|ref|WP_065479071.1|	29.8	571	586	605	4.20e-85	276
k141_62703_5	SARG|gi|921231571|ref|WP_053176464.1|	30.9	579	586	620	6.00e-85	276
k141_62703_5	SARG|gi|948137056|ref|WP_056795395.1|	30.4	575	586	602	7.67e-85	275
k141_62703_5	SARG|gi|917172177|ref|WP_051778889.1|	30.9	579	586	620	8.40e-85	275
k141_62703_5	SARG|gi|917127754|ref|WP_051734466.1|	30.4	575	586	620	8.40e-85	275
k141_62703_5	SARG|gi|1033217078|gb|OAR27197.1|	30.3	571	586	601	1.05e-84	275
k141_62703_5	SARG|gi|664170108|ref|WP_030704355.1|	30.1	571	586	603	1.10e-84	275
k141_62703_5	SARG|gi|695865802|ref|WP_032778631.1|	29.9	571	586	605	1.15e-84	275
k141_62703_5	SARG|gi|917166849|ref|WP_051773561.1|	30.8	575	586	620	1.18e-84	275
k141_286_5	SARG|YP_002850805	32.9	645	893	652	6.54e-93	306
k141_286_5	SARG|ZP_02952732	33.0	645	893	652	3.41e-92	304
k141_286_5	SARG|ZP_02632674	33.0	645	893	660	4.15e-92	304
k141_286_5	SARG|L20800.gene.p01	33.0	645	893	652	6.60e-92	303
k141_286_5	SARG|AAV80410	31.3	642	893	651	6.49e-91	300
k141_286_5	SARG|NP_348076	31.3	651	893	652	2.49e-90	299
k141_286_5	SARG|L42544.gene.p01	31.2	642	893	651	3.38e-90	298
k141_286_5	SARG|Q08425	31.4	621	893	641	2.61e-84	282
k141_286_5	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	31.4	621	893	657	3.78e-84	282
k141_286_5	SARG|Z21523.gene.p01	31.4	621	893	657	3.78e-84	282
k141_286_5	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	31.4	621	893	654	6.79e-84	281
k141_286_5	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	31.4	621	893	670	9.77e-84	281
k141_286_5	SARG|AAB51122	31.4	621	893	670	9.77e-84	281
k141_286_5	SARG|AJ514254.gene.p01	30.4	635	893	640	1.31e-83	280
k141_286_5	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	31.3	617	893	641	1.34e-83	280
k141_286_5	SARG|AAZ79478	31.3	617	893	657	1.94e-83	280
k141_286_5	SARG|Q00937	31.3	617	893	641	4.96e-83	279
k141_286_5	SARG|Q52360	31.6	617	893	641	6.88e-83	278
k141_286_5	SARG|ZP_04557016	31.3	617	893	657	7.16e-83	279
k141_286_5	SARG|P70882	31.4	617	893	641	1.83e-82	277
k141_286_5	SARG|BAD46890	31.4	617	893	657	2.64e-82	277
k141_286_5	NCBI|WP_013646121.1|1|1|tet(O/W/32/O)|tet(O/W/32/O)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_mosaic_protein_Tet(O/W/32/O)|AMR|tetracycline	31.2	621	893	639	3.14e-79	268
k141_286_5	megares|MEG_7177|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	31.2	621	893	639	4.34e-79	268
k141_286_5	SARG|ABF69686	30.9	621	893	639	2.20e-78	266
k141_286_5	megares|MEG_7167|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	31.1	621	893	639	2.20e-78	266
k141_49160_1	SARG|ACF08831	38.5	130	309	639	1.93e-17	81.6
k141_49160_1	NCBI|WP_050824634.1|1|1|tet(O)|tet(O)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(O)|AMR|tetracycline	37.6	133	309	639	5.03e-16	77.4
k141_49160_2	SARG|L42544.gene.p01	30.4	487	720	651	5.21e-56	201
k141_49160_2	SARG|AAV80410	29.2	483	720	651	4.73e-55	199
k141_49160_2	SARG|NP_348076	28.6	483	720	652	6.45e-52	190
k141_49160_2	SARG|YP_002850805	28.8	483	720	652	1.44e-50	186
k141_49160_2	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	29.9	495	720	629	4.98e-50	184
k141_49160_2	ResF|tet(O/W)_3_AM889120_1	29.9	495	720	639	5.71e-50	184
k141_49160_2	SARG|AAO42740	29.7	492	720	639	1.45e-49	183
k141_49160_2	SARG|AY485126.gene.p01	29.7	492	720	639	1.45e-49	183
k141_49160_2	megares|MEG_7175|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	29.7	492	720	639	1.45e-49	183
k141_49160_2	SARG|ABN79417	29.9	495	720	639	1.97e-49	182
k141_49160_2	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	29.9	495	720	629	2.35e-49	182
k141_49160_2	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	29.9	495	720	629	2.35e-49	182
k141_49160_2	megares|MEG_7173|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	29.9	495	720	629	2.35e-49	182
k141_49160_2	ResF|tet(O/W)_1_AM889118_1	29.9	495	720	639	2.69e-49	182
k141_49160_2	ResF|tet(O/W)_4_AM889121_1	29.9	495	720	639	2.69e-49	182
k141_49160_2	ResF|tet(O/W)_5_AM889122_1	29.9	495	720	639	2.69e-49	182
k141_49160_2	SARG|ZP_02952732	28.6	483	720	652	3.19e-49	182
k141_49160_2	SARG|ZP_02632674	28.6	483	720	660	3.53e-49	182
k141_49160_2	SARG|AAY62597	30.2	497	720	639	6.80e-49	181
k141_49160_2	SARG|L20800.gene.p01	28.6	483	720	652	1.09e-48	181
k141_49160_2	megares|MEG_7174|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	29.5	495	720	629	1.10e-48	180
k141_49160_2	SARG|ZP_04576183	30.0	497	720	639	1.26e-48	180
k141_49160_2	ResF|tet(O/W)_2_AM889119_1	29.5	495	720	639	1.26e-48	180
k141_49160_2	SARG|ACA23192	30.0	497	720	639	1.72e-48	180
k141_49160_2	SARG|ACI02041	30.0	497	720	639	1.72e-48	180
k141_49160_13	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	32.8	229	230	233	3.75e-38	131
k141_49160_13	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.2	226	230	230	9.71e-38	130
k141_49160_13	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	31.6	228	230	232	2.03e-37	129
k141_49160_13	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	31.6	228	230	232	2.03e-37	129
k141_49160_13	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	32.8	229	230	229	3.73e-37	129
k141_49160_13	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.1	224	230	231	8.59e-36	125
k141_49160_13	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	30.7	225	230	232	3.47e-35	124
k141_49160_13	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	32.5	228	230	235	7.41e-35	123
k141_49160_13	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.4	230	230	232	1.92e-34	122
k141_49160_13	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.4	224	230	231	7.34e-34	120
k141_49160_13	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.0	230	230	232	1.49e-33	119
k141_49160_13	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	31.6	231	230	239	1.77e-33	119
k141_49160_13	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.0	230	230	232	2.10e-33	119
k141_49160_13	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.0	230	230	232	2.95e-33	119
k141_49160_13	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.9	230	230	232	2.95e-33	119
k141_49160_13	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.9	230	230	232	4.15e-33	118
k141_49160_13	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.9	224	230	231	3.13e-32	116
k141_49160_13	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.9	224	230	231	6.20e-32	115
k141_49160_13	CARD|gb|ATC67679.1|ARO:3000838|arlR	30.5	223	230	219	6.49e-32	115
k141_49160_13	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.9	231	230	231	1.22e-31	114
k141_49160_13	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	29.9	231	230	231	1.22e-31	114
k141_49160_13	CARD|gb|AAD51348.1|ARO:3003066|smeR	32.3	223	230	229	3.51e-30	110
k141_49160_13	CARD|gb|ADM92605.1|ARO:3000553|adeR	29.3	229	230	247	7.06e-25	97.4
k141_49160_14	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.6	227	278	370	6.07e-21	90.1
k141_49160_14	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	28.1	224	278	365	2.05e-20	88.6
k141_49160_14	SARG|gb|AAG05187.1|ARO:3005067|ParS	28.9	225	278	428	3.43e-11	62.0
k141_49160_17	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.5	502	559	579	1.97e-50	181
k141_49160_17	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	28.7	502	559	579	2.71e-50	181
k141_49160_17	SARG|gi|664170108|ref|WP_030704355.1|	28.8	553	559	603	9.47e-49	177
k141_49160_17	SARG|gi|490068471|ref|WP_003970646.1|	28.6	553	559	603	3.38e-48	176
k141_49160_17	SARG|gi|928900436|ref|WP_053931243.1|	28.8	559	559	600	4.46e-48	175
k141_49160_17	SARG|gi|664579989|ref|WP_031094015.1|	28.8	559	559	601	4.52e-48	175
k141_49160_17	SARG|gi|860594225|ref|WP_048475168.1|	27.2	552	559	620	5.83e-48	175
k141_49160_17	SARG|gi|948137056|ref|WP_056795395.1|	28.2	553	559	602	6.30e-48	175
k141_49160_17	SARG|gi|501350226|ref|WP_012381861.1|	28.6	553	559	603	6.39e-48	175
k141_49160_17	SARG|gi|1045390184|ref|WP_065479071.1|	28.6	556	559	605	6.56e-48	175
k141_49160_17	SARG|gi|944009777|ref|WP_055601444.1|	30.1	564	559	628	8.87e-48	175
k141_49160_17	SARG|gi|1033217078|gb|OAR27197.1|	28.2	549	559	601	1.17e-47	174
k141_49160_17	SARG|gi|951183771|ref|WP_057661487.1|	28.2	553	559	603	1.21e-47	174
k141_49160_17	SARG|gi|827013130|ref|WP_047175495.1|	28.2	553	559	603	1.21e-47	174
k141_49160_17	SARG|gi|943896259|ref|WP_055534530.1|	28.1	548	559	601	2.21e-47	173
k141_49160_17	SARG|gi|695891735|ref|WP_032792824.1|	28.2	553	559	603	2.27e-47	173
k141_49160_17	SARG|gi|655401130|ref|WP_028800283.1|	28.8	559	559	599	2.96e-47	173
k141_49160_17	SARG|gi|943909899|ref|WP_055545300.1|	28.5	555	559	601	3.04e-47	173
k141_49160_17	SARG|gi|943938624|ref|WP_055567802.1|	27.9	548	559	602	3.08e-47	173
k141_49160_17	SARG|gi|913055317|ref|WP_050357634.1|	28.2	553	559	603	3.12e-47	173
k141_49160_17	SARG|gi|948040364|ref|WP_056699531.1|	28.2	553	559	603	3.12e-47	173
k141_49160_17	SARG|gi|663155409|ref|WP_030194633.1|	27.8	551	559	605	4.40e-47	172
k141_49160_17	SARG|gi|664538723|ref|WP_031054357.1|	27.8	551	559	605	4.40e-47	172
k141_49160_17	SARG|gi|663330365|ref|WP_030329892.1|	27.8	551	559	607	4.52e-47	172
k141_49160_17	SARG|gi|695865802|ref|WP_032778631.1|	27.8	553	559	605	6.04e-47	172
k141_49160_25	SARG|gb|AAC75089.1|ARO:3003577|ugd	60.2	389	395	388	1.47e-165	468
k141_41137_41	NCBI|WP_005813024.1|1|1|vanW-I|vanW-I||2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_accessory_protein_VanW-I|AMR|glycopeptide	31.6	354	491	373	1.30e-30	121
k141_8407_18	CARD|gb|BAE77778.1|ARO:3000508|gadX	28.7	115	303	274	2.52e-06	47.0
k141_8407_32	NCBI|WP_063856408.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	25.4	460	532	654	2.16e-32	130
k141_8407_32	megares|MEG_7182|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.4	460	532	670	2.31e-32	130
k141_8407_32	SARG|AAB51122	25.4	460	532	670	2.31e-32	130
k141_8407_32	SARG|Q08425	25.4	460	532	641	3.68e-32	129
k141_8407_32	megares|MEG_7181|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETQ_1	25.4	460	532	657	3.96e-32	129
k141_8407_32	SARG|Z21523.gene.p01	25.4	460	532	657	3.96e-32	129
k141_8407_32	SARG|Q52360	25.7	456	532	641	6.66e-32	129
k141_8407_32	SARG|P70882	25.7	456	532	641	6.66e-32	129
k141_8407_32	SARG|BAD46890	25.7	456	532	657	7.15e-32	129
k141_8407_32	NCBI|WP_063856409.1|1|1|tet(Q)|tet(Q)|target_protection|2|TETRACYCLINE|TETRACYCLINE|tetracycline_resistance_ribosomal_protection_protein_Tet(Q)|AMR|tetracycline	26.2	461	532	641	2.18e-31	127
k141_8407_32	SARG|AAZ79478	26.2	461	532	657	2.33e-31	127
k141_8407_32	SARG|Q00937	25.2	456	532	641	5.30e-31	126
k141_8407_32	SARG|ZP_04557016	25.2	456	532	657	5.65e-31	126
k141_8407_56	SARG|ZP_04081918	30.2	215	499	306	8.37e-17	80.1
k141_8407_56	SARG|gi|447195835|ref|WP_001273091.1|	29.8	215	499	306	2.75e-16	78.6
k141_8407_56	SARG|gi|447195836|ref|WP_001273092.1|	29.8	215	499	306	2.75e-16	78.6
k141_8407_56	SARG|gi|542061059|gb|ERI11611.1|	27.1	247	499	316	1.36e-15	76.6
k141_8407_56	SARG|gi|445996710|ref|WP_000074565.1|	28.8	212	499	309	3.06e-15	75.5
k141_8407_56	SARG|gi|500448961|gb|EOP61695.1|	27.8	212	499	306	5.35e-15	74.7
k141_8407_56	SARG|gi|445996719|ref|WP_000074574.1|	28.5	214	499	309	1.80e-14	73.2
k141_8407_56	SARG|gi|445996722|ref|WP_000074577.1|	28.5	214	499	309	2.42e-14	72.8
k141_8407_56	SARG|gi|446026113|ref|WP_000103968.1|	26.6	214	499	306	3.15e-14	72.4
k141_8407_56	SARG|gi|445996723|ref|WP_000074578.1|	28.5	214	499	309	3.25e-14	72.4
k141_8407_56	SARG|gi|500465078|gb|EOP76697.1|	27.4	212	499	306	4.23e-14	72.0
k141_8407_56	SARG|gi|445996724|ref|WP_000074579.1|	28.0	214	499	309	5.85e-14	71.6
k141_8407_56	SARG|gi|447057509|ref|WP_001134765.1|	27.8	212	499	309	5.85e-14	71.6
k141_8407_56	SARG|gi|1043490477|ref|WP_065382463.1|	28.0	214	499	309	7.86e-14	71.2
k141_8407_56	SARG|gi|445996726|ref|WP_000074581.1|	28.0	214	499	309	7.86e-14	71.2
k141_8407_56	SARG|gi|884875933|emb|CKG93789.1|	27.4	212	499	309	7.86e-14	71.2
k141_8407_56	SARG|gi|507054395|ref|WP_016125339.1|	28.0	214	499	309	7.86e-14	71.2
k141_8407_56	SARG|gi|895808656|emb|COR83787.1|	27.4	212	499	309	7.86e-14	71.2
k141_8407_56	SARG|gi|895736250|emb|COF64653.1|	27.4	212	499	309	1.05e-13	70.9
k141_8407_56	SARG|gi|446110087|ref|WP_000187942.1|	27.4	212	499	309	1.05e-13	70.9
k141_8407_56	SARG|gi|445996714|ref|WP_000074569.1|	27.4	212	499	309	1.05e-13	70.9
k141_8407_56	SARG|gi|445996729|ref|WP_000074584.1|	26.3	232	499	309	1.42e-13	70.5
k141_8407_56	SARG|gi|814314593|emb|CKF49145.1|	28.2	209	499	309	1.42e-13	70.5
k141_8407_56	SARG|P42332	27.5	211	499	306	1.84e-13	70.1
k141_8407_56	SARG|ABB80128	27.5	211	499	306	1.84e-13	70.1
k141_103590_3	SARG|gi|1004359922|gb|AMP42228.1|	26.3	434	605	639	2.53e-28	119
k141_103590_3	SARG|ABV82118	23.9	435	605	639	2.52e-27	115
k141_103590_3	megares|MEG_7166|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.2	440	605	639	3.36e-27	115
k141_103590_3	SARG|YP_594556	24.4	434	605	639	3.36e-27	115
k141_103590_3	SARG|AAY62597	25.7	435	605	639	4.48e-27	115
k141_103590_3	megares|MEG_7169|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.7	435	605	629	5.75e-27	114
k141_103590_3	megares|MEG_7170|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.7	435	605	629	5.75e-27	114
k141_103590_3	ResF|tet(O/W)_3_AM889120_1	25.7	435	605	639	5.96e-27	114
k141_103590_3	ResF|tet(O/W)_4_AM889121_1	25.7	435	605	639	5.96e-27	114
k141_103590_3	megares|MEG_7163|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETO_1	25.7	435	605	629	7.67e-27	114
k141_103590_3	SARG|gi|254967129|gb|ACT97610.1|	25.7	435	605	639	7.94e-27	114
k141_103590_3	SARG|AJ222769.gene.p01	25.7	435	605	639	7.94e-27	114
k141_103590_3	SARG|gi|168258996|gb|ACA23181.1|	25.7	435	605	639	7.94e-27	114
k141_103590_3	SARG|gi|1028100281|ref|WP_063856416.1|	25.7	435	605	639	7.94e-27	114
k141_103590_3	ResF|tet(O/W)_5_AM889122_1	25.7	435	605	639	7.94e-27	114
k141_103590_3	SARG|ACA23195	25.7	435	605	639	7.94e-27	114
k141_103590_3	SARG|CAD13485	25.7	435	605	639	7.94e-27	114
k141_103590_3	SARG|gi|104303742|gb|ABF72138.1|	25.7	435	605	639	1.06e-26	114
k141_103590_3	SARG|AJ295238.gene.p01	23.9	435	605	639	1.06e-26	114
k141_103590_3	SARG|gi|1028100289|ref|WP_063856424.1|	25.9	437	605	639	1.06e-26	114
k141_103590_3	megares|MEG_7229|Drugs|Tetracycline|Tetracycline_resistance_ribosomal_protection_proteins|TETW_1	25.9	437	605	644	1.08e-26	114
k141_103590_3	SARG|gb|AMP42147.1|ARO:3004442|tet(W/N/W)	25.5	435	605	639	1.41e-26	113
k141_103590_3	SARG|ZP_03989103	23.2	435	605	639	1.41e-26	113
k141_103590_3	SARG|CAX85496	25.7	435	605	639	1.41e-26	113
k141_103590_3	SARG|ABV82120	23.2	435	605	639	1.41e-26	113
k141_21998_7	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	38.0	221	226	231	2.05e-42	142
k141_21998_7	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	36.7	226	226	233	4.32e-42	141
k141_21998_7	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.7	221	226	219	1.15e-38	132
k141_21998_7	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.3	224	226	219	1.62e-38	132
k141_21998_7	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.8	224	226	219	6.42e-38	130
k141_21998_7	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.8	224	226	220	6.59e-38	130
k141_21998_7	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.8	224	226	220	9.30e-38	130
k141_21998_7	SARG|ZP_02848503	36.0	225	226	221	1.90e-37	129
k141_21998_7	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.8	224	226	220	1.45e-36	127
k141_21998_7	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	35.1	228	226	225	3.39e-32	115
k141_21998_7	CARD|gb|AAC73788.1|ARO:3003841|kdpE	35.1	228	226	225	3.39e-32	115
k141_21998_7	megares|MEG_4290|Drugs|beta-lactam|Mutant_porin_proteins|OMPR_1	33.2	235	226	252	4.31e-28	105
k141_21998_7	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	30.0	223	226	228	2.71e-27	103
k141_21998_7	CARD|gb|AAG06465.1|ARO:3005063|cprR	33.3	198	226	223	3.40e-27	102
k141_21998_7	CARD|gb|AAG05188.1|ARO:3005068|ParR	32.5	203	226	235	6.23e-27	102
k141_21998_7	NCBI|XSG12259.1|1|1|drcR|drcR||1|||daptomycin_efflux_response_regulator_transcription_factor_DrcR|AMR|peptide	31.6	225	226	223	5.40e-25	97.1
k141_21998_7	CARD|gb|BAB36671.1|ARO:3000832|evgA	27.7	83	226	204	1.18e-06	46.6
k141_21998_8	SARG|gb|AAG05187.1|ARO:3005067|ParS	29.6	243	380	428	2.68e-24	102
k141_21998_8	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.5	213	380	381	1.29e-22	97.1
k141_21998_8	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.5	213	380	381	1.29e-22	97.1
k141_21998_8	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.5	213	380	381	6.03e-22	95.1
k141_21998_8	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.5	213	380	381	6.03e-22	95.1
k141_21998_8	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.4	201	380	367	1.79e-21	93.6
k141_21998_8	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.4	201	380	368	1.81e-21	93.6
k141_21998_8	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	30.2	212	380	381	2.06e-21	93.6
k141_21998_8	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	30.2	212	380	381	2.06e-21	93.6
k141_21998_8	CARD|gb|ADM92606.1|ARO:3000549|adeS	27.2	276	380	361	4.95e-20	89.4
k141_21998_8	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	27.5	236	380	364	1.07e-18	85.5
k141_21998_8	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	27.5	236	380	364	1.07e-18	85.5
k141_21998_8	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	27.7	202	380	359	1.87e-18	84.7
k141_21998_8	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	26.9	201	380	380	4.06e-18	84.0
k141_21998_8	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	26.9	201	380	380	4.06e-18	84.0
k141_21998_8	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	27.1	203	380	357	2.79e-17	81.3
k141_21998_8	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	27.1	203	380	357	2.79e-17	81.3
k141_21998_8	megares|MEG_7521|Drugs|Glycopeptide|VanN-type_regulator|VANSN_1	24.6	232	380	364	2.73e-14	72.4
k141_21998_8	NCBI|WP_063856749.1|1|1|vanS-N|vanS-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-N|AMR|glycopeptide	24.6	232	380	364	2.73e-14	72.4
k141_35584_6	SARG|YP_001373621	42.7	232	361	318	3.60e-52	174
k141_35584_6	SARG|P42332	42.7	232	361	306	1.02e-51	173
k141_35584_6	megares|MEG_1213|Drugs|Bacitracin|Bacitracin_ABC_transporter|BCRA_1	42.7	232	361	306	1.02e-51	173
k141_35584_6	SARG|gi|510143239|gb|AGN36970.1|	42.7	232	361	313	1.23e-51	173
k141_35584_6	SARG|ABB80128	42.7	232	361	306	1.44e-51	172
k141_35584_6	SARG|AAD21213	36.6	309	361	306	1.44e-51	172
k141_35584_6	SARG|gi|542061059|gb|ERI11611.1|	37.6	311	361	316	5.19e-51	171
k141_35584_6	SARG|gi|447195835|ref|WP_001273091.1|	43.2	222	361	306	2.19e-50	169
k141_35584_6	SARG|gi|507055561|ref|WP_016126482.1|	41.9	222	361	309	3.33e-50	169
k141_35584_6	SARG|ZP_04081918	42.8	222	361	306	6.07e-50	168
k141_35584_6	SARG|gi|447195836|ref|WP_001273092.1|	42.8	222	361	306	6.07e-50	168
k141_35584_6	SARG|gi|488053456|ref|WP_002124853.1|	41.9	222	361	309	6.56e-50	168
k141_35584_6	SARG|gi|447057509|ref|WP_001134765.1|	42.3	222	361	309	6.56e-50	168
k141_35584_6	SARG|gi|500194536|ref|WP_011867743.1|	42.8	222	361	306	8.52e-50	168
k141_35584_6	SARG|gi|447057510|ref|WP_001134766.1|	41.4	222	361	309	1.30e-49	167
k141_35584_6	SARG|gi|488067981|ref|WP_002139378.1|	41.4	222	361	309	1.82e-49	167
k141_35584_6	SARG|gi|500448961|gb|EOP61695.1|	42.3	222	361	306	2.36e-49	167
k141_35584_6	SARG|gi|445996719|ref|WP_000074574.1|	42.3	222	361	309	2.56e-49	167
k141_35584_6	SARG|gi|488068784|ref|WP_002140181.1|	41.0	222	361	309	2.56e-49	167
k141_35584_6	SARG|gi|488130770|ref|WP_002201978.1|	41.4	222	361	309	3.59e-49	166
k141_35584_6	SARG|gi|507023808|ref|WP_016095885.1|	41.0	222	361	309	5.04e-49	166
k141_35584_6	SARG|gi|487936534|ref|WP_002010000.1|	41.0	222	361	309	5.04e-49	166
k141_35584_6	SARG|gi|446026113|ref|WP_000103968.1|	41.0	222	361	306	9.20e-49	165
k141_35584_6	SARG|gi|507044560|ref|WP_016115614.1|	34.5	313	361	306	9.20e-49	165
k141_35584_6	SARG|gi|507050365|ref|WP_016121371.1|	41.4	222	361	309	1.40e-48	165
k141_35584_13	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	28.0	289	495	359	4.29e-26	108
k141_35584_13	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	25.8	267	495	370	6.83e-26	107
k141_35584_13	SARG|gb|AAG05187.1|ARO:3005067|ParS	25.3	288	495	428	1.26e-23	102
k141_35584_13	megares|MEG_7500|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.0	245	495	352	2.40e-23	100
k141_35584_13	megares|MEG_7497|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.0	245	495	376	3.26e-23	100
k141_35584_13	NCBI|WP_034869172.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	29.0	245	495	376	3.26e-23	100
k141_35584_13	megares|MEG_7501|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.1	247	495	354	1.52e-22	97.8
k141_35584_13	megares|MEG_7503|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.7	247	495	354	1.52e-22	97.8
k141_35584_13	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	23.6	263	495	365	2.36e-22	97.4
k141_35584_13	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.7	225	495	364	4.27e-22	96.7
k141_35584_13	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.7	225	495	364	4.27e-22	96.7
k141_35584_13	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	25.5	220	495	357	3.54e-20	90.9
k141_35584_13	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	25.5	220	495	357	3.54e-20	90.9
k141_35584_13	CARD|gb|AEX49906.1|ARO:3003583|basS	26.1	234	495	477	1.59e-19	90.1
k141_35584_14	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.1	226	230	233	1.10e-60	189
k141_35584_14	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	44.0	225	230	231	2.07e-60	188
k141_35584_14	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	44.0	225	230	232	1.21e-59	186
k141_35584_14	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	40.2	229	230	232	2.77e-58	183
k141_35584_14	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	40.2	229	230	232	2.77e-58	183
k141_35584_14	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.7	228	230	231	5.38e-58	182
k141_35584_14	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.2	228	230	231	1.52e-57	181
k141_35584_14	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	41.0	229	230	231	2.16e-57	181
k141_35584_14	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.0	229	230	231	2.16e-57	181
k141_35584_14	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.2	228	230	231	4.32e-57	180
k141_35584_14	CARD|gb|ATC67679.1|ARO:3000838|arlR	42.5	226	230	219	6.02e-57	179
k141_35584_14	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.0	226	230	232	1.26e-56	179
k141_35584_14	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.0	226	230	232	1.79e-56	178
k141_35584_14	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.0	226	230	232	1.79e-56	178
k141_35584_14	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.0	226	230	232	1.79e-56	178
k141_35584_14	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.0	226	230	232	2.53e-56	178
k141_35584_14	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	41.2	228	230	235	7.84e-56	177
k141_35584_14	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	40.7	226	230	230	5.42e-55	174
k141_35584_14	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.6	226	230	232	1.63e-54	173
k141_35584_14	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	39.6	227	230	231	4.48e-54	172
k141_35584_14	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	39.6	230	230	239	5.67e-54	172
k141_35584_14	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	39.8	226	230	229	5.97e-54	172
k141_35584_14	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.8	224	230	231	2.54e-53	170
k141_35584_14	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.8	224	230	231	7.18e-53	169
k141_35584_14	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.8	224	230	231	1.02e-52	169
k141_35584_71	SARG|gi|822022298|ref|WP_046882271.1|	31.2	141	831	646	5.28e-08	55.5
k141_35584_71	SARG|gi|1016530977|ref|WP_063106245.1|	31.2	141	831	646	5.28e-08	55.5
k141_35584_71	SARG|gi|950164608|ref|WP_057214157.1|	29.2	130	831	646	6.95e-08	55.1
k141_35584_71	SARG|gi|1000904163|ref|WP_061155197.1|	30.5	141	831	646	6.95e-08	55.1
k141_35584_71	SARG|gi|765283866|ref|WP_044612790.1|	30.5	141	831	646	6.95e-08	55.1
k141_35584_71	SARG|gi|985815823|ref|WP_060876116.1|	30.5	141	831	646	6.95e-08	55.1
k141_35584_71	SARG|YP_002239469	30.5	141	831	646	6.95e-08	55.1
k141_35584_71	SARG|gi|1031862522|ref|WP_064180366.1|	30.5	141	831	646	6.95e-08	55.1
k141_35584_71	SARG|gi|695840638|ref|WP_032753940.1|	30.5	141	831	646	9.14e-08	54.7
k141_35584_71	SARG|gi|757718708|ref|WP_042946953.1|	30.5	141	831	646	9.14e-08	54.7
k141_35584_71	SARG|gi|1031824807|ref|WP_064152164.1|	35.2	91	831	646	9.14e-08	54.7
k141_35584_71	SARG|gi|852138723|ref|WP_048293411.1|	30.5	141	831	646	1.20e-07	54.3
k141_35584_71	SARG|gi|496081332|ref|WP_008805839.1|	30.5	141	831	646	1.20e-07	54.3
k141_35584_71	SARG|gi|751264306|ref|WP_040974017.1|	30.5	141	831	646	1.20e-07	54.3
k141_35584_71	SARG|gi|556492128|ref|WP_023339842.1|	30.5	141	831	646	1.20e-07	54.3
k141_35584_71	SARG|gi|742128296|gb|AJA96431.1|	30.5	141	831	646	1.20e-07	54.3
k141_35584_71	SARG|gi|1016069923|ref|WP_062914571.1|	29.2	130	831	646	1.58e-07	53.9
k141_35584_71	SARG|gi|1044231927|emb|SBX14918.1|	32.7	107	831	646	1.58e-07	53.9
k141_35584_71	SARG|gi|749538518|ref|WP_040174114.1|	32.1	112	831	646	1.58e-07	53.9
k141_35584_71	SARG|gi|927316447|ref|WP_053810605.1|	29.2	130	831	646	1.58e-07	53.9
k141_35584_71	SARG|gi|556279336|ref|WP_023289005.1|	30.5	141	831	646	2.08e-07	53.5
k141_35584_71	SARG|gi|694113840|ref|WP_032455777.1|	34.1	91	831	646	2.08e-07	53.5
k141_35584_71	SARG|gi|556195652|ref|WP_023279140.1|	34.1	91	831	646	2.08e-07	53.5
k141_35584_71	SARG|gi|490295685|ref|WP_004191149.1|	34.1	91	831	646	2.08e-07	53.5
k141_35584_71	SARG|gi|1031836330|ref|WP_064161764.1|	29.1	141	831	646	2.08e-07	53.5
k141_35584_75	NCBI|WP_109545033.1|1|1|vanY-D|vanY-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|transpeptidase-like_D-Ala-D-Ala_carboxypeptidase_VanY-D|AMR|glycopeptide	31.4	258	567	355	4.12e-31	123
k141_35584_75	megares|MEG_7602|Drugs|Glycopeptide|VanD-type_accessory_protein|VANYD_1	31.4	258	567	355	4.12e-31	123
k141_35584_75	SARG|ACM47285	31.4	258	567	363	4.75e-31	123
k141_35584_113	SARG|gi|671541568|ref|WP_031525212.1|	27.9	219	507	648	3.67e-19	89.7
k141_35584_113	SARG|gi|742378414|ref|WP_038857601.1|	28.2	220	507	647	1.14e-18	88.2
k141_35584_113	SARG|gi|495067432|ref|WP_007792257.1|	26.9	219	507	647	1.51e-18	87.8
k141_35584_113	SARG|gi|696411918|ref|WP_032982657.1|	28.2	220	507	647	2.01e-18	87.4
k141_35584_113	SARG|gi|696402390|ref|WP_032974230.1|	28.2	220	507	647	2.01e-18	87.4
k141_35584_113	SARG|gi|696423952|ref|WP_032993748.1|	28.2	220	507	647	2.01e-18	87.4
k141_35584_113	SARG|gi|565651791|ref|WP_023899061.1|	28.2	220	507	647	2.67e-18	87.0
k141_35584_113	SARG|gi|639209604|ref|WP_024547784.1|	28.3	219	507	648	2.67e-18	87.0
k141_35584_113	SARG|gi|495004199|ref|WP_007730213.1|	28.6	220	507	647	3.54e-18	86.7
k141_35584_113	SARG|gi|742409107|ref|WP_038888226.1|	28.6	220	507	647	3.54e-18	86.7
k141_35584_113	SARG|gi|696420214|ref|WP_032990021.1|	27.0	237	507	647	3.54e-18	86.7
k141_35584_113	SARG|gi|494938585|ref|WP_007664615.1|	27.4	223	507	647	3.54e-18	86.7
k141_35584_113	SARG|YP_001438541	27.0	237	507	647	4.70e-18	86.3
k141_35584_113	SARG|gi|938461734|ref|WP_054625806.1|	27.0	237	507	647	4.70e-18	86.3
k141_35584_113	SARG|gi|742384718|ref|WP_038863845.1|	27.3	231	507	647	4.70e-18	86.3
k141_35584_113	SARG|gi|938460528|ref|WP_054624864.1|	27.0	237	507	647	4.70e-18	86.3
k141_35584_113	SARG|gi|1020141879|ref|WP_063264839.1|	27.0	237	507	647	4.70e-18	86.3
k141_35584_113	SARG|gi|490522515|ref|WP_004387938.1|	27.0	237	507	647	4.70e-18	86.3
k141_35584_113	SARG|gi|504542119|ref|WP_014729221.1|	27.6	217	507	647	8.28e-18	85.5
k141_35584_113	SARG|gi|655997348|ref|WP_029038923.1|	27.6	217	507	647	8.28e-18	85.5
k141_35584_113	SARG|gi|426326769|emb|CCK10228.1|	27.6	217	507	648	8.29e-18	85.5
k141_35584_113	SARG|gi|554685678|ref|WP_023185565.1|	27.5	207	507	648	8.29e-18	85.5
k141_35584_113	SARG|gi|506220920|ref|WP_015740695.1|	27.7	220	507	647	1.46e-17	84.7
k141_35584_113	SARG|YP_001571041	27.6	199	507	648	1.94e-17	84.3
k141_35584_113	SARG|gi|960873409|ref|WP_058345546.1|	27.6	199	507	648	1.94e-17	84.3
k141_103745_20	megares|MEG_5400|Drugs|beta-lactam|Penicillin_binding_protein|PBP2_1	27.2	353	961	633	6.79e-24	106
k141_103745_37	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.1	291	492	365	2.65e-29	117
k141_103745_37	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	26.4	299	492	370	3.48e-28	114
k141_103745_37	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.7	333	492	381	1.94e-25	106
k141_103745_37	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.7	333	492	381	1.94e-25	106
k141_103745_37	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	334	492	381	3.57e-25	105
k141_103745_37	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	334	492	381	3.57e-25	105
k141_103745_37	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	334	492	381	3.01e-24	103
k141_103745_37	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	334	492	381	3.01e-24	103
k141_103745_37	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.6	334	492	381	4.07e-24	102
k141_103745_37	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.6	334	492	381	4.07e-24	102
k141_103745_37	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.6	304	492	392	8.50e-24	102
k141_103745_37	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	27.0	270	492	381	4.58e-23	99.8
k141_103745_37	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	27.0	270	492	381	4.58e-23	99.8
k141_103745_37	CARD|gb|ABD30512.1|ARO:3000839|arlS	28.2	308	492	451	4.91e-23	100
k141_103745_37	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	25.0	292	492	367	9.47e-20	89.7
k141_103745_37	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	27.5	240	492	368	1.29e-19	89.4
k141_103745_37	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	29.9	211	492	359	1.58e-19	89.0
k141_103745_37	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.3	254	492	382	1.98e-19	89.0
k141_103745_37	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	28.3	254	492	382	1.98e-19	89.0
k141_103745_37	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.4	266	492	384	6.89e-18	84.3
k141_103745_37	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	27.4	266	492	384	6.89e-18	84.3
k141_103745_37	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	28.1	253	492	386	7.00e-18	84.3
k141_103745_37	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	28.1	253	492	386	7.00e-18	84.3
k141_103745_37	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	24.2	269	492	380	8.95e-18	84.0
k141_103745_37	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	24.2	269	492	380	8.95e-18	84.0
k141_103745_38	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.6	225	220	231	7.42e-50	161
k141_103745_38	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.9	217	220	219	1.05e-49	160
k141_103745_38	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.6	217	220	219	1.48e-49	160
k141_103745_38	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.6	217	220	220	1.52e-49	160
k141_103745_38	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.6	217	220	220	4.31e-49	159
k141_103745_38	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.3	226	220	232	8.63e-49	158
k141_103745_38	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	39.2	217	220	219	1.19e-48	157
k141_103745_38	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	38.7	217	220	220	6.90e-48	155
k141_103745_38	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.7	229	220	229	2.52e-47	154
k141_103745_38	SARG|ZP_02848503	40.1	217	220	221	4.01e-47	154
k141_103745_38	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.2	224	220	231	1.70e-45	150
k141_103745_38	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	39.4	218	220	228	2.20e-45	149
k141_103745_38	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	37.7	231	220	239	2.99e-45	149
k141_103745_38	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	35.5	228	220	232	3.91e-44	146
k141_103745_38	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	35.5	228	220	232	3.91e-44	146
k141_103745_38	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	35.3	224	220	231	2.14e-43	144
k141_103745_38	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.8	224	220	231	2.14e-43	144
k141_103745_38	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	34.8	224	220	231	3.02e-43	144
k141_103745_38	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	34.9	232	220	235	1.89e-42	142
k141_103745_38	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	36.6	224	220	231	4.77e-42	141
k141_103745_38	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	33.6	229	220	233	1.12e-40	137
k141_103745_38	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	33.9	230	220	232	2.41e-39	134
k141_103745_38	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	33.9	230	220	232	4.80e-39	133
k141_103745_38	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	33.5	230	220	232	9.55e-39	132
k141_103745_38	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	32.7	223	220	230	1.28e-38	132
k141_120064_17	SARG|YP_002929946	55.9	299	303	282	2.59e-107	312
k141_120064_17	SARG|ZP_04528247	58.3	302	303	279	1.55e-105	308
k141_120064_17	SARG|ZP_03958019	53.6	304	303	317	1.03e-102	302
k141_120064_17	SARG|YP_002937728	55.7	298	303	289	1.89e-101	298
k141_120064_17	SARG|ZP_04433866	50.3	298	303	288	8.84e-87	260
k141_120064_17	SARG|ZP_03949893	50.3	298	303	288	8.84e-87	260
k141_120064_17	SARG|ZP_03984017	50.0	298	303	288	1.77e-86	259
k141_120064_17	SARG|ZP_03938934	52.1	303	303	288	6.57e-84	253
k141_120064_17	SARG|ZP_03941859	51.8	303	303	288	2.64e-83	251
k141_120064_17	SARG|ZP_03945515	48.9	307	303	291	8.63e-80	243
k141_120064_17	SARG|ZP_03916453	43.0	300	303	290	6.65e-68	212
k141_120064_17	SARG|ZP_03930663	42.8	311	303	293	4.63e-66	207
k141_120064_17	SARG|ZP_04049838	40.9	303	303	293	2.93e-64	203
k141_120064_17	SARG|ZP_02635322	41.4	304	303	304	2.44e-56	183
k141_120064_17	SARG|ZP_02865688	40.8	309	303	304	1.92e-55	181
k141_120064_17	SARG|YP_001389785	41.9	301	303	284	2.19e-55	180
k141_120064_17	SARG|YP_001382798	41.9	301	303	284	2.19e-55	180
k141_120064_17	SARG|YP_001785754	41.9	301	303	284	4.36e-55	179
k141_120064_17	SARG|YP_001780068	41.5	301	303	284	6.15e-55	179
k141_120064_17	SARG|ACQ53948	41.5	301	303	284	2.43e-54	177
k141_120064_17	SARG|YP_698526	40.1	304	303	304	5.96e-54	177
k141_120064_17	SARG|YP_695835	40.1	304	303	304	4.67e-53	174
k141_120064_17	SARG|ZP_02643483	39.8	304	303	304	4.67e-53	174
k141_120064_17	SARG|Q8XL56	40.1	304	303	304	4.67e-53	174
k141_120064_17	SARG|YP_581244	39.0	295	303	280	4.80e-53	174
k141_120064_45	SARG|YP_302230	21.2	387	465	451	1.15e-26	110
k141_120064_45	SARG|gi|446573707|ref|WP_000651053.1|	21.9	379	465	451	1.15e-26	110
k141_120064_45	SARG|gi|537465183|ref|WP_020976941.1|	21.6	379	465	451	1.56e-26	110
k141_120064_45	SARG|gi|565830932|ref|WP_023914633.1|	21.6	379	465	451	2.86e-26	109
k141_120064_45	SARG|gi|763462741|ref|WP_044292157.1|	21.6	379	465	451	3.88e-26	109
k141_120064_45	SARG|gi|686334333|ref|WP_031881350.1|	21.6	379	465	451	5.25e-26	108
k141_120064_45	SARG|gi|446573710|ref|WP_000651056.1|	21.9	379	465	451	5.25e-26	108
k141_120064_45	SARG|Q2G140	21.6	379	465	451	5.25e-26	108
k141_120064_45	SARG|gi|757671144|ref|WP_042903632.1|	21.6	379	465	451	7.11e-26	108
k141_120064_45	SARG|gi|686390606|ref|WP_031905637.1|	21.6	379	465	451	7.11e-26	108
k141_120064_45	SARG|gi|686329335|ref|WP_031878923.1|	21.9	379	465	451	7.11e-26	108
k141_120064_45	SARG|gi|486215009|ref|WP_001556470.1|	21.6	379	465	451	7.11e-26	108
k141_120064_45	SARG|gi|686123390|ref|WP_031769354.1|	21.6	379	465	451	9.63e-26	108
k141_120064_45	SARG|gi|686309117|ref|WP_031870179.1|	21.9	379	465	451	9.63e-26	108
k141_120064_45	SARG|gi|686294396|ref|WP_031862836.1|	21.6	379	465	451	9.63e-26	108
k141_120064_45	SARG|gi|686113687|ref|WP_031764317.1|	21.6	379	465	451	9.63e-26	108
k141_120064_45	SARG|gi|727749287|ref|WP_033861814.1|	21.6	379	465	451	9.63e-26	108
k141_120064_45	SARG|gi|446573718|ref|WP_000651064.1|	21.4	379	465	451	1.30e-25	107
k141_120064_45	SARG|gi|1006223553|ref|WP_061745579.1|	21.4	379	465	451	1.30e-25	107
k141_120064_45	SARG|gi|486285962|ref|WP_001572033.1|	21.6	379	465	451	1.30e-25	107
k141_120064_45	SARG|gi|686448604|ref|WP_031928572.1|	21.4	379	465	451	1.30e-25	107
k141_120064_45	SARG|gi|686309068|ref|WP_031870147.1|	21.6	379	465	451	1.30e-25	107
k141_120064_45	SARG|gi|487138435|ref|WP_001629863.1|	21.6	379	465	451	1.30e-25	107
k141_120064_45	SARG|gi|446573690|ref|WP_000651036.1|	21.4	379	465	451	1.76e-25	107
k141_120064_45	SARG|gi|686319982|ref|WP_031875468.1|	21.6	379	465	451	1.76e-25	107
k141_120064_46	SARG|gi|488156254|ref|WP_002227462.1|	21.0	420	462	459	2.93e-16	79.7
k141_120064_46	NCBI|EFF39147.1|1|1|norM-NG|norM-NG|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_NorM|AMR|efflux	21.2	415	462	459	3.90e-16	79.3
k141_120064_46	SARG|NC_011035.1.6448920.p01	21.2	415	462	459	3.90e-16	79.3
k141_120064_46	SARG|gi|488158065|ref|WP_002229273.1|	21.5	413	462	459	6.93e-16	78.6
k141_82054_12	SARG|gb|AAK76137.1|ARO:3000024|patA	28.4	222	330	564	1.45e-16	79.3
k141_82054_12	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	24.2	231	330	574	6.68e-15	74.3
k141_82054_13	SARG|gi|696368937|ref|WP_032943949.1|	33.6	232	334	648	2.47e-26	108
k141_82054_13	SARG|gi|851913025|ref|WP_048215946.1|	33.6	232	334	648	2.47e-26	108
k141_82054_13	SARG|gi|489930965|ref|WP_003834285.1|	33.6	232	334	648	2.47e-26	108
k141_82054_13	SARG|YP_002850060	33.6	232	334	648	3.34e-26	108
k141_82054_13	SARG|gi|696361545|ref|WP_032936694.1|	33.6	232	334	648	4.51e-26	107
k141_82054_13	SARG|gi|489936909|ref|WP_003840216.1|	33.6	232	334	648	4.51e-26	107
k141_82054_13	SARG|gi|507079862|ref|WP_016150620.1|	33.6	232	334	648	4.51e-26	107
k141_82054_13	SARG|gi|949791377|ref|WP_057104572.1|	33.6	232	334	648	4.51e-26	107
k141_82054_13	SARG|gi|936194420|ref|WP_054528571.1|	33.6	232	334	648	6.10e-26	107
k141_82054_13	SARG|gi|835233765|ref|WP_047410073.1|	31.9	257	334	648	6.10e-26	107
k141_82054_13	SARG|gi|507086196|ref|WP_016156937.1|	33.6	232	334	648	6.10e-26	107
k141_82054_13	SARG|YP_001571041	32.2	239	334	648	6.10e-26	107
k141_82054_13	SARG|gi|960873409|ref|WP_058345546.1|	32.2	239	334	648	6.10e-26	107
k141_82054_13	SARG|gi|446048013|ref|WP_000125868.1|	34.6	228	334	648	8.24e-26	107
k141_82054_13	SARG|gi|491270241|ref|WP_005128370.1|	33.2	232	334	648	1.51e-25	106
k141_82054_13	SARG|gi|754951242|ref|WP_042307417.1|	31.9	257	334	648	1.51e-25	106
k141_82054_13	SARG|gi|851902043|ref|WP_048212057.1|	33.2	232	334	648	1.51e-25	106
k141_82054_13	SARG|gi|992380339|ref|WP_061067665.1|	33.2	232	334	648	1.51e-25	106
k141_82054_13	SARG|gi|740610794|ref|WP_038396317.1|	32.2	239	334	648	1.51e-25	106
k141_82054_13	SARG|gi|757799695|ref|WP_043016897.1|	33.2	232	334	648	2.04e-25	105
k141_82054_13	SARG|gi|1045891604|ref|WP_065554100.1|	33.2	232	334	648	2.04e-25	105
k141_82054_13	SARG|gi|507082903|ref|WP_016153652.1|	33.2	232	334	648	2.04e-25	105
k141_82054_13	SARG|gi|740856590|ref|WP_038641842.1|	33.2	232	334	648	2.04e-25	105
k141_82054_13	SARG|gi|851922185|ref|WP_048218206.1|	33.6	232	334	648	2.04e-25	105
k141_82054_13	SARG|gi|949718947|ref|WP_057063453.1|	33.6	232	334	648	2.04e-25	105
k141_82054_22	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	32.3	217	833	370	4.62e-24	103
k141_82054_22	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	27.9	294	833	365	1.12e-22	99.8
k141_82054_23	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	48.9	233	238	232	3.94e-78	234
k141_82054_23	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	48.9	233	238	232	3.94e-78	234
k141_82054_23	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	49.8	239	238	239	4.94e-78	234
k141_82054_23	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	49.1	232	238	235	1.88e-74	224
k141_82054_23	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	48.3	234	238	233	2.03e-73	222
k141_82054_23	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	48.3	232	238	231	1.77e-71	217
k141_82054_23	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	47.0	232	238	231	2.50e-71	216
k141_82054_23	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.0	232	238	231	2.50e-71	216
k141_82054_23	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	47.0	232	238	231	5.77e-70	213
k141_82054_23	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	46.6	232	238	231	8.17e-70	213
k141_82054_23	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.8	231	238	232	9.67e-69	210
k141_82054_23	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.8	231	238	232	1.94e-68	209
k141_82054_23	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	45.0	231	238	229	3.54e-68	208
k141_82054_23	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	45.9	231	238	232	1.11e-67	207
k141_82054_23	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.3	231	238	232	1.57e-67	207
k141_82054_23	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.3	231	238	232	2.22e-67	206
k141_82054_23	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	46.3	231	238	232	2.22e-67	206
k141_82054_23	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.9	230	238	231	2.82e-65	201
k141_82054_23	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.2	231	238	231	8.02e-65	200
k141_82054_23	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	43.7	231	238	231	8.02e-65	200
k141_82054_23	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.3	231	238	231	6.47e-64	197
k141_82054_23	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.3	231	238	231	2.60e-63	196
k141_82054_23	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	43.3	231	238	231	3.68e-63	196
k141_82054_23	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	43.7	231	238	230	5.06e-63	195
k141_82054_23	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	227	238	232	9.08e-59	184
k141_82054_33	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	24.0	175	387	314	5.95e-10	58.9
k141_82054_41	SARG|gb|ABA71729.1|ARO:3002959|vanYG1	43.5	184	365	279	1.13e-41	146
k141_82054_41	SARG|gi|403023847|gb|EJY36064.1|	42.0	181	365	200	1.42e-41	143
k141_82054_41	SARG|gi|403219412|emb|CCJ27774.1|	42.0	181	365	268	3.30e-41	144
k141_82054_41	SARG|gi|452996227|gb|AGG19410.1|	42.0	181	365	252	5.98e-41	143
k141_82054_41	SARG|Q47746	42.0	181	365	268	6.47e-41	144
k141_82054_41	SARG|gi|452996213|gb|AGG19398.1|	42.0	181	365	268	6.47e-41	144
k141_82054_41	SARG|gi|498515090|ref|WP_010815297.1|	42.0	181	365	268	6.47e-41	144
k141_82054_41	SARG|gi|488259314|ref|WP_002330522.1|	42.0	181	365	268	9.07e-41	143
k141_82054_41	SARG|gi|1036536100|emb|SAM71699.1|	42.0	181	365	268	9.07e-41	143
k141_82054_41	SARG|KF823969.1.gene3.p01	42.0	181	365	268	9.07e-41	143
k141_82054_41	SARG|AAF71279	40.2	184	365	278	2.13e-33	124
k141_82054_41	SARG|AF155139.2.gene4.p01	36.3	171	365	293	5.24e-26	104
k141_82054_41	SARG|gi|1025843957|ref|WP_063576302.1|	35.8	204	365	287	8.55e-25	101
k141_82054_41	SARG|FJ349556.1.gene4.p01	32.3	189	365	233	2.83e-24	98.6
k141_82054_41	NCBI|WP_063856813.1|1|1|vanXY-E|vanXY-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_dipeptidase/D-Ala-D-Ala_carboxypeptidase_VanXY-E|AMR|glycopeptide	34.0	194	365	193	4.18e-24	97.1
k141_82054_41	NCBI|WP_107309513.1|1|1|vanY-M|vanY-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-M|AMR|glycopeptide	32.3	189	365	287	8.08e-24	98.6
k141_82054_41	NCBI|WP_063856916.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	33.3	204	365	299	4.88e-23	96.7
k141_82054_41	SARG|AAY52007	33.3	204	365	294	6.18e-23	96.3
k141_82054_41	NCBI|WP_063856920.1|1|1|vanY-Pt|vanY-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-Ala-D-Ala_carboxypeptidase_VanY-Pt|AMR|glycopeptide	33.3	204	365	296	8.77e-23	95.9
k141_82054_41	SARG|CAB61224	34.0	194	365	297	1.23e-22	95.5
k141_82054_41	SARG|ACP19238	32.4	204	365	296	4.29e-22	94.0
k141_82054_41	megares|MEG_7597|Drugs|Glycopeptide|VanA-type_accessory_protein|VANYA_1	32.4	204	365	296	4.29e-22	94.0
k141_82054_41	SARG|AAA65958	32.4	204	365	303	4.78e-22	94.0
k141_82054_41	SARG|gi|503204183|ref|WP_013438844.1|	32.4	204	365	303	4.78e-22	94.0
k141_82054_41	SARG|gi|309385867|gb|ADO66792.1|	32.4	204	365	305	4.92e-22	94.0
k141_27776_2	SARG|gi|445996710|ref|WP_000074565.1|	29.6	267	514	309	2.21e-22	96.7
k141_27776_2	SARG|gi|895808656|emb|COR83787.1|	29.6	267	514	309	3.00e-22	96.3
k141_27776_2	SARG|gi|445996719|ref|WP_000074574.1|	32.3	220	514	309	5.51e-22	95.5
k141_27776_2	SARG|gi|895736250|emb|COF64653.1|	29.6	267	514	309	5.51e-22	95.5
k141_27776_2	SARG|gi|445996714|ref|WP_000074569.1|	29.2	267	514	309	1.01e-21	94.7
k141_27776_2	SARG|gi|763399392|ref|WP_044256358.1|	29.5	234	514	648	1.29e-21	97.4
k141_27776_2	SARG|gi|446110087|ref|WP_000187942.1|	29.2	267	514	309	1.37e-21	94.4
k141_27776_2	SARG|gi|757782629|ref|WP_043001213.1|	28.6	231	514	648	1.72e-21	97.1
k141_27776_2	SARG|gi|992390012|ref|WP_061077002.1|	28.6	231	514	648	1.72e-21	97.1
k141_27776_2	SARG|gi|763407609|ref|WP_044264203.1|	28.6	231	514	648	1.72e-21	97.1
k141_27776_2	SARG|gi|754927849|ref|WP_042284850.1|	28.6	234	514	648	1.72e-21	97.1
k141_27776_2	SARG|gi|447057509|ref|WP_001134765.1|	30.6	222	514	309	1.86e-21	94.0
k141_27776_2	SARG|gi|968563772|ref|WP_058587854.1|	28.6	231	514	648	2.28e-21	96.7
k141_27776_2	SARG|gi|445996724|ref|WP_000074579.1|	32.3	220	514	309	2.52e-21	93.6
k141_27776_2	SARG|gi|507050365|ref|WP_016121371.1|	30.6	222	514	309	2.52e-21	93.6
k141_27776_2	SARG|gi|445996698|ref|WP_000074553.1|	26.9	271	514	309	2.52e-21	93.6
k141_27776_2	SARG|gi|445996722|ref|WP_000074577.1|	32.3	220	514	309	2.52e-21	93.6
k141_27776_2	SARG|gi|445996729|ref|WP_000074584.1|	28.8	267	514	309	3.41e-21	93.2
k141_27776_2	SARG|gi|1043490477|ref|WP_065382463.1|	31.8	220	514	309	3.41e-21	93.2
k141_27776_2	SARG|gi|445996726|ref|WP_000074581.1|	31.8	220	514	309	3.41e-21	93.2
k141_27776_2	SARG|gi|488053456|ref|WP_002124853.1|	30.6	222	514	309	3.41e-21	93.2
k141_27776_2	SARG|gi|884875933|emb|CKG93789.1|	32.3	220	514	309	3.41e-21	93.2
k141_27776_2	SARG|gi|445996723|ref|WP_000074578.1|	31.8	220	514	309	3.41e-21	93.2
k141_27776_2	SARG|gi|507054395|ref|WP_016125339.1|	31.8	220	514	309	3.41e-21	93.2
k141_27776_2	SARG|gi|488042066|ref|WP_002113463.1|	30.3	221	514	309	4.61e-21	92.8
k141_63054_12	CARD|gb|AAC75429.1|ARO:3000833|evgS	32.1	106	531	1197	8.95e-07	50.8
k141_926_24	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	28.1	199	261	578	2.54e-17	80.1
k141_926_30	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	46.4	220	233	255	1.95e-56	179
k141_926_30	SARG|gi|823326845|ref|WP_047080664.1|	46.2	221	233	648	7.12e-53	179
k141_926_30	SARG|gi|823302270|ref|WP_047057473.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|976146774|ref|WP_059305359.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|1022664304|ref|WP_063420886.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|823309640|ref|WP_047064288.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|505807117|ref|WP_015704872.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|518923394|ref|WP_020079269.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|695797094|ref|WP_032711285.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|823299155|ref|WP_047054544.1|	46.2	221	233	648	1.38e-52	178
k141_926_30	SARG|gi|695793471|ref|WP_032707680.1|	45.7	221	233	648	1.91e-52	178
k141_926_30	SARG|gi|1022688710|ref|WP_063443532.1|	45.2	221	233	648	3.69e-52	177
k141_926_30	SARG|gi|505180394|ref|WP_015367496.1|	45.7	221	233	648	5.13e-52	177
k141_926_30	SARG|gi|754927849|ref|WP_042284850.1|	45.2	221	233	648	2.65e-51	175
k141_926_30	SARG|gi|895898290|ref|WP_048999361.1|	45.2	221	233	646	4.99e-51	174
k141_926_30	SARG|gi|823291602|ref|WP_047047573.1|	45.2	221	233	648	5.10e-51	174
k141_926_30	SARG|gi|754964360|ref|WP_042320280.1|	44.8	221	233	648	5.10e-51	174
k141_926_30	SARG|gi|1033064422|ref|WP_064375412.1|	45.2	221	233	648	9.83e-51	173
k141_926_30	SARG|gi|757782629|ref|WP_043001213.1|	44.8	221	233	648	1.36e-50	173
k141_926_30	SARG|gi|763407609|ref|WP_044264203.1|	44.8	221	233	648	1.36e-50	173
k141_926_30	SARG|gi|742378414|ref|WP_038857601.1|	43.8	235	233	647	1.87e-50	172
k141_926_30	SARG|gi|992390012|ref|WP_061077002.1|	44.8	221	233	648	1.89e-50	172
k141_926_30	SARG|gi|764278838|ref|WP_044327089.1|	42.8	236	233	648	1.89e-50	172
k141_926_30	SARG|gi|817104523|ref|WP_046477871.1|	44.8	221	233	648	2.63e-50	172
k141_926_30	SARG|gi|968563772|ref|WP_058587854.1|	44.3	221	233	648	3.65e-50	172
k141_926_31	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	46.7	60	212	210	1.02e-08	52.4
k141_926_31	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	46.7	60	212	210	1.02e-08	52.4
k141_65781_37	NCBI|ACF30254.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	45.1	51	214	210	3.16e-07	48.1
k141_65781_37	NCBI|CAA81047.1|1|1|mtrR|mtrR|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_system_transcriptional_repressor_MtrR|AMR|efflux	45.1	51	214	210	3.16e-07	48.1
k141_65781_63	SARG|YP_001779894	54.7	53	198	212	3.03e-14	67.4
k141_65781_63	SARG|YP_002861121	51.0	51	198	212	8.09e-14	66.2
k141_65781_63	SARG|YP_001389621	52.8	53	198	212	8.09e-14	66.2
k141_65781_63	SARG|YP_001785579	52.8	53	198	212	1.55e-13	65.5
k141_65781_63	SARG|U19459.gene.p01	39.7	68	198	212	4.12e-13	64.3
k141_65781_63	SARG|AAF24171	34.9	109	198	214	2.81e-11	59.3
k141_65781_63	SARG|AF139725.gene.p01	33.9	109	198	214	5.34e-11	58.5
k141_65781_63	NCBI|WP_063856931.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	109	198	214	5.34e-11	58.5
k141_65781_63	NCBI|WP_063856932.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	109	198	214	5.34e-11	58.5
k141_65781_63	NCBI|WP_063856933.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	109	198	214	5.34e-11	58.5
k141_65781_63	NCBI|WP_063856934.1|1|1|vat(E)|vat(E)|acetyltransferase|2|STREPTOGRAMIN|STREPTOGRAMIN|streptogramin_A_O-acetyltransferase_Vat(E)|AMR|streptogramin	33.9	109	198	214	5.34e-11	58.5
k141_65781_63	SARG|AAG21695	33.9	109	198	214	5.34e-11	58.5
k141_65781_63	SARG|AAK91782	33.9	109	198	214	5.34e-11	58.5
k141_65781_63	SARG|gb|AAF63432|ARO:3003744|vatF	41.4	58	198	221	5.34e-10	55.8
k141_65781_63	SARG|AF015628.1.gene2.p01	37.3	67	198	212	9.18e-10	55.1
k141_65781_63	NCBI|KGT34314.1|1|1|catC|catC|acetyltransferase|1|CHLORAMPHENICOL|PHENICOL|type_C_phenicol_O-acetyltransferase|AMR|phenicol	34.9	83	198	219	9.86e-10	55.1
k141_65781_63	SARG|GQ205627.2.gene3.p01	30.4	138	198	216	7.73e-08	49.7
k141_8766_10	NCBI|WP_268871842.1|1|1|nimK|nimK||2|NITROIMIDAZOLE|NITROIMIDAZOLE|5-nitroimidazole_reductase_NimK|AMR|nitroimidazole	30.8	159	163	168	7.02e-11	56.6
k141_71306_19	SARG|gb|ADZ12699.1|ARO:3005091|RanA	29.2	250	331	258	3.01e-36	130
k141_71306_19	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	33.5	203	331	255	4.84e-31	116
k141_71306_19	SARG|gi|895865878|ref|WP_048974758.1|	36.3	226	331	646	5.36e-29	116
k141_71306_19	SARG|gb|AAK76136.1|ARO:3000025|patB	28.1	217	331	588	2.13e-15	75.9
k141_71306_19	SARG|gb|AYV52072.1|ARO:3002882|lmrD	26.8	220	331	664	5.47e-15	74.7
k141_71306_19	SARG|gb|CDO61516.1|ARO:3003949|efrB	27.5	200	331	362	5.74e-14	70.9
k141_71306_19	SARG|gb|APB03219.1|ARO:3003986|TaeA	28.1	221	331	648	1.39e-11	64.3
k141_71306_19	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	25.6	211	331	579	9.88e-11	61.6
k141_71306_19	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	25.5	216	331	579	1.32e-10	61.2
k141_71306_19	ResF|poxtA-Ef_1_WP094899500.1_1	20.5	146	331	538	8.64e-06	46.2
k141_71306_19	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	20.5	146	331	543	8.67e-06	46.2
k141_71306_19	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	20.5	146	331	543	8.67e-06	46.2
k141_109932_11	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	45.0	229	230	232	1.27e-69	212
k141_109932_11	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	45.0	229	230	232	1.27e-69	212
k141_109932_11	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	41.8	232	230	239	2.38e-66	204
k141_109932_11	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	41.9	229	230	229	3.50e-66	203
k141_109932_11	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	42.6	230	230	233	5.62e-66	202
k141_109932_11	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	43.6	227	230	231	7.48e-66	202
k141_109932_11	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.6	227	230	231	7.48e-66	202
k141_109932_11	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	43.3	224	230	232	1.55e-65	201
k141_109932_11	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.6	223	230	231	4.27e-65	200
k141_109932_11	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	42.4	231	230	235	4.83e-65	200
k141_109932_11	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.7	227	230	231	1.72e-64	199
k141_109932_11	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.7	227	230	231	9.79e-64	197
k141_109932_11	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.4	229	230	232	1.01e-63	197
k141_109932_11	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	41.9	227	230	231	3.94e-63	195
k141_109932_11	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.9	229	230	232	1.15e-62	194
k141_109932_11	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.9	229	230	232	1.15e-62	194
k141_109932_11	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.9	227	230	231	1.58e-62	194
k141_109932_11	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.9	229	230	232	1.63e-62	194
k141_109932_11	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.5	229	230	232	1.63e-62	194
k141_109932_11	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.5	229	230	232	3.28e-62	193
k141_109932_11	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	41.7	230	230	230	3.52e-61	190
k141_109932_11	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.5	227	230	231	4.72e-59	185
k141_109932_11	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.5	227	230	231	6.68e-59	184
k141_109932_11	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	38.8	227	230	231	9.46e-59	184
k141_109932_11	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	40.8	228	230	231	1.90e-58	183
k141_109932_12	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	31.0	287	806	365	1.05e-26	111
k141_109932_12	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.7	289	806	370	4.71e-23	100
k141_109932_12	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	26.4	242	806	381	2.98e-15	77.4
k141_109932_12	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	26.4	242	806	381	2.98e-15	77.4
k141_109932_12	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	25.7	296	806	381	1.67e-14	75.1
k141_109932_12	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	25.7	296	806	381	1.67e-14	75.1
k141_109932_12	CARD|gb|ABD30512.1|ARO:3000839|arlS	18.4	282	806	451	2.28e-08	56.2
k141_109932_15	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.6	227	257	575	1.29e-14	72.0
k141_109932_15	SARG|gi|1033151784|ref|WP_064457526.1|	28.2	206	257	614	3.24e-14	70.9
k141_109932_15	SARG|gi|987887954|ref|WP_060953374.1|	28.2	206	257	614	3.24e-14	70.9
k141_109932_15	SARG|gi|664304639|ref|WP_030834011.1|	28.2	206	257	614	3.24e-14	70.9
k141_109932_15	SARG|gi|1011069317|ref|WP_062010695.1|	28.2	206	257	614	3.24e-14	70.9
k141_109932_15	SARG|gi|1045390184|ref|WP_065479071.1|	27.5	204	257	605	7.91e-14	69.7
k141_109932_15	SARG|gi|664170108|ref|WP_030704355.1|	28.3	205	257	603	1.06e-13	69.3
k141_109932_15	SARG|gi|501350226|ref|WP_012381861.1|	28.3	205	257	603	1.06e-13	69.3
k141_109932_15	SARG|gi|490068471|ref|WP_003970646.1|	28.3	205	257	603	1.06e-13	69.3
k141_109932_15	SARG|gi|664042835|ref|WP_030582300.1|	27.3	205	257	604	1.94e-13	68.6
k141_109932_15	SARG|gi|497748188|ref|WP_010062372.1|	27.9	204	257	605	1.94e-13	68.6
k141_109932_15	SARG|gi|764446018|ref|WP_044369325.1|	27.0	204	257	605	2.61e-13	68.2
k141_109932_15	SARG|gi|662129758|ref|WP_030081404.1|	27.3	205	257	605	2.61e-13	68.2
k141_109932_15	SARG|gi|695887424|ref|WP_032788534.1|	27.0	204	257	605	3.52e-13	67.8
k141_109932_15	SARG|gi|664085850|ref|WP_030624018.1|	27.3	205	257	605	3.52e-13	67.8
k141_109932_15	SARG|gi|695865802|ref|WP_032778631.1|	27.0	204	257	605	3.52e-13	67.8
k141_109932_15	SARG|gi|664180077|ref|WP_030714054.1|	27.0	204	257	605	3.52e-13	67.8
k141_109932_15	SARG|gi|827013130|ref|WP_047175495.1|	27.3	205	257	603	4.73e-13	67.4
k141_109932_15	SARG|gi|663330365|ref|WP_030329892.1|	26.8	228	257	607	4.75e-13	67.4
k141_109932_15	SARG|gi|662175949|ref|WP_030118884.1|	27.5	204	257	605	6.38e-13	67.0
k141_109932_15	SARG|gi|663155409|ref|WP_030194633.1|	27.5	204	257	605	6.38e-13	67.0
k141_109932_15	SARG|gi|664538723|ref|WP_031054357.1|	27.5	204	257	605	6.38e-13	67.0
k141_109932_15	SARG|gi|695891735|ref|WP_032792824.1|	26.8	205	257	603	8.59e-13	66.6
k141_109932_15	SARG|gi|517787730|ref|WP_018957938.1|	27.3	205	257	610	8.63e-13	66.6
k141_109932_15	SARG|gi|913055317|ref|WP_050357634.1|	26.8	205	257	603	1.16e-12	66.2
k141_109932_26	SARG|gi|657888313|ref|WP_029592374.1|	52.8	246	239	648	7.82e-79	248
k141_109932_26	SARG|gi|696411918|ref|WP_032982657.1|	53.5	228	239	647	4.18e-78	246
k141_109932_26	SARG|gi|696402390|ref|WP_032974230.1|	54.5	224	239	647	5.87e-78	246
k141_109932_26	SARG|gi|696423952|ref|WP_032993748.1|	54.5	224	239	647	5.87e-78	246
k141_109932_26	SARG|gi|639225329|ref|WP_024561799.1|	55.4	224	239	648	8.42e-78	245
k141_109932_26	SARG|gi|639218559|ref|WP_024556062.1|	55.4	224	239	648	8.42e-78	245
k141_109932_26	SARG|gi|742378414|ref|WP_038857601.1|	54.5	224	239	647	3.20e-77	244
k141_109932_26	SARG|gi|506220920|ref|WP_015740695.1|	54.5	224	239	647	4.50e-77	243
k141_109932_26	SARG|gi|696420214|ref|WP_032990021.1|	54.0	224	239	647	6.31e-77	243
k141_109932_26	SARG|gi|565651791|ref|WP_023899061.1|	54.0	224	239	647	8.86e-77	243
k141_109932_26	SARG|YP_001438541	54.0	224	239	647	1.24e-76	242
k141_109932_26	SARG|gi|938461734|ref|WP_054625806.1|	54.0	224	239	647	1.24e-76	242
k141_109932_26	SARG|gi|938460528|ref|WP_054624864.1|	54.0	224	239	647	1.24e-76	242
k141_109932_26	SARG|gi|490522515|ref|WP_004387938.1|	54.0	224	239	647	1.24e-76	242
k141_109932_26	SARG|gi|495004199|ref|WP_007730213.1|	54.5	224	239	647	2.45e-76	241
k141_109932_26	SARG|gi|742409107|ref|WP_038888226.1|	54.5	224	239	647	2.45e-76	241
k141_109932_26	SARG|gi|494938585|ref|WP_007664615.1|	53.6	224	239	647	3.44e-76	241
k141_109932_26	SARG|gi|896325272|ref|WP_049294291.1|	54.5	224	239	648	3.51e-76	241
k141_109932_26	SARG|gi|1020141879|ref|WP_063264839.1|	53.6	224	239	647	4.83e-76	241
k141_109932_26	SARG|gi|504542119|ref|WP_014729221.1|	53.6	224	239	647	6.77e-76	240
k141_109932_26	SARG|gi|742384718|ref|WP_038863845.1|	54.0	224	239	647	9.51e-76	240
k141_109932_26	SARG|gi|639216333|ref|WP_024554080.1|	54.0	224	239	648	9.70e-76	240
k141_109932_26	SARG|gi|851928815|ref|WP_048221086.1|	53.4	221	239	648	1.36e-75	239
k141_109932_26	SARG|gi|780033092|ref|WP_045444768.1|	53.4	221	239	648	1.36e-75	239
k141_109932_26	SARG|gi|655997348|ref|WP_029038923.1|	53.6	224	239	647	1.87e-75	239
k141_109932_27	SARG|gi|488960346|ref|WP_002871376.1|	21.6	204	523	390	8.56e-12	65.9
k141_109932_27	SARG|gi|488943946|ref|WP_002855021.1|	21.6	204	523	390	1.14e-11	65.5
k141_109932_28	SARG|gb|AAV85982.1|ARO:3000535|macB	32.0	410	404	644	5.23e-43	158
k141_109932_28	SARG|YP_001438541	34.0	415	404	647	3.28e-41	153
k141_109932_28	SARG|gi|938460528|ref|WP_054624864.1|	34.0	415	404	647	3.28e-41	153
k141_109932_28	SARG|gi|506220920|ref|WP_015740695.1|	34.0	415	404	647	3.28e-41	153
k141_109932_28	SARG|gi|490522515|ref|WP_004387938.1|	34.0	415	404	647	3.28e-41	153
k141_109932_28	SARG|gi|495067432|ref|WP_007792257.1|	34.0	415	404	647	3.28e-41	153
k141_109932_28	SARG|gi|696420214|ref|WP_032990021.1|	34.0	415	404	647	3.28e-41	153
k141_109932_28	SARG|gi|938461734|ref|WP_054625806.1|	34.0	415	404	647	6.15e-41	152
k141_109932_28	SARG|gi|504542119|ref|WP_014729221.1|	33.7	415	404	647	1.15e-40	151
k141_109932_28	SARG|gi|1020141879|ref|WP_063264839.1|	33.7	415	404	647	2.16e-40	150
k141_109932_28	SARG|gi|655997348|ref|WP_029038923.1|	33.7	415	404	647	2.16e-40	150
k141_109932_28	SARG|gi|494938585|ref|WP_007664615.1|	33.5	415	404	647	2.16e-40	150
k141_109932_28	SARG|gi|554685678|ref|WP_023185565.1|	33.2	413	404	648	2.18e-40	150
k141_109932_28	SARG|gi|554689873|ref|WP_023186409.1|	33.4	413	404	648	2.99e-40	150
k141_109932_28	SARG|gi|446048048|ref|WP_000125903.1|	33.2	413	404	648	2.99e-40	150
k141_109932_28	SARG|gi|489039527|ref|WP_002949857.1|	33.4	413	404	648	2.99e-40	150
k141_109932_28	SARG|gi|446048047|ref|WP_000125902.1|	33.4	413	404	648	2.99e-40	150
k141_109932_28	SARG|gi|495004199|ref|WP_007730213.1|	33.5	415	404	647	4.06e-40	150
k141_109932_28	SARG|gi|742384718|ref|WP_038863845.1|	33.5	415	404	647	4.06e-40	150
k141_109932_28	SARG|gi|742409107|ref|WP_038888226.1|	33.5	415	404	647	4.06e-40	150
k141_109932_28	SARG|gi|896325272|ref|WP_049294291.1|	33.5	415	404	648	4.09e-40	150
k141_109932_28	SARG|gi|639216333|ref|WP_024554080.1|	33.5	415	404	648	4.09e-40	150
k141_109932_28	SARG|YP_001571041	33.2	413	404	648	7.65e-40	149
k141_109932_28	SARG|gi|960873409|ref|WP_058345546.1|	33.2	413	404	648	7.65e-40	149
k141_109932_28	SARG|gi|740610794|ref|WP_038396317.1|	33.2	413	404	648	7.65e-40	149
k141_96170_16	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	32.4	216	514	293	9.13e-25	103
k141_96170_16	SARG|gb|AAK76137.1|ARO:3000024|patA	25.9	220	514	564	1.04e-08	56.6
k141_57846_2	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	44.9	1026	1050	1033	0.0	925
k141_57846_2	SARG|gb|AEY83581|ARO:3000510|mupB	44.9	1026	1050	1033	0.0	925
k141_57846_2	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	44.0	1019	1050	1024	1.87e-319	910
k141_57846_2	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.0	1019	1050	1024	1.87e-319	910
k141_57846_2	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	44.0	1012	1050	1024	9.40e-317	903
k141_57846_2	SARG|gb|CAA53189|ARO:3000521|mupA	44.0	1012	1050	1024	9.40e-317	903
k141_57846_2	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	35.8	1110	1050	1107	5.88e-218	652
k141_57846_2	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	35.8	1110	1050	1107	5.88e-218	652
k141_52611_5	NCBI|WP_005480402.1|1|1|tet(35)|tet(35)|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_Na+/H+_antiporter_family_transporter_Tet(35)|AMR|tetracycline	40.8	505	515	533	2.54e-102	316
k141_52611_5	SARG|AF353562.gene.p01	37.4	348	515	369	2.10e-55	189
k141_52611_26	NCBI|CCA59315.1|1|1|helR|helR||1|rifamycin|rifamycin|RNA_polymerase_recycling_motor_ATPase_HelR|AMR|rifamycin	26.8	194	1029	722	1.11e-13	74.3
k141_52611_30	SARG|YP_001186705	26.1	1013	1020	1017	1.83e-75	268
k141_52611_30	SARG|YP_350221	24.1	1018	1020	1009	3.44e-72	258
k141_52611_30	SARG|YP_001670703	24.1	1017	1020	1014	4.90e-72	258
k141_52611_30	SARG|YP_001266290	24.2	1006	1020	1014	8.98e-72	257
k141_52611_30	SARG|YP_001350280	25.1	1008	1020	1018	1.26e-71	256
k141_52611_30	SARG|YP_792720	24.9	1008	1020	1018	1.71e-71	256
k141_52611_30	SARG|AAG07763	24.9	1008	1020	1018	1.71e-71	256
k141_52611_30	SARG|CAY51926	23.6	1026	1020	1008	3.56e-69	249
k141_52611_30	SARG|YP_606823	23.8	1020	1020	1011	1.81e-67	244
k141_52611_30	SARG|gb|CAH14033.1|ARO:3004100|LpeB	24.5	1016	1020	1014	1.46e-62	229
k141_52611_30	SARG|YP_371056	22.6	1038	1020	1066	1.65e-57	214
k141_52611_30	SARG|YP_838977	22.5	1038	1020	1061	3.82e-57	213
k141_52611_30	SARG|CAR56416	22.5	1038	1020	1066	5.20e-57	213
k141_52611_30	SARG|YP_001811890	22.6	1038	1020	1066	9.23e-57	212
k141_52611_30	SARG|ZP_02889083	22.6	1038	1020	1071	1.25e-56	212
k141_52611_30	NCBI|AAN33534.1|1|1|bepG|bepG|efflux|1|EFFLUX|EFFLUX|multidrug_efflux_RND_transporter_permease_subunit_BepG|AMR|efflux	23.8	1041	1020	1074	2.25e-56	211
k141_52611_30	SARG|YP_001116031	22.4	1038	1020	1066	3.87e-56	210
k141_52611_30	SARG|YP_776582	22.5	1038	1020	1071	5.25e-56	210
k141_52611_30	SARG|gi|487969243|ref|WP_002042236.1|	23.5	1047	1020	1031	1.05e-55	209
k141_52611_30	SARG|gi|565648659|ref|WP_023896298.1|	23.5	1047	1020	1031	1.40e-55	208
k141_52611_30	SARG|gi|505264501|ref|WP_015451603.1|	23.5	1047	1020	1031	2.48e-55	207
k141_52611_30	SARG|gi|446871990|ref|WP_000949246.1|	23.5	1047	1020	1031	2.48e-55	207
k141_52611_30	SARG|NC_011595.7057907.p01	23.4	1047	1020	1031	2.48e-55	207
k141_52611_30	SARG|gi|490805434|ref|WP_004667559.1|	23.2	1073	1020	1063	2.83e-55	207
k141_52611_30	SARG|gi|929551065|ref|WP_054089584.1|	23.2	1073	1020	1063	3.77e-55	207
k141_49928_13	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	30.3	271	476	370	2.69e-25	105
k141_49928_13	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	29.8	258	476	365	8.59e-25	104
k141_49928_13	megares|MEG_7507|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	215	476	381	1.12e-21	95.5
k141_49928_13	NCBI|WP_063856738.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	215	476	381	1.12e-21	95.5
k141_49928_13	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.5	221	476	381	1.52e-21	95.1
k141_49928_13	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.5	221	476	381	1.52e-21	95.1
k141_49928_13	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.3	215	476	381	3.73e-21	94.0
k141_49928_13	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.3	215	476	381	3.73e-21	94.0
k141_49928_13	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.3	215	476	381	3.01e-20	91.3
k141_49928_13	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.3	215	476	381	3.01e-20	91.3
k141_49928_13	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.7	212	476	367	9.33e-19	86.7
k141_49928_13	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	29.7	212	476	368	9.42e-19	86.7
k141_49928_13	NCBI|WP_011461302.1|1|1|vanS-I|vanS-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-I|AMR|glycopeptide	26.0	242	476	392	5.04e-18	84.7
k141_49928_13	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	28.1	228	476	380	2.67e-17	82.4
k141_49928_13	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	28.1	228	476	380	2.67e-17	82.4
k141_49928_13	NCBI|WP_063856734.1|1|1|vanS-E|vanS-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-E|AMR|glycopeptide	25.8	244	476	357	2.96e-17	82.0
k141_49928_13	megares|MEG_7511|Drugs|Glycopeptide|VanE-type_regulator|VANSE_1	25.8	244	476	357	2.96e-17	82.0
k141_49928_13	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	26.6	233	476	364	5.92e-16	78.2
k141_49928_13	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	26.6	233	476	364	5.92e-16	78.2
k141_49928_13	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	26.2	244	476	382	9.21e-15	74.7
k141_49928_13	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	26.2	244	476	382	9.21e-15	74.7
k141_49928_13	CARD|gb|CYF42523.1|ARO:3004047|kdpD	27.2	232	476	885	5.25e-14	73.6
k141_49928_13	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	25.0	244	476	384	5.28e-14	72.4
k141_49928_13	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	25.0	244	476	384	5.28e-14	72.4
k141_49928_13	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.0	244	476	386	7.13e-14	72.0
k141_49928_14	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	39.1	225	218	231	8.85e-48	155
k141_49928_14	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	36.4	225	218	232	1.83e-44	147
k141_49928_14	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.1	227	218	231	3.56e-44	146
k141_49928_14	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	36.0	228	218	229	6.72e-44	145
k141_49928_14	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	37.7	231	218	235	3.15e-43	144
k141_49928_14	CARD|gb|ATC67679.1|ARO:3000838|arlR	35.9	217	218	219	3.21e-42	141
k141_49928_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	36.7	218	218	228	4.12e-42	141
k141_49928_14	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.9	227	218	231	4.47e-42	141
k141_49928_14	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.9	227	218	231	8.90e-42	140
k141_49928_14	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	33.9	227	218	231	8.90e-42	140
k141_49928_14	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.7	216	218	219	2.55e-41	139
k141_49928_14	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.7	216	218	220	2.62e-41	139
k141_49928_14	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	35.8	229	218	233	3.73e-41	139
k141_49928_14	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.7	216	218	220	7.38e-41	137
k141_49928_14	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.3	216	218	219	2.02e-40	136
k141_49928_14	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	34.8	227	218	231	3.94e-40	136
k141_49928_14	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.8	227	218	231	3.94e-40	136
k141_49928_14	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	34.7	216	218	220	5.84e-40	135
k141_49928_14	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.2	229	218	232	3.19e-39	134
k141_49928_14	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	33.2	229	218	230	8.51e-39	132
k141_49928_14	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.8	229	218	232	1.78e-38	132
k141_49928_14	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.8	227	218	231	2.45e-38	131
k141_49928_14	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.8	229	218	232	2.52e-38	131
k141_49928_14	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.8	229	218	232	5.00e-38	130
k141_49928_14	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.8	227	218	231	6.87e-38	130
k141_79877_5	SARG|gi|643601187|ref|WP_025237288.1|	41.2	233	336	648	7.58e-45	161
k141_79877_5	SARG|gi|974628291|ref|WP_059215695.1|	41.2	233	336	648	7.58e-45	161
k141_79877_5	SARG|gi|446110298|ref|WP_000188153.1|	41.2	233	336	648	7.58e-45	161
k141_79877_5	SARG|gi|974633183|ref|WP_059219858.1|	41.2	233	336	648	7.58e-45	161
k141_79877_5	SARG|gi|974684692|ref|WP_059267998.1|	41.2	233	336	648	7.58e-45	161
k141_79877_5	SARG|gi|974672242|ref|WP_059256507.1|	41.2	233	336	648	1.05e-44	160
k141_79877_5	SARG|gi|974641719|ref|WP_059227752.1|	41.2	233	336	648	1.05e-44	160
k141_79877_5	SARG|gi|446110299|ref|WP_000188154.1|	41.2	233	336	648	1.05e-44	160
k141_79877_5	SARG|ZP_02903696	41.2	233	336	648	1.05e-44	160
k141_79877_5	SARG|gi|974688082|ref|WP_059271287.1|	41.2	233	336	648	1.05e-44	160
k141_79877_5	SARG|gi|545254099|ref|WP_021550525.1|	37.5	261	336	648	2.74e-44	159
k141_79877_5	SARG|gi|974652669|ref|WP_059238406.1|	41.2	233	336	648	2.74e-44	159
k141_79877_5	SARG|gi|446110277|ref|WP_000188132.1|	37.2	261	336	648	3.77e-44	159
k141_79877_5	SARG|gi|446110301|ref|WP_000188156.1|	39.7	234	336	648	3.77e-44	159
k141_79877_5	SARG|gi|693057297|ref|WP_032225054.1|	37.2	261	336	648	7.16e-44	158
k141_79877_5	SARG|gi|749017716|ref|WP_040076354.1|	40.0	240	336	646	9.68e-44	158
k141_79877_5	SARG|gi|550712535|ref|WP_022645444.1|	39.3	234	336	648	9.86e-44	158
k141_79877_5	SARG|gi|919943616|ref|WP_052915800.1|	39.3	234	336	648	9.86e-44	158
k141_79877_5	SARG|gi|446110295|ref|WP_000188150.1|	39.7	234	336	648	9.86e-44	158
k141_79877_5	SARG|gi|446110333|ref|WP_000188188.1|	39.3	234	336	648	9.86e-44	158
k141_79877_5	SARG|gi|486425021|ref|WP_001614493.1|	39.7	234	336	648	9.86e-44	158
k141_79877_5	SARG|gi|486420890|ref|WP_001612725.1|	38.9	234	336	648	9.86e-44	158
k141_79877_5	SARG|gi|754697027|ref|WP_042073841.1|	39.7	234	336	648	1.36e-43	157
k141_79877_5	SARG|A1A9B7	39.7	234	336	648	1.36e-43	157
k141_79877_5	SARG|gi|545231548|ref|WP_021531156.1|	39.7	234	336	648	1.36e-43	157
k141_79877_37	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.4	823	880	1024	4.31e-65	235
k141_79877_37	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.4	823	880	1024	4.31e-65	235
k141_79877_37	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.4	823	880	1024	1.44e-64	234
k141_79877_37	SARG|gb|CAA53189|ARO:3000521|mupA	24.4	823	880	1024	1.44e-64	234
k141_44748_11	SARG|gi|516510995|ref|WP_017899433.1|	39.4	221	255	646	3.10e-38	140
k141_44748_11	SARG|gi|1031822889|ref|WP_064150402.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|490306253|ref|WP_004201358.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|950164608|ref|WP_057214157.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|694113305|ref|WP_032455256.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|764951644|ref|WP_044521907.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|896073592|ref|WP_049116987.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|927316447|ref|WP_053810605.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|556468297|ref|WP_023320056.1|	39.4	221	255	646	4.26e-38	139
k141_44748_11	SARG|gi|895903124|ref|WP_049003730.1|	39.4	221	255	646	5.85e-38	139
k141_44748_11	SARG|gi|1039430674|ref|WP_064794447.1|	39.4	221	255	646	8.03e-38	139
k141_44748_11	SARG|gi|1016069923|ref|WP_062914571.1|	39.4	221	255	646	1.51e-37	138
k141_44748_11	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	35.7	230	255	255	1.07e-36	129
k141_44748_11	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	238	255	655	7.09e-18	81.6
k141_44748_11	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	238	255	655	7.09e-18	81.6
k141_44748_11	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	27.7	238	255	655	9.58e-18	81.3
k141_44748_24	SARG|gb|WP_104671188.1|ARO:3003948|efrA	38.2	550	582	575	1.07e-119	365
k141_44748_24	SARG|gb|AAK76137.1|ARO:3000024|patA	32.8	570	582	564	3.81e-90	288
k141_44748_24	SARG|gb|AAC74000.1|ARO:3003950|msbA	27.2	580	582	582	4.53e-64	219
k141_44748_24	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	28.1	583	582	579	8.20e-61	210
k141_44748_24	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	29.6	584	582	579	2.19e-60	209
k141_44748_24	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	31.8	471	582	579	3.04e-60	209
k141_44748_24	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	30.6	470	582	579	3.04e-60	209
k141_44748_24	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.7	501	582	664	4.44e-57	202
k141_44748_24	SARG|gi|919568551|ref|WP_052871170.1|	28.1	534	582	620	1.07e-55	197
k141_44748_24	SARG|gi|917229923|ref|WP_051836635.1|	27.9	534	582	620	1.48e-55	197
k141_44748_24	SARG|gi|926351744|ref|WP_053683383.1|	27.9	534	582	648	2.28e-55	197
k141_44748_24	SARG|gb|AAK76136.1|ARO:3000025|patB	26.9	591	582	588	2.30e-55	196
k141_44748_24	SARG|gi|917166849|ref|WP_051773561.1|	28.4	536	582	620	7.43e-55	195
k141_44748_24	SARG|gi|917155568|ref|WP_051762280.1|	28.4	536	582	620	1.03e-54	194
k141_44748_24	SARG|gi|921231571|ref|WP_053176464.1|	27.9	534	582	620	1.03e-54	194
k141_44748_24	SARG|gi|917172177|ref|WP_051778889.1|	27.9	534	582	620	1.41e-54	194
k141_44748_24	SARG|gi|648667297|ref|WP_026359044.1|	26.4	579	582	605	7.69e-54	192
k141_44748_24	SARG|gi|917203192|ref|WP_051809904.1|	28.0	536	582	620	9.73e-54	192
k141_44748_24	SARG|gi|860594225|ref|WP_048475168.1|	27.0	571	582	620	1.85e-53	191
k141_44748_24	SARG|gi|695887424|ref|WP_032788534.1|	27.1	538	582	605	2.02e-53	191
k141_44748_24	SARG|gi|926376632|ref|WP_053705806.1|	27.5	534	582	620	3.51e-53	190
k141_44748_24	SARG|gi|1045390184|ref|WP_065479071.1|	26.8	541	582	605	3.84e-53	190
k141_44748_24	SARG|gi|695865802|ref|WP_032778631.1|	27.0	538	582	605	5.30e-53	189
k141_44748_24	SARG|gi|917127754|ref|WP_051734466.1|	26.3	566	582	620	6.67e-53	189
k141_44748_24	SARG|gi|926294973|ref|WP_053631154.1|	27.3	534	582	620	6.67e-53	189
k141_44748_25	SARG|gb|AAK76136.1|ARO:3000025|patB	34.6	578	581	588	2.09e-105	328
k141_44748_25	SARG|gb|AYV52072.1|ARO:3002882|lmrD	37.7	509	581	664	2.28e-99	315
k141_44748_25	SARG|gb|CDO61516.1|ARO:3003949|efrB	43.8	333	581	362	1.17e-88	277
k141_44748_25	SARG|gi|944009777|ref|WP_055601444.1|	32.8	580	581	628	1.65e-85	277
k141_44748_25	SARG|gi|860594225|ref|WP_048475168.1|	32.3	576	581	620	3.75e-85	276
k141_44748_25	SARG|gi|944152509|ref|WP_055644808.1|	32.2	580	581	616	3.61e-84	273
k141_44748_25	SARG|gi|926376632|ref|WP_053705806.1|	32.5	576	581	620	1.09e-83	272
k141_44748_25	SARG|gi|947982677|ref|WP_056642336.1|	32.2	580	581	626	1.75e-83	272
k141_44748_25	SARG|gi|639892676|ref|WP_024755698.1|	32.2	580	581	631	1.96e-83	272
k141_44748_25	SARG|gi|917172177|ref|WP_051778889.1|	31.9	576	581	620	5.83e-83	270
k141_44748_25	SARG|gi|917166849|ref|WP_051773561.1|	31.8	576	581	620	8.16e-83	270
k141_44748_25	SARG|gi|917127754|ref|WP_051734466.1|	32.1	576	581	620	8.16e-83	270
k141_44748_25	SARG|gi|926294973|ref|WP_053631154.1|	32.1	576	581	620	8.16e-83	270
k141_44748_25	SARG|gi|917155568|ref|WP_051762280.1|	31.8	576	581	620	1.14e-82	270
k141_44748_25	SARG|gi|917229923|ref|WP_051836635.1|	32.1	576	581	620	1.14e-82	270
k141_44748_25	SARG|gi|926356413|ref|WP_053687351.1|	32.1	576	581	620	1.14e-82	270
k141_44748_25	SARG|gi|799286378|ref|WP_045936958.1|	32.1	576	581	620	1.14e-82	270
k141_44748_25	SARG|gi|921231571|ref|WP_053176464.1|	31.9	576	581	620	1.60e-82	269
k141_44748_25	SARG|gi|926345639|ref|WP_053677539.1|	32.1	576	581	620	1.60e-82	269
k141_44748_25	SARG|gi|928900436|ref|WP_053931243.1|	30.7	576	581	600	2.75e-82	268
k141_44748_25	SARG|gi|664579989|ref|WP_031094015.1|	30.7	576	581	601	2.81e-82	268
k141_44748_25	SARG|gi|496018010|ref|WP_008742581.1|	32.5	544	581	623	3.35e-82	268
k141_44748_25	SARG|gi|772774655|ref|WP_045322518.1|	31.9	576	581	620	4.37e-82	268
k141_44748_25	SARG|gi|917203192|ref|WP_051809904.1|	31.9	576	581	620	6.12e-82	268
k141_44748_25	SARG|gi|919568551|ref|WP_052871170.1|	31.8	576	581	620	6.12e-82	268
k141_44748_30	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.0	579	586	582	1.21e-95	303
k141_44748_30	SARG|gi|926351744|ref|WP_053683383.1|	30.8	575	586	648	9.31e-89	286
k141_44748_30	SARG|gi|917203192|ref|WP_051809904.1|	29.8	571	586	620	2.58e-88	285
k141_44748_30	SARG|gi|860594225|ref|WP_048475168.1|	29.8	571	586	620	2.58e-88	285
k141_44748_30	SARG|gi|497748188|ref|WP_010062372.1|	29.3	567	586	605	6.92e-88	283
k141_44748_30	SARG|gi|919568551|ref|WP_052871170.1|	30.4	575	586	620	7.10e-88	283
k141_44748_30	SARG|gi|926376632|ref|WP_053705806.1|	29.8	571	586	620	7.10e-88	283
k141_44748_30	SARG|gi|917127754|ref|WP_051734466.1|	29.8	571	586	620	9.95e-88	283
k141_44748_30	SARG|gi|799286378|ref|WP_045936958.1|	29.8	571	586	620	1.39e-87	283
k141_44748_30	SARG|gi|926294973|ref|WP_053631154.1|	29.8	571	586	620	1.39e-87	283
k141_44748_30	SARG|gi|496018010|ref|WP_008742581.1|	30.4	573	586	623	1.50e-87	283
k141_44748_30	SARG|gi|695887424|ref|WP_032788534.1|	29.3	567	586	605	1.90e-87	282
k141_44748_30	SARG|gi|1045390184|ref|WP_065479071.1|	28.9	567	586	605	1.90e-87	282
k141_44748_30	SARG|gi|926356413|ref|WP_053687351.1|	29.8	571	586	620	1.95e-87	282
k141_44748_30	SARG|gi|926345639|ref|WP_053677539.1|	29.8	571	586	620	1.95e-87	282
k141_44748_30	SARG|gi|664100597|ref|WP_030638327.1|	29.6	571	586	601	2.42e-87	281
k141_44748_30	SARG|gi|917229923|ref|WP_051836635.1|	30.4	575	586	620	3.84e-87	281
k141_44748_30	SARG|gi|921231571|ref|WP_053176464.1|	30.1	575	586	620	3.84e-87	281
k141_44748_30	SARG|gi|928900436|ref|WP_053931243.1|	29.2	571	586	600	4.64e-87	281
k141_44748_30	SARG|gi|662754041|ref|WP_030125200.1|	29.9	571	586	601	4.76e-87	281
k141_44748_30	SARG|gi|664579989|ref|WP_031094015.1|	29.2	571	586	601	4.76e-87	281
k141_44748_30	SARG|gi|917172177|ref|WP_051778889.1|	30.1	575	586	620	5.37e-87	281
k141_44748_30	SARG|gi|917155568|ref|WP_051762280.1|	29.9	571	586	620	5.37e-87	281
k141_44748_30	SARG|gi|1033217078|gb|OAR27197.1|	29.5	567	586	601	6.67e-87	280
k141_44748_30	SARG|gi|503923650|ref|WP_014157644.1|	29.4	571	586	601	6.67e-87	280
k141_52854_3	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.0	112	337	219	1.47e-07	50.4
k141_52854_3	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	23.6	110	337	228	4.16e-06	46.2
k141_52854_3	CARD|gb|BAB36671.1|ARO:3000832|evgA	24.8	121	337	204	4.55e-06	45.8
k141_58018_58	SARG|YP_302230	22.0	387	459	451	9.07e-30	119
k141_58018_58	SARG|gi|537465183|ref|WP_020976941.1|	22.4	379	459	451	4.27e-29	117
k141_58018_58	SARG|gi|446573707|ref|WP_000651053.1|	22.7	379	459	451	4.27e-29	117
k141_58018_58	SARG|gi|565830932|ref|WP_023914633.1|	22.4	379	459	451	7.92e-29	117
k141_58018_58	SARG|gi|686334333|ref|WP_031881350.1|	22.4	379	459	451	1.47e-28	116
k141_58018_58	SARG|gi|763462741|ref|WP_044292157.1|	22.4	379	459	451	1.47e-28	116
k141_58018_58	SARG|Q2G140	22.4	379	459	451	1.47e-28	116
k141_58018_58	SARG|gi|757671144|ref|WP_042903632.1|	22.4	379	459	451	2.00e-28	115
k141_58018_58	SARG|gi|446573710|ref|WP_000651056.1|	22.7	379	459	451	2.00e-28	115
k141_58018_58	SARG|gi|686390606|ref|WP_031905637.1|	22.4	379	459	451	2.00e-28	115
k141_58018_58	SARG|gi|686329335|ref|WP_031878923.1|	22.7	379	459	451	2.00e-28	115
k141_58018_58	SARG|gi|486215009|ref|WP_001556470.1|	22.4	379	459	451	2.00e-28	115
k141_58018_58	SARG|gi|686123390|ref|WP_031769354.1|	22.4	379	459	451	2.72e-28	115
k141_58018_58	SARG|gi|686309117|ref|WP_031870179.1|	22.7	379	459	451	2.72e-28	115
k141_58018_58	SARG|gi|686294396|ref|WP_031862836.1|	22.4	379	459	451	2.72e-28	115
k141_58018_58	SARG|gi|686113687|ref|WP_031764317.1|	22.4	379	459	451	2.72e-28	115
k141_58018_58	SARG|gi|727749287|ref|WP_033861814.1|	22.4	379	459	451	2.72e-28	115
k141_58018_58	SARG|gi|486285962|ref|WP_001572033.1|	22.4	379	459	451	3.69e-28	115
k141_58018_58	SARG|gi|686448604|ref|WP_031928572.1|	22.2	379	459	451	3.69e-28	115
k141_58018_58	SARG|gi|686309068|ref|WP_031870147.1|	22.4	379	459	451	3.69e-28	115
k141_58018_58	SARG|gi|487138435|ref|WP_001629863.1|	22.4	379	459	451	3.69e-28	115
k141_58018_58	SARG|gi|446573690|ref|WP_000651036.1|	22.2	379	459	451	5.02e-28	114
k141_58018_58	SARG|gi|686319982|ref|WP_031875468.1|	22.4	379	459	451	5.02e-28	114
k141_58018_58	SARG|Q99WP2	22.4	379	459	451	5.02e-28	114
k141_58018_58	SARG|gi|516415429|ref|WP_017804827.1|	22.4	379	459	451	5.02e-28	114
k141_58018_59	SARG|gi|488156254|ref|WP_002227462.1|	22.5	418	462	459	1.65e-16	80.5
k141_58018_59	NCBI|EFF39147.1|1|1|norM-NG|norM-NG|efflux|1|EFFLUX|EFFLUX|sodium-coupled_multidrug_efflux_MATE_transporter_NorM|AMR|efflux	22.7	415	462	459	2.93e-16	79.7
k141_58018_59	SARG|NC_011035.1.6448920.p01	22.7	415	462	459	2.93e-16	79.7
k141_58018_59	SARG|gi|488158065|ref|WP_002229273.1|	22.6	411	462	459	6.93e-16	78.6
k141_58018_74	CARD|gb|AAN28945.1|ARO:3003785|Ctra_murA_FOF	32.5	434	430	444	3.94e-59	198
k141_41712_9	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.9	232	220	232	8.73e-46	150
k141_41712_9	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.9	232	220	232	8.73e-46	150
k141_41712_9	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	39.0	231	220	232	1.39e-44	147
k141_41712_9	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.6	232	220	235	3.00e-44	147
k141_41712_9	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.8	229	220	229	5.08e-44	146
k141_41712_9	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.6	234	220	232	3.10e-43	144
k141_41712_9	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.0	230	220	232	1.23e-42	142
k141_41712_9	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	37.7	223	220	231	2.39e-42	142
k141_41712_9	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.0	230	220	232	2.46e-42	142
k141_41712_9	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.0	230	220	232	3.47e-42	141
k141_41712_9	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.0	230	220	232	4.90e-42	141
k141_41712_9	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.0	229	220	231	6.73e-42	140
k141_41712_9	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	220	231	6.73e-42	140
k141_41712_9	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.0	229	220	231	9.50e-42	140
k141_41712_9	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.7	218	220	219	3.84e-41	138
k141_41712_9	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	36.4	228	220	231	1.50e-40	137
k141_41712_9	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.6	229	220	231	1.50e-40	137
k141_41712_9	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	36.2	229	220	233	1.58e-40	137
k141_41712_9	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.8	220	220	219	4.29e-40	135
k141_41712_9	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	36.6	235	220	239	5.20e-40	136
k141_41712_9	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	220	220	219	1.70e-39	134
k141_41712_9	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	35.0	223	220	232	1.71e-39	134
k141_41712_9	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	220	220	220	1.75e-39	134
k141_41712_9	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	36.4	220	220	220	2.47e-39	134
k141_41712_9	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	35.2	219	220	228	1.21e-38	132
k141_93450_14	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	31.8	311	320	323	1.53e-27	108
k141_93450_14	SARG|gi|552942232|ref|WP_023043160.1|	31.3	304	320	323	2.07e-26	105
k141_93450_14	SARG|AY082011.1.gene6.p01	30.9	304	320	323	1.45e-25	103
k141_93450_14	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	29.0	303	320	337	1.80e-25	103
k141_93450_14	SARG|KF478993.1.gene2.p01	27.1	310	320	350	4.11e-25	102
k141_52922_18	SARG|gb|AAK76136.1|ARO:3000025|patB	32.7	611	641	588	2.57e-98	311
k141_52922_18	SARG|gb|AYV52072.1|ARO:3002882|lmrD	33.5	546	641	664	9.66e-91	294
k141_52922_18	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	31.2	616	641	579	1.88e-89	288
k141_52922_18	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	31.7	618	641	579	1.50e-87	283
k141_52922_18	SARG|gb|AET10445.1|ARO:3004033|tetB(46)	32.6	622	641	578	3.20e-85	277
k141_52922_18	SARG|gi|664556405|ref|WP_031071225.1|	32.4	531	641	602	1.13e-84	276
k141_52922_18	SARG|gi|944009777|ref|WP_055601444.1|	32.1	533	641	628	1.11e-83	274
k141_52922_18	SARG|gi|695887424|ref|WP_032788534.1|	32.6	530	641	605	1.77e-83	273
k141_52922_18	SARG|gi|664180077|ref|WP_030714054.1|	32.5	530	641	605	3.46e-83	272
k141_52922_18	SARG|gi|497748188|ref|WP_010062372.1|	32.3	530	641	605	6.76e-83	271
k141_52922_18	SARG|gi|1033217078|gb|OAR27197.1|	32.7	535	641	601	1.20e-82	271
k141_52922_18	SARG|gi|764446018|ref|WP_044369325.1|	32.3	530	641	605	2.58e-82	270
k141_52922_18	SARG|gi|951183771|ref|WP_057661487.1|	32.3	535	641	603	3.44e-82	270
k141_52922_18	SARG|gi|695891735|ref|WP_032792824.1|	32.3	535	641	603	4.81e-82	269
k141_52922_18	SARG|gi|695865802|ref|WP_032778631.1|	32.3	530	641	605	5.04e-82	269
k141_52922_18	SARG|gi|947982677|ref|WP_056642336.1|	32.3	541	641	626	5.88e-82	270
k141_52922_18	SARG|gi|944152509|ref|WP_055644808.1|	32.3	541	641	616	6.52e-82	269
k141_52922_18	SARG|gi|639892676|ref|WP_024755698.1|	32.3	541	641	631	6.59e-82	270
k141_52922_18	SARG|gi|505420018|ref|WP_015607120.1|	32.6	530	641	603	9.39e-82	268
k141_52922_18	SARG|gi|663330365|ref|WP_030329892.1|	32.3	535	641	607	1.44e-81	268
k141_52922_18	SARG|gi|913055317|ref|WP_050357634.1|	32.1	535	641	603	1.83e-81	268
k141_52922_18	SARG|gb|CDO61516.1|ARO:3003949|efrB	38.4	378	641	362	3.33e-81	259
k141_52922_18	SARG|gi|928900436|ref|WP_053931243.1|	31.7	526	641	600	3.34e-81	267
k141_52922_18	SARG|gi|664579989|ref|WP_031094015.1|	31.7	526	641	601	3.42e-81	267
k141_52922_18	SARG|gi|695842130|ref|WP_032755430.1|	32.5	530	641	603	3.58e-81	267
k141_52922_19	SARG|gb|WP_104671188.1|ARO:3003948|efrA	35.2	543	584	575	6.69e-108	334
k141_52922_19	SARG|gb|AAK76137.1|ARO:3000024|patA	35.6	570	584	564	3.27e-105	327
k141_52922_19	SARG|gb|AAK76136.1|ARO:3000025|patB	30.2	486	584	588	1.94e-67	228
k141_52922_19	SARG|gb|AYV52072.1|ARO:3002882|lmrD	28.4	486	584	664	1.59e-64	222
k141_52922_19	SARG|gb|CDO61516.1|ARO:3003949|efrB	36.1	332	584	362	1.05e-62	209
k141_52922_19	SARG|gi|943938624|ref|WP_055567802.1|	42.0	264	584	602	6.59e-59	206
k141_52922_19	SARG|gi|748767925|ref|WP_040019608.1|	42.4	269	584	623	9.49e-59	206
k141_52922_19	SARG|gi|943909899|ref|WP_055545300.1|	29.3	540	584	601	1.24e-58	205
k141_52922_19	SARG|gi|517347347|ref|WP_018522839.1|	41.0	278	584	601	3.29e-58	204
k141_52922_19	SARG|gi|516795764|ref|WP_018105258.1|	28.8	548	584	601	3.29e-58	204
k141_52922_19	SARG|gi|664556405|ref|WP_031071225.1|	42.4	264	584	602	6.42e-58	203
k141_52922_19	SARG|gi|926400371|ref|WP_053728483.1|	41.8	263	584	603	6.53e-58	203
k141_52922_19	SARG|gi|1045390184|ref|WP_065479071.1|	28.7	529	584	605	9.36e-58	202
k141_52922_19	SARG|gi|944470764|ref|WP_055701183.1|	29.6	540	584	601	1.21e-57	202
k141_52922_19	SARG|gi|648667297|ref|WP_026359044.1|	29.1	540	584	605	1.30e-57	202
k141_52922_19	SARG|gi|655401130|ref|WP_028800283.1|	43.0	258	584	599	1.61e-57	202
k141_52922_19	SARG|gi|493394434|ref|WP_006350564.1|	28.9	544	584	602	1.70e-57	202
k141_52922_19	SARG|gi|501350226|ref|WP_012381861.1|	28.7	533	584	603	2.39e-57	201
k141_52922_19	SARG|gi|516574297|ref|WP_017949361.1|	41.7	264	584	620	4.41e-57	201
k141_52922_19	SARG|gi|497748188|ref|WP_010062372.1|	28.7	537	584	605	4.74e-57	201
k141_52922_19	SARG|gi|948137056|ref|WP_056795395.1|	41.3	269	584	602	6.23e-57	200
k141_52922_19	SARG|gi|664395661|ref|WP_030922045.1|	40.6	278	584	601	8.47e-57	200
k141_52922_19	SARG|gi|1011969930|ref|WP_062776015.1|	28.9	540	584	601	1.17e-56	199
k141_52922_19	SARG|gi|664170108|ref|WP_030704355.1|	28.5	533	584	603	1.21e-56	199
k141_52922_19	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.6	586	584	579	1.52e-56	199
k141_52922_41	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	24.7	829	892	1024	1.04e-68	246
k141_52922_41	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.7	829	892	1024	1.04e-68	246
k141_52922_41	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	24.7	829	892	1024	3.50e-68	244
k141_52922_41	SARG|gb|CAA53189|ARO:3000521|mupA	24.7	829	892	1024	3.50e-68	244
k141_6589_22	CARD|gb|WKR28567.1|ARO:3007678|IreK	33.4	622	712	718	2.57e-90	296
k141_6589_24	megares|MEG_1680|Drugs|MLS|23S_rRNA_methyltransferases|CFR_1	39.4	320	357	416	1.56e-58	194
k141_6589_24	NCBI|WP_111690898.1|1|1|cfr(C)|cfr(C)|target_modification|2|CHLORAMPHENICOL/CLINDAMYCIN/FLORFENICOL/LINEZOLID/STREPTOGRAMIN/TIAMULIN|LINCOSAMIDE/OXAZOLIDINONE/PHENICOL/PLEUROMUTILIN/STREPTOGRAMIN|23S_rRNA_(adenine(2503)-C(8))-methyltransferase_Cfr(C)|AMR|multidrug	38.8	320	357	379	3.43e-58	192
k141_6589_24	SARG|VXQ21601.1	35.0	320	357	344	3.54e-55	183
k141_6589_24	SARG|AXY65402.1	34.4	320	357	357	6.67e-51	172
k141_6589_24	SARG|gb|BAH45481.1|ARO:3002815|clbB	36.9	282	357	343	9.98e-50	169
k141_78010_10	SARG|gi|542061059|gb|ERI11611.1|	42.9	205	214	316	8.18e-46	153
k141_78010_10	SARG|gi|488120365|ref|WP_002191762.1|	41.0	205	214	309	2.13e-44	149
k141_78010_10	SARG|gi|507023808|ref|WP_016095885.1|	41.5	205	214	309	2.13e-44	149
k141_78010_10	SARG|gi|445996719|ref|WP_000074574.1|	41.5	205	214	309	3.00e-44	149
k141_78010_10	SARG|gi|507050365|ref|WP_016121371.1|	41.0	205	214	309	4.22e-44	148
k141_78010_10	SARG|gi|895808656|emb|COR83787.1|	40.8	211	214	309	4.22e-44	148
k141_78010_10	SARG|gi|488068784|ref|WP_002140181.1|	41.5	205	214	309	5.94e-44	148
k141_78010_10	SARG|gi|445996729|ref|WP_000074584.1|	40.8	211	214	309	8.37e-44	147
k141_78010_10	SARG|gi|895736250|emb|COF64653.1|	41.5	205	214	309	8.37e-44	147
k141_78010_10	SARG|gi|446110087|ref|WP_000187942.1|	41.5	205	214	309	8.37e-44	147
k141_78010_10	SARG|gi|445996714|ref|WP_000074569.1|	41.5	205	214	309	8.37e-44	147
k141_78010_10	SARG|gi|445996723|ref|WP_000074578.1|	40.8	211	214	309	8.37e-44	147
k141_78010_10	SARG|gi|445996722|ref|WP_000074577.1|	40.8	211	214	309	8.37e-44	147
k141_78010_10	SARG|gi|488053456|ref|WP_002124853.1|	41.0	205	214	309	1.18e-43	147
k141_78010_10	SARG|gi|447057509|ref|WP_001134765.1|	41.0	205	214	309	1.18e-43	147
k141_78010_10	SARG|gi|445996710|ref|WP_000074565.1|	41.0	205	214	309	1.18e-43	147
k141_78010_10	SARG|gi|447057510|ref|WP_001134766.1|	41.5	205	214	309	1.18e-43	147
k141_78010_10	SARG|gi|488067981|ref|WP_002139378.1|	41.0	205	214	309	1.66e-43	147
k141_78010_10	SARG|gi|487936534|ref|WP_002010000.1|	41.0	205	214	309	1.66e-43	147
k141_78010_10	SARG|gi|445996724|ref|WP_000074579.1|	40.3	211	214	309	2.34e-43	146
k141_78010_10	SARG|gi|1043490477|ref|WP_065382463.1|	40.3	211	214	309	2.34e-43	146
k141_78010_10	SARG|gi|445996726|ref|WP_000074581.1|	40.3	211	214	309	2.34e-43	146
k141_78010_10	SARG|gi|488042066|ref|WP_002113463.1|	41.5	205	214	309	2.34e-43	146
k141_78010_10	SARG|gi|507054395|ref|WP_016125339.1|	40.3	211	214	309	2.34e-43	146
k141_78010_10	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	39.5	210	214	307	3.14e-43	146
k141_78010_13	SARG|gi|895736250|emb|COF64653.1|	35.7	221	291	309	3.82e-35	127
k141_78010_13	SARG|gi|446110087|ref|WP_000187942.1|	35.7	221	291	309	3.82e-35	127
k141_78010_13	SARG|gi|445996710|ref|WP_000074565.1|	35.7	221	291	309	3.82e-35	127
k141_78010_13	SARG|gi|445996719|ref|WP_000074574.1|	36.6	213	291	309	5.35e-35	127
k141_78010_13	SARG|gi|445996709|ref|WP_000074564.1|	35.7	221	291	309	5.35e-35	127
k141_78010_13	SARG|gi|445996714|ref|WP_000074569.1|	36.6	213	291	309	5.35e-35	127
k141_78010_13	SARG|gi|814314593|emb|CKF49145.1|	35.7	221	291	309	5.35e-35	127
k141_78010_13	SARG|gi|445996723|ref|WP_000074578.1|	36.6	213	291	309	7.48e-35	127
k141_78010_13	SARG|gi|445996722|ref|WP_000074577.1|	36.2	213	291	309	1.05e-34	126
k141_78010_13	SARG|gi|1043490477|ref|WP_065382463.1|	36.2	213	291	309	2.04e-34	125
k141_78010_13	SARG|gi|445996726|ref|WP_000074581.1|	36.2	213	291	309	2.04e-34	125
k141_78010_13	SARG|gi|507054395|ref|WP_016125339.1|	36.2	213	291	309	2.04e-34	125
k141_78010_13	SARG|gi|542061059|gb|ERI11611.1|	35.9	217	291	316	2.37e-34	125
k141_78010_13	SARG|gi|445996724|ref|WP_000074579.1|	35.7	213	291	309	2.86e-34	125
k141_78010_13	SARG|gi|445996695|ref|WP_000074550.1|	35.7	213	291	309	2.86e-34	125
k141_78010_13	SARG|gi|884875933|emb|CKG93789.1|	35.7	213	291	309	2.86e-34	125
k141_78010_13	SARG|gi|445996729|ref|WP_000074584.1|	34.8	221	291	309	4.00e-34	125
k141_78010_13	SARG|gi|500448961|gb|EOP61695.1|	35.4	229	291	306	5.25e-34	124
k141_78010_13	SARG|gi|488130770|ref|WP_002201978.1|	36.2	213	291	309	5.59e-34	124
k141_78010_13	SARG|gi|507044560|ref|WP_016115614.1|	35.7	213	291	306	7.33e-34	124
k141_78010_13	SARG|gi|447057509|ref|WP_001134765.1|	36.2	213	291	309	7.81e-34	124
k141_78010_13	SARG|gi|507035724|ref|WP_016107411.1|	34.1	229	291	309	1.09e-33	124
k141_78010_13	SARG|gi|488067981|ref|WP_002139378.1|	35.7	213	291	309	1.09e-33	124
k141_78010_13	SARG|gi|445996698|ref|WP_000074553.1|	34.1	229	291	309	1.09e-33	124
k141_78010_13	SARG|gi|487936534|ref|WP_002010000.1|	35.7	213	291	309	1.09e-33	124
k141_91516_4	CARD|gb|CYF42523.1|ARO:3004047|kdpD	28.5	656	658	885	1.18e-79	270
k141_91516_4	CARD|gb|AEX49906.1|ARO:3003583|basS	25.9	239	658	477	2.09e-15	78.2
k141_91516_4	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.1	220	658	361	5.95e-11	63.5
k141_91516_5	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	44.4	225	233	225	4.50e-64	197
k141_91516_5	CARD|gb|AAC73788.1|ARO:3003841|kdpE	44.4	225	233	225	4.50e-64	197
k141_91516_5	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	35.5	228	233	231	3.62e-42	142
k141_91516_5	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.5	222	233	219	7.32e-42	140
k141_91516_5	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	33.6	226	233	232	2.94e-41	139
k141_91516_5	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	33.6	226	233	232	2.94e-41	139
k141_91516_5	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	33.3	228	233	232	2.57e-39	134
k141_91516_5	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.3	223	233	231	3.52e-39	134
k141_91516_5	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	30.6	222	233	229	6.64e-39	133
k141_91516_5	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.8	223	233	231	7.00e-39	133
k141_91516_5	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	32.3	223	233	228	9.12e-39	133
k141_91516_5	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	33.0	227	233	235	2.18e-38	132
k141_91516_5	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	31.8	223	233	231	2.77e-38	132
k141_91516_5	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	33.3	225	233	233	4.11e-38	131
k141_91516_5	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	30.5	223	233	230	5.35e-38	131
k141_91516_5	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	33.0	230	233	239	9.53e-38	130
k141_91516_5	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.5	228	233	231	4.30e-37	129
k141_91516_5	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	30.9	223	233	231	4.30e-37	129
k141_91516_5	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	33.3	228	233	231	6.06e-37	128
k141_91516_5	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.9	228	233	231	6.06e-37	128
k141_91516_5	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	33.3	228	233	231	6.06e-37	128
k141_91516_5	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.4	225	233	231	8.54e-37	128
k141_91516_5	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	32.5	228	233	231	3.36e-36	126
k141_91516_5	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.1	225	233	232	1.06e-34	122
k141_91516_5	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	31.6	225	233	232	1.49e-34	122
k141_15269_14	SARG|AUI09862.1	45.2	279	271	287	6.68e-83	249
k141_15269_14	SARG|AJ459418.gene.p01	33.2	262	271	263	2.91e-40	139
k141_15269_14	SARG|gi|970263436|ref|WP_058647620.1|	32.8	262	271	263	6.27e-39	135
k141_15269_14	SARG|gi|553729091|ref|WP_023063817.1|	34.4	247	271	271	1.51e-38	135
k141_15269_14	SARG|gi|638947703|ref|WP_024439711.1|	34.4	247	271	271	2.12e-38	134
k141_15269_14	SARG|gi|754661150|ref|WP_042043527.1|	34.0	247	271	271	4.19e-38	134
k141_15269_14	SARG|gi|771529592|ref|WP_045178654.1|	34.0	247	271	271	4.19e-38	134
k141_15269_14	SARG|gi|504199703|ref|WP_014386805.1|	34.0	247	271	271	4.19e-38	134
k141_15269_14	SARG|gi|550552396|ref|WP_022631488.1|	34.0	247	271	271	5.89e-38	133
k141_15269_14	SARG|gi|916164813|ref|WP_050960181.1|	34.0	247	271	271	5.89e-38	133
k141_15269_14	SARG|gi|487670925|ref|WP_001756235.1|	34.0	247	271	271	8.27e-38	133
k141_15269_14	SARG|gi|835825825|ref|WP_047670793.1|	34.4	247	271	271	8.27e-38	133
k141_15269_14	SARG|gb|AAL59753.1|ARO:3000412|sul2	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|499589343|ref|WP_011270126.1|	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|728806562|ref|WP_033917658.1|	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|499192666|ref|WP_010890206.1|	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|503278284|ref|WP_013512945.1|	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|490108656|ref|WP_004009399.1|	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|446966006|ref|WP_001043262.1|	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|920213921|ref|WP_052970363.1|	34.0	247	271	271	1.16e-37	132
k141_15269_14	SARG|gi|695268609|ref|WP_032490786.1|	34.0	247	271	272	1.19e-37	132
k141_15269_14	SARG|gi|846280841|gb|AKN19373.1|	34.0	247	271	279	1.41e-37	132
k141_15269_14	SARG|gi|499589362|ref|WP_011270145.1|	34.0	247	271	283	1.55e-37	132
k141_15269_14	SARG|gi|1028099083|ref|WP_063855540.1|	34.0	247	271	271	1.63e-37	132
k141_15269_14	SARG|gi|836556079|ref|WP_047715692.1|	34.0	247	271	271	1.63e-37	132
k141_15269_66	SARG|gi|686436876|ref|WP_031922735.1|	22.7	225	379	491	5.41e-10	59.7
k141_15269_66	SARG|YP_254220	21.8	225	379	488	5.23e-09	56.6
k141_15269_66	SARG|gi|686444151|ref|WP_031925491.1|	21.8	225	379	488	6.95e-09	56.2
k141_15269_66	SARG|gi|581672381|gb|EVQ77821.1|	21.8	225	379	394	7.76e-09	55.8
k141_15269_66	SARG|gi|587321226|gb|EWW03298.1|	21.8	225	379	413	8.11e-09	55.8
k141_15269_66	SARG|YP_001569068	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|686379454|ref|WP_031899389.1|	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|727749040|ref|WP_033861720.1|	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|686337405|ref|WP_031882938.1|	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|686300118|ref|WP_031865761.1|	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|686196490|ref|WP_031807261.1|	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|686335175|ref|WP_031881860.1|	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|486216135|ref|WP_001556865.1|	21.8	225	379	488	9.23e-09	55.8
k141_15269_66	SARG|gi|582362524|gb|EVW57639.1|	21.8	225	379	490	9.25e-09	55.8
k141_15269_66	SARG|gi|486352750|ref|WP_001590778.1|	21.8	225	379	488	1.22e-08	55.5
k141_15269_66	SARG|gi|580336413|gb|EVD62957.1|	22.1	213	379	478	1.60e-08	55.1
k141_15269_66	SARG|ABA02367	21.3	225	379	488	1.63e-08	55.1
k141_15269_66	SARG|gi|127359|sp|P23212.1|MSRA_STAEP	21.3	225	379	488	1.63e-08	55.1
k141_15269_66	SARG|gb|CAA36304.1|ARO:3000251|msrA	21.3	225	379	488	1.63e-08	55.1
k141_15269_66	SARG|BAD86537	21.3	225	379	488	1.63e-08	55.1
k141_15269_66	SARG|gi|686386599|ref|WP_031903183.1|	21.8	225	379	488	2.87e-08	54.3
k141_15269_66	SARG|QHW12308.1	22.0	218	379	486	5.03e-08	53.5
k141_15269_66	megares|MEG_4068|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|MSRA_1	22.5	204	379	176	5.65e-08	51.2
k141_15269_66	SARG|gb|QHW12375.1|ARO:3005087|msrF	21.6	218	379	486	1.18e-07	52.4
k141_15269_66	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	23.9	213	379	568	2.24e-07	51.6
k141_15269_87	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	34.6	205	290	307	2.07e-32	120
k141_15269_87	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	35.3	204	290	293	4.23e-32	119
k141_15269_87	SARG|gi|507055561|ref|WP_016126482.1|	34.6	205	290	309	8.18e-32	119
k141_15269_87	SARG|gi|488120365|ref|WP_002191762.1|	34.6	205	290	309	1.59e-31	118
k141_15269_87	SARG|gi|488130770|ref|WP_002201978.1|	34.1	208	290	309	1.59e-31	118
k141_15269_87	SARG|gi|447057509|ref|WP_001134765.1|	34.6	205	290	309	1.59e-31	118
k141_15269_87	SARG|gi|488053456|ref|WP_002124853.1|	34.6	205	290	309	2.22e-31	117
k141_15269_87	SARG|gi|507050365|ref|WP_016121371.1|	34.1	205	290	309	3.10e-31	117
k141_15269_87	SARG|gi|488068784|ref|WP_002140181.1|	34.1	205	290	309	3.10e-31	117
k141_15269_87	SARG|gi|488067981|ref|WP_002139378.1|	34.1	205	290	309	6.03e-31	116
k141_15269_87	SARG|gi|507023808|ref|WP_016095885.1|	34.1	205	290	309	6.03e-31	116
k141_15269_87	SARG|gi|487936534|ref|WP_002010000.1|	34.1	205	290	309	6.03e-31	116
k141_15269_87	SARG|gi|447057510|ref|WP_001134766.1|	34.6	205	290	309	6.03e-31	116
k141_15269_87	SARG|gi|488042066|ref|WP_002113463.1|	34.1	208	290	309	8.41e-31	116
k141_15269_87	SARG|gi|445996708|ref|WP_000074563.1|	34.1	208	290	309	3.17e-30	114
k141_15269_87	SARG|gb|AAA26793|ARO:3003748|oleC	34.4	215	290	325	4.27e-30	114
k141_15269_87	megares|MEG_4276|Drugs|MLS|MLS_resistance_ABC_efflux_pumps|OLEC_1	34.4	215	290	325	4.27e-30	114
k141_15269_87	SARG|gi|445996732|ref|WP_000074587.1|	34.6	208	290	309	4.42e-30	114
k141_15269_87	SARG|gi|445996695|ref|WP_000074550.1|	34.6	208	290	309	4.42e-30	114
k141_15269_87	SARG|gi|507035724|ref|WP_016107411.1|	34.6	208	290	309	6.16e-30	114
k141_15269_87	SARG|gi|445996698|ref|WP_000074553.1|	34.6	208	290	309	6.16e-30	114
k141_15269_87	SARG|gi|445996723|ref|WP_000074578.1|	33.7	205	290	309	8.59e-30	113
k141_15269_87	SARG|gi|445996696|ref|WP_000074551.1|	34.6	208	290	309	8.59e-30	113
k141_15269_87	SARG|gi|445996722|ref|WP_000074577.1|	33.2	205	290	309	1.20e-29	113
k141_15269_87	SARG|gi|1043490477|ref|WP_065382463.1|	33.7	205	290	309	1.67e-29	112
k141_15269_89	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	35.3	235	232	239	7.87e-49	159
k141_15269_89	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	35.3	232	232	231	1.77e-48	158
k141_15269_89	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.5	232	232	231	3.53e-48	157
k141_15269_89	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	34.9	232	232	231	4.99e-48	157
k141_15269_89	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.5	232	232	231	2.81e-47	155
k141_15269_89	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	35.5	231	232	229	2.11e-46	152
k141_15269_89	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	34.1	232	232	231	2.24e-46	152
k141_15269_89	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	31.8	236	232	235	1.57e-44	148
k141_15269_89	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	32.9	234	232	233	2.10e-44	147
k141_15269_89	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.9	231	232	231	7.91e-44	146
k141_15269_89	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	31.3	230	232	231	3.14e-43	144
k141_15269_89	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.5	231	232	231	6.26e-43	144
k141_15269_89	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.5	231	232	231	1.25e-42	143
k141_15269_89	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	32.5	231	232	231	2.49e-42	142
k141_15269_89	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	32.3	226	232	231	1.96e-41	140
k141_15269_89	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	30.8	234	232	232	2.02e-41	140
k141_15269_89	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	31.4	226	232	230	3.80e-41	139
k141_15269_89	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	30.9	230	232	232	5.66e-41	139
k141_15269_89	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.1	234	232	232	1.39e-38	132
k141_15269_89	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	30.3	234	232	232	3.88e-38	131
k141_15269_89	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.9	234	232	232	5.47e-38	131
k141_15269_89	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.5	234	232	232	1.09e-37	130
k141_15269_89	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.5	234	232	232	1.53e-37	130
k141_15269_89	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	29.5	234	232	232	1.53e-37	130
k141_15269_89	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	29.4	228	232	225	1.87e-33	119
k141_53104_3	SARG|YP_302230	23.2	375	460	451	1.95e-30	121
k141_113392_10	SARG|gb|ADZ12699.1|ARO:3005091|RanA	36.4	214	240	258	9.25e-42	142
k141_113392_24	SARG|gi|648667297|ref|WP_026359044.1|	32.4	494	568	605	1.01e-64	221
k141_113392_24	SARG|gi|663350985|ref|WP_030349761.1|	32.6	485	568	613	1.63e-63	218
k141_113392_24	SARG|gi|497748188|ref|WP_010062372.1|	31.4	493	568	605	2.71e-63	217
k141_113392_24	SARG|gi|928900436|ref|WP_053931243.1|	32.4	485	568	600	4.75e-63	216
k141_113392_24	SARG|gi|664579989|ref|WP_031094015.1|	32.4	485	568	601	4.84e-63	216
k141_113392_24	SARG|gi|1045390184|ref|WP_065479071.1|	31.6	488	568	605	1.40e-62	215
k141_113392_24	SARG|gb|AAC74000.1|ARO:3003950|msbA	33.7	487	568	582	1.74e-62	214
k141_113392_24	SARG|gi|764446018|ref|WP_044369325.1|	31.2	493	568	605	1.94e-62	215
k141_113392_24	SARG|gi|664170108|ref|WP_030704355.1|	31.4	487	568	603	2.60e-62	214
k141_113392_24	SARG|gi|926376632|ref|WP_053705806.1|	32.6	484	568	620	3.55e-62	214
k141_113392_24	SARG|gi|948040364|ref|WP_056699531.1|	31.2	481	568	603	3.61e-62	214
k141_113392_24	SARG|gi|695891735|ref|WP_032792824.1|	30.9	486	568	603	5.01e-62	214
k141_113392_24	SARG|gi|664042835|ref|WP_030582300.1|	31.6	487	568	604	5.10e-62	214
k141_113392_24	SARG|gi|663155409|ref|WP_030194633.1|	31.2	493	568	605	5.20e-62	214
k141_113392_24	SARG|gi|664538723|ref|WP_031054357.1|	31.2	493	568	605	5.20e-62	214
k141_113392_24	SARG|gi|662129758|ref|WP_030081404.1|	31.4	493	568	605	5.20e-62	214
k141_113392_24	SARG|gi|663330365|ref|WP_030329892.1|	31.2	493	568	607	5.40e-62	214
k141_113392_24	SARG|gi|799286378|ref|WP_045936958.1|	32.6	484	568	620	6.84e-62	214
k141_113392_24	SARG|gi|917127754|ref|WP_051734466.1|	32.6	484	568	620	6.84e-62	214
k141_113392_24	SARG|gi|926294973|ref|WP_053631154.1|	32.6	484	568	620	6.84e-62	214
k141_113392_24	SARG|gi|913055317|ref|WP_050357634.1|	30.9	486	568	603	6.95e-62	213
k141_113392_24	SARG|gi|695887424|ref|WP_032788534.1|	31.2	493	568	605	7.22e-62	213
k141_113392_24	SARG|gi|664085850|ref|WP_030624018.1|	31.4	493	568	605	7.22e-62	213
k141_113392_24	SARG|gi|917229923|ref|WP_051836635.1|	32.3	483	568	620	9.49e-62	213
k141_113392_24	SARG|gi|926356413|ref|WP_053687351.1|	32.6	484	568	620	9.49e-62	213
k141_113392_25	SARG|gb|AAC74000.1|ARO:3003950|msbA	32.7	513	559	582	1.31e-68	231
k141_113392_25	SARG|gb|CDO61516.1|ARO:3003949|efrB	37.8	267	559	362	8.67e-53	182
k141_113392_25	SARG|gb|AET10444.1|ARO:3004032|tetA(46)	27.0	467	559	574	1.99e-52	187
k141_113392_25	SARG|FR772051.1.gene9.p01	26.3	217	559	524	1.07e-11	66.2
k141_113392_25	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	23.7	219	559	524	4.03e-10	61.2
k141_113392_25	SARG|U82085.gene.p01	23.4	205	559	552	3.99e-06	48.5
k141_113392_30	SARG|gb|APB03219.1|ARO:3003986|TaeA	47.4	644	606	648	3.40e-190	549
k141_113392_30	SARG|M80346.gene.p01	33.4	557	606	551	7.49e-67	226
k141_113392_30	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	33.4	557	606	551	7.49e-67	226
k141_113392_30	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	524	606	655	8.40e-67	229
k141_113392_30	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.0	523	606	655	1.17e-66	228
k141_113392_30	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	524	606	655	3.11e-66	227
k141_113392_30	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.5	524	606	655	3.11e-66	227
k141_113392_30	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	524	606	655	8.31e-66	226
k141_113392_30	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	524	606	655	1.15e-65	226
k141_113392_30	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	524	606	655	1.15e-65	226
k141_113392_30	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	524	606	655	1.15e-65	226
k141_113392_30	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.3	524	606	655	1.15e-65	226
k141_113392_30	SARG|gb|AKA86814|ARO:3003746|optrA	30.3	524	606	655	1.15e-65	226
k141_113392_30	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	523	606	655	1.60e-65	225
k141_113392_30	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	524	606	655	1.13e-64	223
k141_113392_30	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	524	606	655	1.13e-64	223
k141_113392_30	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	524	606	655	1.13e-64	223
k141_113392_30	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	524	606	655	1.13e-64	223
k141_113392_30	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	524	606	655	1.13e-64	223
k141_113392_30	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.2	524	606	655	1.13e-64	223
k141_113392_30	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.0	524	606	655	5.79e-64	221
k141_113392_30	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	30.0	524	606	655	1.11e-63	220
k141_113392_30	SARG|X63451.gene.p01	31.3	559	606	550	7.52e-61	210
k141_113392_30	megares|MEG_6558|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|SRMB_1	31.3	559	606	550	7.52e-61	210
k141_113392_30	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	29.3	518	606	524	2.23e-58	203
k141_93571_2	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	39.6	690	640	703	5.47e-140	423
k141_34335_2	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	530	545	655	2.07e-67	229
k141_34335_2	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	530	545	655	5.57e-67	228
k141_34335_2	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	530	545	655	7.74e-67	227
k141_34335_2	SARG|gb|AKA86814|ARO:3003746|optrA	29.6	530	545	655	7.74e-67	227
k141_34335_2	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	530	545	655	2.08e-66	226
k141_34335_2	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	530	545	655	2.08e-66	226
k141_34335_2	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.8	530	545	655	2.08e-66	226
k141_34335_2	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	530	545	655	2.08e-66	226
k141_34335_2	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	530	545	655	2.08e-66	226
k141_34335_2	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	530	545	655	2.89e-66	226
k141_34335_2	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.6	530	545	655	2.89e-66	226
k141_34335_2	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	7.76e-66	224
k141_34335_2	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	1.50e-65	224
k141_34335_2	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	1.50e-65	224
k141_34335_2	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	1.50e-65	224
k141_34335_2	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	2.08e-65	223
k141_34335_2	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	2.08e-65	223
k141_34335_2	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	2.08e-65	223
k141_34335_2	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	29.4	530	545	655	2.08e-65	223
k141_34335_2	SARG|gb|APB03219.1|ARO:3003986|TaeA	28.6	531	545	648	1.29e-61	213
k141_34335_2	SARG|U82085.gene.p01	26.8	556	545	552	2.57e-50	180
k141_34335_2	SARG|gb|AHB37625.1|ARO:3004715|vga(E)	33.7	403	545	524	1.02e-47	172
k141_34335_2	SARG|FR772051.1.gene9.p01	33.8	399	545	524	2.54e-46	169
k141_34335_2	SARG|GQ205627.2.gene1.p01	34.0	379	545	525	1.20e-44	164
k141_34335_2	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	25.8	554	545	550	3.03e-43	160
k141_34335_5	SARG|X55652.1.gene2.p01	22.7	251	264	271	3.24e-10	58.2
k141_34335_11	SARG|gb|AML99881.1|ARO:3001327|mdtK	28.1	430	448	474	5.84e-50	175
k141_64227_37	SARG|YP_002333394	37.2	320	329	323	5.00e-55	181
k141_64227_37	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	37.2	320	329	323	5.00e-55	181
k141_64227_37	SARG|AF310956.2.gene5.p01	37.2	320	329	323	7.03e-55	181
k141_64227_37	SARG|gi|985522333|ref|WP_060811962.1|	38.5	296	329	323	9.90e-55	180
k141_64227_37	SARG|gi|498515089|ref|WP_010815296.1|	38.5	296	329	323	1.39e-54	180
k141_64227_37	SARG|gb|AAB05626.1|ARO:3002943|vanHB	38.5	296	329	323	2.76e-54	179
k141_64227_37	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	35.0	320	329	343	4.66e-54	179
k141_64227_37	SARG|Q47748	38.5	296	329	323	5.48e-54	178
k141_64227_37	NCBI|WP_011029109.1|1|1|vanH-Sc|vanH-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Sc|AMR|glycopeptide	34.4	308	329	337	9.37e-52	173
k141_64227_37	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	34.2	316	329	348	1.74e-51	172
k141_64227_37	SARG|DQ018711.1.gene4.p01	32.5	317	329	322	3.51e-51	171
k141_64227_37	SARG|gi|740152780|ref|WP_037997109.1|	33.4	317	329	322	4.93e-51	171
k141_64227_37	SARG|gi|737310392|ref|WP_035293250.1|	32.5	317	329	323	1.98e-50	169
k141_64227_37	SARG|NP_878015	32.8	317	329	322	2.71e-50	169
k141_64227_37	SARG|KF478993.1.gene2.p01	34.9	298	329	350	3.89e-50	169
k141_64227_37	SARG|gi|746609237|ref|WP_039635344.1|	33.1	317	329	322	1.06e-49	167
k141_64227_37	NCBI|WP_063856710.1|1|1|vanH-Pt2|vanH-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Pt2|AMR|glycopeptide	33.0	321	329	322	2.09e-49	166
k141_64227_37	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	33.6	295	329	323	2.15e-49	166
k141_64227_37	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	34.1	299	329	351	4.30e-49	166
k141_64227_37	SARG|CAB61228	33.4	317	329	322	8.17e-49	165
k141_64227_37	SARG|FJ349556.1.gene5.p01	31.2	317	329	326	6.95e-48	162
k141_64227_37	SARG|gi|749574782|ref|WP_040203616.1|	32.5	317	329	323	1.79e-47	161
k141_64227_37	SARG|gb|MBY8651254.1|ARO:3007188|vanH_in_vanP_cl	35.5	265	329	314	2.82e-47	160
k141_64227_37	SARG|AF155139.2.gene6.p01	32.5	317	329	322	9.53e-47	159
k141_64227_37	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	36.4	242	329	237	5.52e-43	147
k141_64227_48	SARG|gb|CZT31773.1|ARO:3004094|Erm(48)	31.7	202	284	243	2.10e-18	81.3
k141_64227_48	SARG|L22689.1.gene1.p01	30.0	210	284	257	6.42e-17	77.4
k141_64227_48	SARG|gb|QKE44141.1|ARO:3007033|Erm(51)	30.8	211	284	263	6.99e-17	77.4
k141_64227_48	NCBI|WP_052259183.1|1|1|erm(42)|erm(42)|target_modification|2|CLINDAMYCIN/ERYTHROMYCIN|LINCOSAMIDE/MACROLIDE|23S_rRNA_(adenine(2058)-N(6))-methyltransferase_Erm(42)|AMR|multidrug	30.9	181	284	301	3.87e-16	75.9
k141_64227_48	megares|MEG_2781|Drugs|MLS|23S_rRNA_methyltransferases|ERM42_1	30.9	181	284	303	3.95e-16	75.9
k141_64227_48	SARG|gb|CBY77552.1|ARO:3003106|Erm(42)	30.9	181	284	301	7.23e-16	75.1
k141_64227_53	megares|MEG_4304|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.1	499	517	655	6.13e-89	285
k141_64227_53	SARG|gb|AKA86814|ARO:3003746|optrA	33.1	499	517	655	6.13e-89	285
k141_64227_53	megares|MEG_4313|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.1	499	517	655	1.69e-88	284
k141_64227_53	megares|MEG_4312|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.1	499	517	655	1.69e-88	284
k141_64227_53	megares|MEG_4315|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.1	499	517	655	1.69e-88	284
k141_64227_53	megares|MEG_4307|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.1	499	517	655	2.37e-88	283
k141_64227_53	megares|MEG_4323|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.1	499	517	655	3.32e-88	283
k141_64227_53	megares|MEG_4309|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	6.53e-88	282
k141_64227_53	megares|MEG_4318|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.28e-87	281
k141_64227_53	megares|MEG_4322|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	33.1	499	517	655	1.28e-87	281
k141_64227_53	megares|MEG_4306|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.28e-87	281
k141_64227_53	megares|MEG_4321|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.80e-87	281
k141_64227_53	megares|MEG_4317|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.80e-87	281
k141_64227_53	megares|MEG_4314|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.80e-87	281
k141_64227_53	megares|MEG_4308|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.80e-87	281
k141_64227_53	megares|MEG_4319|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.80e-87	281
k141_64227_53	megares|MEG_4311|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.80e-87	281
k141_64227_53	megares|MEG_4305|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.9	499	517	655	1.80e-87	281
k141_64227_53	megares|MEG_4316|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|OPTRA_1	32.7	499	517	655	4.95e-87	280
k141_64227_53	SARG|gb|AVI44920.1|ARO:3004470|poxtA	31.1	512	517	542	7.29e-76	248
k141_64227_53	NCBI|WP_209691075.1|1|1|poxtA2|poxtA|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA2|AMR|multidrug	31.1	512	517	544	7.64e-76	248
k141_64227_53	ResF|poxtA-Ef_1_WP094899500.1_1	30.2	500	517	538	1.04e-73	242
k141_64227_53	megares|MEG_8639|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|POXT_1	30.2	500	517	543	1.17e-73	242
k141_64227_53	NCBI|WP_094899500.1|1|1|poxtA-Ef|poxtA-Ef|target_protection|2|CHLORAMPHENICOL/FLORFENICOL/LINEZOLID|OXAZOLIDINONE/PHENICOL|ABC-F_type_ribosomal_protection_protein_PoxtA-Ef|AMR|multidrug	30.2	500	517	543	1.17e-73	242
k141_64227_53	SARG|FR772051.1.gene9.p01	31.3	383	517	524	1.72e-49	177
k141_53282_3	SARG|gi|505177635|ref|WP_015364737.1|	20.5	404	443	451	1.83e-12	67.8
k141_53282_3	SARG|gi|488374619|ref|WP_002444004.1|	20.5	404	443	452	4.31e-12	66.6
k141_53282_3	SARG|YP_302230	21.5	404	443	451	1.01e-11	65.5
k141_47847_10	SARG|gi|505177635|ref|WP_015364737.1|	27.8	421	459	451	4.79e-45	162
k141_47847_10	SARG|gi|488374619|ref|WP_002444004.1|	28.0	421	459	452	1.81e-44	160
k141_47847_10	SARG|ZP_04679156	27.3	421	459	451	6.44e-43	156
k141_47847_10	SARG|gi|516415429|ref|WP_017804827.1|	27.0	422	459	451	3.07e-40	149
k141_47847_10	SARG|gi|486285962|ref|WP_001572033.1|	27.0	422	459	451	4.24e-40	148
k141_47847_10	SARG|gi|686309068|ref|WP_031870147.1|	27.0	422	459	451	4.24e-40	148
k141_47847_10	SARG|gi|686396521|ref|WP_031908504.1|	27.0	422	459	451	5.86e-40	148
k141_47847_10	SARG|gi|686355454|ref|WP_031890196.1|	27.0	422	459	451	5.86e-40	148
k141_47847_10	SARG|Q99WP2	27.0	422	459	451	5.86e-40	148
k141_47847_10	SARG|gi|686302738|ref|WP_031866896.1|	27.0	422	459	451	5.86e-40	148
k141_47847_10	SARG|gi|493203634|ref|WP_006191797.1|	27.0	422	459	451	5.86e-40	148
k141_47847_10	SARG|gi|686320684|ref|WP_031875798.1|	27.0	422	459	451	5.86e-40	148
k141_47847_10	SARG|gi|487138435|ref|WP_001629863.1|	26.8	422	459	451	5.86e-40	148
k141_47847_10	SARG|gi|446573690|ref|WP_000651036.1|	26.8	422	459	451	8.09e-40	147
k141_47847_10	SARG|gi|686123390|ref|WP_031769354.1|	27.0	422	459	451	8.09e-40	147
k141_47847_10	SARG|gi|686432388|ref|WP_031921070.1|	26.8	422	459	451	8.09e-40	147
k141_47847_10	SARG|gi|686329335|ref|WP_031878923.1|	27.0	422	459	451	8.09e-40	147
k141_47847_10	SARG|gi|446573700|ref|WP_000651046.1|	27.6	424	459	451	8.09e-40	147
k141_47847_10	SARG|gi|1006223553|ref|WP_061745579.1|	26.6	421	459	451	1.12e-39	147
k141_47847_10	SARG|gi|686172137|ref|WP_031795999.1|	27.0	422	459	451	1.54e-39	147
k141_47847_10	SARG|gi|686309117|ref|WP_031870179.1|	26.8	422	459	451	1.54e-39	147
k141_47847_10	SARG|ZP_03986195	26.8	422	459	451	1.54e-39	147
k141_47847_10	SARG|gi|446573693|ref|WP_000651039.1|	26.8	422	459	451	1.54e-39	147
k141_47847_10	SARG|gi|446573692|ref|WP_000651038.1|	26.8	422	459	451	1.54e-39	147
k141_47847_10	SARG|gi|446573695|ref|WP_000651041.1|	26.8	422	459	451	1.54e-39	147
k141_47847_14	CARD|gb|BAB36671.1|ARO:3000832|evgA	25.2	115	538	204	5.96e-10	58.2
k141_47847_14	CARD|gb|AAG05188.1|ARO:3005068|ParR	26.5	117	538	235	2.39e-08	53.9
k141_47847_14	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	23.4	124	538	228	5.39e-08	52.8
k141_66900_2	SARG|AF170880.4.gene1.p01	30.3	531	554	615	1.29e-41	157
k141_66900_2	SARG|gi|558888514|ref|WP_023543283.1|	30.1	531	554	615	6.05e-41	155
k141_66900_2	SARG|gi|860594225|ref|WP_048475168.1|	28.4	529	554	620	2.57e-39	150
k141_66900_2	SARG|gi|496018010|ref|WP_008742581.1|	28.5	529	554	623	3.05e-38	147
k141_66900_2	SARG|gi|663350985|ref|WP_030349761.1|	29.1	532	554	613	9.52e-38	146
k141_66900_2	SARG|gi|926400371|ref|WP_053728483.1|	28.7	530	554	603	1.61e-37	145
k141_66900_2	SARG|gb|CDO61516.1|ARO:3003949|efrB	36.4	269	554	362	7.57e-37	139
k141_66900_2	NCBI|WP_011116970.1|1|1|tetAB_B|tetAB_B|efflux|2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_TetAB_subunit_B|AMR|tetracycline	27.3	176	554	528	2.61e-12	68.2
k141_66900_3	SARG|gi|739906046|ref|WP_037756452.1|	25.0	496	591	620	4.73e-38	147
k141_66900_3	SARG|gi|516574297|ref|WP_017949361.1|	24.8	496	591	620	5.32e-37	144
k141_66900_3	SARG|gi|919568551|ref|WP_052871170.1|	24.3	564	591	620	1.32e-36	143
k141_66900_3	SARG|gi|921231571|ref|WP_053176464.1|	24.5	563	591	620	1.78e-36	143
k141_66900_3	SARG|gi|917172177|ref|WP_051778889.1|	24.3	564	591	620	2.40e-36	142
k141_66900_3	SARG|gi|917166849|ref|WP_051773561.1|	24.2	557	591	620	5.92e-36	141
k141_66900_3	SARG|gi|917155568|ref|WP_051762280.1|	24.2	557	591	620	7.99e-36	141
k141_66900_3	SARG|gi|917229923|ref|WP_051836635.1|	23.7	565	591	620	6.50e-35	138
k141_66900_3	SARG|gi|930482089|ref|WP_054228897.1|	24.5	552	591	599	7.49e-35	138
k141_66900_3	SARG|gi|926294973|ref|WP_053631154.1|	23.7	556	591	620	1.18e-34	137
k141_66900_3	SARG|gi|985844137|ref|WP_060895163.1|	24.5	552	591	599	1.36e-34	137
k141_66900_3	SARG|gi|926356413|ref|WP_053687351.1|	23.7	556	591	620	1.59e-34	137
k141_66900_3	SARG|gi|799286378|ref|WP_045936958.1|	23.7	557	591	620	1.59e-34	137
k141_66900_3	SARG|gi|917127754|ref|WP_051734466.1|	23.7	557	591	620	1.59e-34	137
k141_66900_3	SARG|gi|926345639|ref|WP_053677539.1|	23.7	557	591	620	2.14e-34	137
k141_66900_3	SARG|gi|944009777|ref|WP_055601444.1|	24.3	511	591	628	2.26e-34	137
k141_66900_3	SARG|gi|926376632|ref|WP_053705806.1|	23.7	557	591	620	2.89e-34	136
k141_66900_3	SARG|gi|772774655|ref|WP_045322518.1|	23.9	552	591	620	2.89e-34	136
k141_66900_3	SARG|gi|1033217078|gb|OAR27197.1|	24.7	502	591	601	4.58e-34	135
k141_66900_3	SARG|gi|917203192|ref|WP_051809904.1|	23.6	567	591	620	5.24e-34	135
k141_66900_3	SARG|gb|WP_104671188.1|ARO:3003948|efrA	24.2	517	591	575	6.78e-34	135
k141_66900_3	SARG|gi|558888514|ref|WP_023543283.1|	24.1	511	591	615	6.82e-34	135
k141_66900_3	SARG|gi|926351744|ref|WP_053683383.1|	23.6	555	591	648	2.03e-33	134
k141_66900_3	SARG|gi|1045390184|ref|WP_065479071.1|	24.1	497	591	605	2.09e-33	134
k141_66900_3	SARG|AF170880.4.gene1.p01	23.9	511	591	615	3.01e-33	133
k141_124254_10	SARG|gi|445996719|ref|WP_000074574.1|	29.5	234	252	309	1.32e-27	106
k141_124254_10	SARG|gi|500465078|gb|EOP76697.1|	29.9	234	252	306	4.73e-27	105
k141_124254_10	SARG|gi|507055561|ref|WP_016126482.1|	29.5	234	252	309	4.98e-27	105
k141_124254_10	SARG|gi|895736250|emb|COF64653.1|	29.7	229	252	309	9.66e-27	104
k141_124254_10	SARG|gi|446110087|ref|WP_000187942.1|	29.7	229	252	309	9.66e-27	104
k141_124254_10	SARG|gi|445996714|ref|WP_000074569.1|	29.7	229	252	309	9.66e-27	104
k141_124254_10	SARG|gi|445996710|ref|WP_000074565.1|	29.3	229	252	309	1.34e-26	103
k141_124254_10	SARG|gi|488068784|ref|WP_002140181.1|	29.5	234	252	309	1.34e-26	103
k141_124254_10	SARG|gi|445996696|ref|WP_000074551.1|	30.0	233	252	309	1.34e-26	103
k141_124254_10	SARG|gi|507035724|ref|WP_016107411.1|	30.0	233	252	309	1.87e-26	103
k141_124254_10	SARG|gi|445996729|ref|WP_000074584.1|	29.1	234	252	309	1.87e-26	103
k141_124254_10	SARG|gi|445996698|ref|WP_000074553.1|	30.0	233	252	309	1.87e-26	103
k141_124254_10	SARG|gi|507023808|ref|WP_016095885.1|	29.1	234	252	309	1.87e-26	103
k141_124254_10	SARG|gi|447057510|ref|WP_001134766.1|	29.1	234	252	309	1.87e-26	103
k141_124254_10	SARG|gi|488067981|ref|WP_002139378.1|	29.1	234	252	309	2.60e-26	103
k141_124254_10	SARG|gi|488053456|ref|WP_002124853.1|	29.1	234	252	309	2.60e-26	103
k141_124254_10	SARG|gi|445996697|ref|WP_000074552.1|	30.0	233	252	309	2.60e-26	103
k141_124254_10	SARG|gi|488042066|ref|WP_002113463.1|	29.6	233	252	309	2.60e-26	103
k141_124254_10	SARG|gi|487936534|ref|WP_002010000.1|	29.1	234	252	309	2.60e-26	103
k141_124254_10	SARG|gi|895808656|emb|COR83787.1|	29.3	229	252	309	2.60e-26	103
k141_124254_10	SARG|gi|445996708|ref|WP_000074563.1|	29.2	233	252	309	3.62e-26	102
k141_124254_10	SARG|gi|447195835|ref|WP_001273091.1|	28.1	235	252	306	4.79e-26	102
k141_124254_10	SARG|gi|1043490477|ref|WP_065382463.1|	28.6	234	252	309	5.04e-26	102
k141_124254_10	SARG|gi|445996726|ref|WP_000074581.1|	28.6	234	252	309	5.04e-26	102
k141_124254_10	SARG|gi|488130770|ref|WP_002201978.1|	29.1	234	252	309	5.04e-26	102
k141_124254_11	SARG|gi|542061059|gb|ERI11611.1|	25.9	220	236	316	1.92e-22	92.4
k141_124254_11	SARG|gi|921979807|ref|WP_053271336.1|	26.0	231	236	648	1.01e-18	83.6
k141_124254_11	SARG|gb|AAK76137.1|ARO:3000024|patA	24.2	219	236	564	4.97e-17	78.6
k141_124254_11	SARG|gb|AYV52072.1|ARO:3002882|lmrD	22.7	211	236	664	6.66e-12	63.5
k141_124254_11	SARG|gb|AAK76136.1|ARO:3000025|patB	23.6	212	236	588	2.12e-11	62.0
k141_124254_11	SARG|gb|CDO61516.1|ARO:3003949|efrB	28.0	150	236	362	2.66e-09	55.5
k141_124254_11	SARG|AXF35727.1	25.7	183	236	497	1.54e-06	47.4
k141_26472_6	CARD|gb|BAD59497.1|ARO:3000501|rpoB2	46.0	650	632	1162	1.56e-169	513
k141_26472_6	CARD|gb|WP_041777404.1|ARO:3004480|Bado_rpoB_RIF	43.8	658	632	1186	1.00e-160	491
k141_26472_6	megares|MEG_8674|Drugs|Rifampin|Rifampin-resistant_beta-subunit_of_RNA_polymerase_RpoB|RPOB_1	43.8	658	632	1186	1.00e-160	491
k141_28699_29	megares|MEG_4091|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPB_1	23.3	824	803	1033	8.08e-32	132
k141_28699_29	SARG|gb|AEY83581|ARO:3000510|mupB	23.3	824	803	1033	8.08e-32	132
k141_28699_29	megares|MEG_4090|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.4	811	803	1024	1.84e-31	131
k141_28699_29	SARG|gb|CAA53189|ARO:3000521|mupA	23.4	811	803	1024	1.84e-31	131
k141_28699_29	NCBI|WP_000163435.1|1|1|mupA|mupA|insensitivity|2|mupirocin|mupirocin|mupirocin-resistant_isoleucine--tRNA_ligase_MupA|AMR|mupirocin	23.4	811	803	1024	3.22e-31	130
k141_28699_29	megares|MEG_4089|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|MUPA_1	23.4	811	803	1024	3.22e-31	130
k141_28699_29	megares|MEG_3295|Drugs|Mupirocin|Mupirocin-resistant_isoleucyl-tRNA_synthetase|ILES_1	21.7	849	803	1107	3.62e-15	79.0
k141_28699_29	SARG|gb|ADP36409.1|ARO:3003730|Bifidobacteria	21.7	849	803	1107	3.62e-15	79.0
k141_28699_46	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	45.7	232	232	239	1.97e-73	222
k141_28699_46	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	43.9	230	232	232	2.24e-73	221
k141_28699_46	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	43.9	230	232	232	2.24e-73	221
k141_28699_46	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	45.4	227	232	231	4.35e-73	221
k141_28699_46	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	45.4	227	232	231	4.35e-73	221
k141_28699_46	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	45.5	231	232	235	7.01e-73	220
k141_28699_46	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	45.7	230	232	233	9.32e-73	220
k141_28699_46	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	44.5	227	232	231	7.09e-72	218
k141_28699_46	NCBI|WP_063856718.1|1|1|vanR-E|vanR-E|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-E|AMR|glycopeptide	43.7	229	232	229	1.34e-71	217
k141_28699_46	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	43.6	227	232	231	3.28e-70	213
k141_28699_46	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	42.7	227	232	231	1.88e-69	211
k141_28699_46	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	42.7	225	232	231	7.01e-67	205
k141_28699_46	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	43.2	229	232	232	2.06e-66	204
k141_28699_46	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	44.3	230	232	231	2.82e-66	203
k141_28699_46	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.8	229	232	232	5.85e-66	202
k141_28699_46	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	42.1	228	232	231	2.28e-65	201
k141_28699_46	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.8	229	232	232	6.69e-65	200
k141_28699_46	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.8	229	232	232	9.48e-65	199
k141_28699_46	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	42.8	229	232	232	9.48e-65	199
k141_28699_46	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	41.5	224	232	232	1.34e-64	199
k141_28699_46	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.4	227	232	231	1.84e-64	199
k141_28699_46	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	41.9	229	232	232	2.69e-64	198
k141_28699_46	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.4	227	232	231	5.24e-64	197
k141_28699_46	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	41.4	227	232	231	7.42e-64	197
k141_28699_46	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	41.3	230	232	230	1.44e-63	196
k141_28699_47	NCBI|WP_063856748.1|1|1|vanS-M|vanS-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-M|AMR|glycopeptide	28.5	281	893	370	9.21e-31	124
k141_28699_47	megares|MEG_7505|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	242	893	381	2.75e-30	122
k141_28699_47	NCBI|WP_063856730.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	242	893	381	2.75e-30	122
k141_28699_47	NCBI|WP_006285582.1|1|1|vanS-F|vanS-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-F|AMR|glycopeptide	30.1	282	893	365	3.77e-30	122
k141_28699_47	NCBI|WP_063856732.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	33.0	224	893	367	3.91e-30	122
k141_28699_47	NCBI|WP_021418927.1|1|1|vanS-G|vanS-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-G|AMR|glycopeptide	33.0	224	893	368	3.98e-30	122
k141_28699_47	NCBI|WP_028530133.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	29.8	242	893	381	9.12e-30	121
k141_28699_47	megares|MEG_7506|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	29.8	242	893	381	9.12e-30	121
k141_28699_47	NCBI|WP_023042297.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	28.9	242	893	381	1.66e-29	120
k141_28699_47	megares|MEG_7509|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	28.9	242	893	381	1.66e-29	120
k141_28699_47	NCBI|WP_063856744.1|1|1|vanS-D|vanS-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-D|AMR|glycopeptide	31.0	226	893	381	3.57e-27	113
k141_28699_47	megares|MEG_7504|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	31.0	226	893	381	3.57e-27	113
k141_28699_47	NCBI|AXB64455.1|1|1|vanS-Cd|vanS-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|VanG-Cd-type_glycopeptide_resistance_histidine_kinase_VanS|AMR|glycopeptide	29.9	241	893	380	6.38e-27	112
k141_28699_47	megares|MEG_7498|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	29.9	241	893	380	6.38e-27	112
k141_28699_47	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	29.0	248	893	364	1.21e-26	111
k141_28699_47	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	29.0	248	893	364	1.21e-26	111
k141_28699_47	megares|MEG_7502|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.6	256	893	361	6.02e-24	103
k141_28699_47	NCBI|WP_063856733.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	31.6	256	893	361	6.02e-24	103
k141_28699_47	NCBI|WP_063856743.1|1|1|vanS-C|vanS-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-C|AMR|glycopeptide	31.6	256	893	361	8.11e-24	103
k141_28699_47	megares|MEG_7499|Drugs|Glycopeptide|VanC-type_regulator|VANSC_1	31.6	256	893	361	8.11e-24	103
k141_28699_47	CARD|gb|CYF42523.1|ARO:3004047|kdpD	24.6	289	893	885	2.15e-10	63.5
k141_28699_47	CARD|gb|ACM47284.1|ARO:3002934|vanS_in_vanD_cl	32.9	85	893	233	4.13e-09	57.0
k141_28699_47	megares|MEG_7508|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.9	85	893	233	4.13e-09	57.0
k141_28699_47	megares|MEG_7510|Drugs|Glycopeptide|VanD-type_regulator|VANSD_1	32.6	86	893	233	5.55e-09	56.6
k141_28699_65	SARG|gb|ADZ12699.1|ARO:3005091|RanA	30.7	254	357	258	8.37e-33	122
k141_28699_65	SARG|gi|500448961|gb|EOP61695.1|	30.8	211	357	306	6.23e-28	110
k141_28699_65	SARG|gi|500465078|gb|EOP76697.1|	30.8	211	357	306	8.62e-28	109
k141_28699_65	SARG|gi|507050365|ref|WP_016121371.1|	25.2	290	357	309	6.37e-27	107
k141_28699_65	SARG|gi|895865878|ref|WP_048974758.1|	33.9	221	357	646	9.41e-26	107
k141_28699_65	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.7	212	357	664	3.63e-19	87.8
k141_28699_65	SARG|gb|CDO61516.1|ARO:3003949|efrB	29.5	200	357	362	3.11e-17	80.9
k141_28699_65	SARG|gb|AAK76136.1|ARO:3000025|patB	25.9	212	357	588	6.78e-16	77.8
k141_28699_65	SARG|M80346.gene.p01	25.0	252	357	551	6.64e-15	74.7
k141_28699_65	megares|MEG_1491|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|CARA_1	24.9	249	357	551	1.59e-14	73.6
k141_28699_65	NCBI|WP_289811733.1|1|1|tetB(60)|tetB(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_B|AMR|tetracycline	26.1	222	357	579	1.25e-12	67.8
k141_28699_65	SARG|gb|ANZ79241.1|ARO:3004036|tetB(60)	26.1	222	357	579	1.67e-12	67.4
k141_28699_71	NCBI|WP_002389535.1|1|1|bcrA_Lm|bcrA_Lm||2|peptide|peptide|peptide_resistance_ABC_transporter_ATP-binding_subunit_BcrA|AMR|peptide	29.5	288	514	307	1.42e-28	114
k141_28699_71	SARG|gi|446048013|ref|WP_000125868.1|	27.6	228	514	648	2.32e-22	99.8
k141_28699_71	SARG|gi|974588181|ref|WP_059178476.1|	26.8	228	514	646	1.26e-20	94.4
k141_28699_71	SARG|YP_001176128	26.8	228	514	646	1.26e-20	94.4
k141_28699_71	SARG|gi|654544841|ref|WP_028012549.1|	27.2	228	514	646	2.96e-20	93.2
k141_28699_71	SARG|gi|949731360|ref|WP_057072003.1|	26.8	228	514	646	3.94e-20	92.8
k141_28699_71	SARG|gi|895898290|ref|WP_048999361.1|	26.8	228	514	646	3.94e-20	92.8
k141_28699_71	SARG|gi|896106549|ref|WP_049136608.1|	26.8	228	514	646	3.94e-20	92.8
k141_28699_71	SARG|gi|1032819400|ref|WP_064325534.1|	26.8	228	514	646	3.94e-20	92.8
k141_28699_71	SARG|gi|754493745|ref|WP_041910640.1|	26.8	228	514	646	6.95e-20	92.0
k141_28699_71	SARG|gi|498115003|ref|WP_010429159.1|	26.8	228	514	646	6.95e-20	92.0
k141_28699_71	SARG|gi|895905590|ref|WP_049005458.1|	26.8	228	514	646	6.95e-20	92.0
k141_28699_71	SARG|gi|896083144|ref|WP_049122651.1|	26.8	228	514	646	6.95e-20	92.0
k141_28699_71	SARG|gi|695748190|ref|WP_032674455.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|544824889|ref|WP_021240890.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|765031087|ref|WP_044596899.1|	26.3	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|556495988|ref|WP_023343675.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|836589868|ref|WP_047747112.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|782756348|ref|WP_045630015.1|	26.3	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|779861244|ref|WP_045352062.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|556301718|ref|WP_023292894.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|495775415|ref|WP_008499994.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	SARG|gi|1022680162|ref|WP_063435808.1|	26.8	228	514	646	9.23e-20	91.7
k141_28699_71	NCBI|QHA94808.1|1|1|narA|narA||1|MADURAMICIN/NARASIN/SALINOMYCIN|IONOPHORE|ionophore_ABC_transporter_ATP-binding_subunit_NarA|AMR|ionophore	27.0	230	514	293	1.01e-19	88.6
k141_28699_71	SARG|gi|851931792|ref|WP_048222288.1|	26.3	228	514	646	1.23e-19	91.3
k141_28699_75	SARG|gb|AEA37904.1|ARO:3003112|lsaC	26.2	191	257	492	1.30e-09	57.0
k141_28699_78	NCBI|WP_063856705.1|1|1|vanH-D|vanH-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-D|AMR|glycopeptide	38.2	170	203	323	2.30e-27	104
k141_28699_78	megares|MEG_7399|Drugs|Glycopeptide|VanA-type_resistance_protein|VANHA_1	33.5	185	203	237	3.42e-27	102
k141_28699_78	NCBI|WP_063856700.1|1|1|vanH-Ao2|vanH-Ao2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao2|AMR|glycopeptide	34.8	184	203	343	6.05e-27	103
k141_28699_78	SARG|YP_002333394	35.8	176	203	323	8.69e-27	103
k141_28699_78	NCBI|WP_063856698.1|1|1|vanH-Ac1|vanH-Ac1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ac1|AMR|glycopeptide	33.5	185	203	351	2.53e-26	102
k141_28699_78	SARG|AF310956.2.gene5.p01	35.2	176	203	323	3.28e-26	101
k141_28699_78	NCBI|WP_063856701.1|1|1|vanH-B|vanH-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-B|AMR|glycopeptide	35.2	176	203	323	3.28e-26	101
k141_28699_78	NCBI|WP_063856699.1|1|1|vanH-Ao1|vanH-Ao1|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|D-lactate_dehydrogenase_VanH-Ao1|AMR|glycopeptide	35.2	176	203	348	1.26e-25	100
k141_28699_78	SARG|KF478993.1.gene2.p01	32.1	212	203	350	2.50e-25	99.8
k141_28699_78	SARG|gi|740152780|ref|WP_037997109.1|	34.5	171	203	322	8.86e-25	97.8
k141_28699_78	SARG|AAF72362	34.8	178	203	323	3.36e-24	96.3
k141_28699_80	SARG|gi|1035706844|ref|WP_064548272.1|	33.6	110	954	648	2.12e-08	57.0
k141_28699_99	CARD|gb|BAB80490.1|ARO:3007644|Cper_cplR	33.3	78	247	568	9.89e-08	51.2
k141_28699_99	SARG|AAG08983	37.1	97	247	524	1.29e-07	50.8
k141_28699_99	NCBI|WP_063856937.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	37.2	86	247	522	4.15e-07	49.3
k141_28699_99	SARG|gb|AEO25219.1|ARO:3004651|lin	34.4	90	247	523	4.15e-07	49.3
k141_28699_99	NCBI|WP_032492560.1|1|1|vga(A)|vga(A)|target_protection|2|LINCOSAMIDE|LINCOSAMIDE|ABC-F_type_ribosomal_protection_protein_Vga(A)|AMR|lincosamide	37.2	86	247	522	7.45e-07	48.5
k141_28699_99	SARG|DQ823382.1.gene1.p01	37.2	86	247	522	7.45e-07	48.5
k141_28699_99	megares|MEG_7687|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	37.2	86	247	522	7.45e-07	48.5
k141_28699_99	megares|MEG_7686|Drugs|Multi-drug_resistance|Multi-drug_ABC_efflux_pumps|VGA_1	37.2	86	247	522	7.45e-07	48.5
k141_28699_99	SARG|AAF24091	37.2	86	247	522	7.45e-07	48.5
k141_28699_99	SARG|YP_002332257	37.2	86	247	522	7.45e-07	48.5
k141_28699_99	SARG|KC539823.1.gene1.p01	37.2	86	247	522	1.33e-06	47.8
k141_28699_99	NCBI|AJP12342.1|1|1|cplR|cplR|target_protection|1|CLINDAMYCIN/LINCOMYCIN/RETAPAMULIN/VIRGINIAMYCIN|LINCOSAMIDE/PLEUROMUTILIN/STREPTOGRAMIN|ABC-F_type_ribosomal_protection_protein_CplR|AMR|multidrug	28.6	91	247	550	5.82e-06	45.8
k141_28699_103	NCBI|XSG12260.1|1|1|drcA|drcA||1|||daptomycin_efflux_ABC_transporter_ATP-binding_protein_DrcA|AMR|peptide	34.8	224	240	255	2.91e-39	135
k141_28699_103	SARG|gi|740610794|ref|WP_038396317.1|	34.4	221	240	648	8.89e-37	135
k141_28699_103	SARG|YP_001571041	33.9	221	240	648	3.14e-36	134
k141_28699_103	SARG|gi|960873409|ref|WP_058345546.1|	33.9	221	240	648	3.14e-36	134
k141_28699_103	SARG|gi|446048013|ref|WP_000125868.1|	33.9	221	240	648	5.91e-36	133
k141_28699_103	SARG|gb|AYV52072.1|ARO:3002882|lmrD	29.4	221	240	664	6.41e-21	90.1
k141_28699_103	SARG|gb|ANZ79240.1|ARO:3004035|tetA(60)	28.8	215	240	579	1.84e-16	77.0
k141_28699_103	SARG|gb|AAC75271.1|ARO:3003952|yojI	29.9	197	240	547	8.14e-16	75.1
k141_28699_103	NCBI|WP_289811734.1|1|1|tetA(60)|tetA(60)||2|TETRACYCLINE|TETRACYCLINE|tetracycline_efflux_ABC_transporter_Tet(60)_subunit_A|AMR|tetracycline	29.2	209	240	579	2.79e-15	73.6
k141_28699_103	megares|MEG_4383|Drugs|Tetracycline|Tetracycline_resistance_ABC_efflux_pumps|OTRC_1	24.1	220	240	351	2.80e-14	70.1
k141_28699_103	SARG|gb|AAR96051.1|ARO:3002894|otrC	24.1	220	240	351	3.81e-14	69.7
k141_126245_11	CARD|gb|AAC16242.1|ARO:3005069|rsmA	49.1	53	72	61	4.98e-15	61.6
k141_126245_23	SARG|gi|542061059|gb|ERI11611.1|	27.3	227	507	316	2.67e-14	72.8
k141_126245_23	SARG|gb|WP_104671188.1|ARO:3003948|efrA	25.6	219	507	575	8.98e-11	63.2
k141_126245_23	SARG|gi|497748188|ref|WP_010062372.1|	24.7	243	507	605	1.40e-08	56.2
k141_126245_23	SARG|gi|1045390184|ref|WP_065479071.1|	24.7	243	507	605	3.21e-08	55.1
k141_126245_23	SARG|gi|764446018|ref|WP_044369325.1|	24.3	243	507	605	1.29e-07	53.1
k141_126245_23	SARG|gi|695865802|ref|WP_032778631.1|	24.3	243	507	605	1.29e-07	53.1
k141_126245_23	SARG|gi|695887424|ref|WP_032788534.1|	24.3	243	507	605	1.70e-07	52.8
k141_126245_23	SARG|gi|664180077|ref|WP_030714054.1|	24.3	243	507	605	1.70e-07	52.8
k141_126245_23	SARG|gi|926286457|ref|WP_053623344.1|	24.0	250	507	605	2.24e-07	52.4
k141_126245_23	SARG|gi|517347347|ref|WP_018522839.1|	25.2	246	507	601	2.95e-07	52.0
k141_126245_23	SARG|gi|951183771|ref|WP_057661487.1|	25.0	244	507	603	5.15e-07	51.2
k141_126245_23	SARG|gi|662175949|ref|WP_030118884.1|	24.0	250	507	605	5.15e-07	51.2
k141_126245_23	SARG|gi|663155409|ref|WP_030194633.1|	24.0	250	507	605	5.15e-07	51.2
k141_126245_23	SARG|gi|664538723|ref|WP_031054357.1|	24.0	250	507	605	5.15e-07	51.2
k141_126245_23	SARG|gi|664042835|ref|WP_030582300.1|	25.0	244	507	604	6.79e-07	50.8
k141_126245_23	SARG|gi|664317010|ref|WP_030845774.1|	24.0	250	507	605	8.97e-07	50.4
k141_126245_23	SARG|gi|663286402|ref|WP_030292859.1|	24.0	250	507	605	8.97e-07	50.4
k141_126245_23	SARG|gi|663342223|ref|WP_030341347.1|	24.0	250	507	605	8.97e-07	50.4
k141_126245_23	SARG|gi|759527374|ref|WP_043247487.1|	24.0	250	507	605	8.97e-07	50.4
k141_126245_23	SARG|gi|662129758|ref|WP_030081404.1|	24.6	244	507	605	8.97e-07	50.4
k141_126245_23	SARG|gi|664194237|ref|WP_030727956.1|	24.0	250	507	605	8.97e-07	50.4
k141_126245_23	SARG|gi|664244930|ref|WP_030776974.1|	24.0	242	507	601	1.18e-06	50.1
k141_126245_23	SARG|gi|664458452|ref|WP_030980047.1|	24.8	246	507	601	1.18e-06	50.1
k141_126245_23	SARG|gi|664395661|ref|WP_030922045.1|	24.8	246	507	601	1.18e-06	50.1
k141_126245_23	SARG|gi|664170108|ref|WP_030704355.1|	24.9	245	507	603	1.18e-06	50.1
k141_126245_26	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	25.9	112	534	228	1.30e-07	51.6
k141_126245_26	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.7	101	534	204	1.44e-06	48.1
k141_126245_45	SARG|gi|511041762|ref|WP_016295754.1|	32.7	370	393	343	1.33e-58	193
k141_126245_45	SARG|AF277571.gene.p01	32.7	370	393	343	2.85e-57	189
k141_126245_45	SARG|gi|1002798395|gb|AMN85478.1|	32.9	368	393	343	2.85e-57	189
k141_126245_45	SARG|gi|696673086|ref|WP_033144146.1|	33.0	370	393	343	4.01e-57	189
k141_126245_45	SARG|ACM47287	33.2	371	393	343	3.09e-56	187
k141_126245_45	SARG|BAE96117	32.4	370	393	343	6.09e-56	186
k141_126245_45	SARG|AAD42184	32.4	370	393	343	8.56e-56	186
k141_126245_45	SARG|gi|552941803|ref|WP_023042860.1|	32.4	370	393	343	8.56e-56	186
k141_126245_45	SARG|AAR37060	31.9	370	393	343	1.82e-54	182
k141_126245_45	SARG|ABS72058	31.9	370	393	343	1.39e-53	180
k141_126245_45	SARG|gi|1028100561|ref|WP_063856696.1|	32.2	367	393	349	2.28e-53	179
k141_126245_45	SARG|gi|748291566|ref|WP_039833224.1|	33.1	372	393	343	2.75e-53	179
k141_126245_45	SARG|AAN60573	31.9	367	393	342	1.04e-52	177
k141_126245_45	SARG|AAV74570	31.9	367	393	343	1.06e-52	177
k141_126245_45	SARG|DQ212986.1.gene8.p01	33.1	363	393	349	1.24e-52	177
k141_126245_45	SARG|ACQ66105	31.9	367	393	342	1.46e-52	177
k141_126245_45	SARG|gi|1028848468|ref|WP_064017431.1|	32.0	366	393	343	1.49e-52	177
k141_126245_45	SARG|gi|670466158|ref|WP_031414935.1|	31.7	366	393	343	1.49e-52	177
k141_126245_45	SARG|CAB61227	31.8	374	393	343	1.49e-52	177
k141_126245_45	SARG|AAD51060	31.6	370	393	343	1.49e-52	177
k141_126245_45	SARG|gi|405945042|pdb|4FU0|A	33.1	363	393	357	1.52e-52	177
k141_126245_45	SARG|Q06893	31.9	367	393	342	2.04e-52	177
k141_126245_45	SARG|AAY52005	31.3	371	393	343	2.10e-52	177
k141_126245_45	SARG|gb|KTE89608.1|ARO:3003723|vanI	32.2	366	393	348	2.38e-52	177
k141_126245_45	SARG|gi|765411304|ref|WP_044689514.1|	33.1	363	393	349	2.44e-52	177
k141_93896_7	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	41.0	222	227	220	1.73e-58	183
k141_93896_7	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	222	227	220	6.95e-58	181
k141_93896_7	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	222	227	219	9.54e-58	181
k141_93896_7	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.5	222	227	220	9.84e-58	181
k141_93896_7	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	40.1	222	227	219	7.69e-57	179
k141_93896_7	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	40.2	229	227	232	2.94e-54	172
k141_93896_7	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	38.5	231	227	231	6.48e-53	169
k141_93896_7	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	37.6	229	227	232	7.56e-52	166
k141_93896_7	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	37.6	229	227	232	7.56e-52	166
k141_93896_7	NCBI|WP_063856728.1|1|1|vanR-N|vanR-N|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-N|AMR|glycopeptide	37.3	228	227	230	1.43e-51	166
k141_93896_7	NCBI|WP_063856724.1|1|1|vanR-L|vanR-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-L|AMR|glycopeptide	37.6	229	227	231	1.33e-49	160
k141_93896_7	CARD|gb|AAD51348.1|ARO:3003066|smeR	38.7	222	227	229	3.54e-49	159
k141_93896_7	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	38.0	229	227	231	5.30e-49	159
k141_93896_7	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.4	231	227	232	1.54e-48	158
k141_93896_7	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	36.4	231	227	232	2.18e-48	157
k141_93896_7	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.7	229	227	231	2.99e-48	157
k141_93896_7	CARD|gb|ATC67679.1|ARO:3000838|arlR	36.7	218	227	219	2.99e-48	157
k141_93896_7	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.5	231	227	232	3.08e-48	157
k141_93896_7	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.7	229	227	231	5.98e-48	156
k141_93896_7	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.7	231	227	232	6.15e-48	156
k141_93896_7	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	36.5	233	227	235	6.70e-48	156
k141_93896_7	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	37.1	229	227	231	8.45e-48	156
k141_93896_7	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	36.7	229	227	231	8.45e-48	156
k141_93896_7	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	37.1	229	227	231	8.45e-48	156
k141_93896_7	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	35.9	231	227	232	8.69e-48	156
k141_93896_8	megares|MEG_7514|Drugs|Glycopeptide|VanL-type_regulator|VANSL_1	24.5	319	498	364	2.98e-25	105
k141_93896_8	NCBI|WP_063856745.1|1|1|vanS-L|vanS-L|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-L|AMR|glycopeptide	24.5	319	498	364	2.98e-25	105
k141_93896_8	CARD|gb|ABD30512.1|ARO:3000839|arlS	23.0	378	498	451	1.45e-24	105
k141_93896_8	NCBI|WP_002368696.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	27.0	300	498	447	2.54e-24	104
k141_93896_8	NCBI|WP_002382867.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	26.6	301	498	447	3.70e-23	100
k141_93896_8	NCBI|WP_012579101.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	26.6	301	498	447	3.70e-23	100
k141_93896_8	NCBI|WP_063856739.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	26.6	301	498	447	3.70e-23	100
k141_93896_8	NCBI|WP_063856751.1|1|1|vanS-B|vanS-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-B|AMR|glycopeptide	25.2	301	498	454	1.00e-21	96.7
k141_93896_8	NCBI|WP_002305818.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.3	282	498	384	1.08e-20	92.8
k141_93896_8	megares|MEG_7454|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	27.3	282	498	384	1.08e-20	92.8
k141_93896_8	NCBI|WP_063856742.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	25.5	290	498	388	1.51e-20	92.4
k141_93896_8	megares|MEG_7489|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.5	290	498	388	1.51e-20	92.4
k141_93896_8	NCBI|WP_063856741.1|1|1|vanS-Pt|vanS-Pt|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt|AMR|glycopeptide	25.5	290	498	386	2.67e-20	91.7
k141_93896_8	megares|MEG_7488|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	25.5	290	498	386	2.67e-20	91.7
k141_93896_8	megares|MEG_7486|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.3	282	498	382	3.46e-20	91.3
k141_93896_8	NCBI|WP_063856731.1|1|1|vanS-A|vanS-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-A|AMR|glycopeptide	27.3	282	498	382	3.46e-20	91.3
k141_93896_8	megares|MEG_7487|Drugs|Glycopeptide|VanA-type_regulator|VANSA_1	27.0	282	498	386	6.50e-20	90.5
k141_93896_8	NCBI|WP_063856740.1|1|1|vanS-Pt2|vanS-Pt2|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-Pt2|AMR|glycopeptide	27.0	282	498	386	6.50e-20	90.5
k141_93896_8	NCBI|WP_222891058.1|1|1|vanS-P|vanS-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_histidine_kinase_VanS-P|AMR|glycopeptide	24.6	199	498	359	9.66e-19	86.7
k141_93896_8	CARD|gb|ADM92606.1|ARO:3000549|adeS	24.2	207	498	361	1.20e-13	71.2
k141_58833_19	SARG|gb|CAE00499.1|ARO:3003835|cdeA	37.6	434	443	441	4.90e-98	300
k141_29070_28	CARD|gb|BAB36671.1|ARO:3000832|evgA	28.7	209	214	204	7.11e-25	95.9
k141_29070_28	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	23.7	169	214	228	1.44e-07	49.3
k141_29070_28	CARD|gb|ATC67679.1|ARO:3000838|arlR	25.0	128	214	219	4.61e-07	47.8
k141_29070_42	megares|MEG_5396|Drugs|Aminocoumarins|Aminocoumarin-resistant_DNA_topoisomerases|PARY_1	40.2	753	747	703	5.39e-162	484
k141_29070_44	SARG|gi|1001786599|ref|WP_061324791.1|	25.5	388	392	563	2.13e-18	85.9
k141_29070_44	SARG|YP_001605795	25.8	392	392	562	3.82e-18	85.1
k141_29070_44	SARG|gi|896190680|ref|WP_049199932.1|	24.5	396	392	563	9.15e-18	84.0
k141_29070_44	SARG|AAS61092	25.7	389	392	563	9.15e-18	84.0
k141_29070_44	SARG|gi|740410309|ref|WP_038243756.1|	24.4	389	392	563	3.91e-17	82.0
k141_29070_44	SARG|YP_001477377	24.1	402	392	563	5.22e-17	81.6
k141_29070_44	SARG|ZP_04612557	25.6	386	392	543	6.75e-17	81.3
k141_29070_44	SARG|YP_001401994	25.4	389	392	563	6.98e-17	81.3
k141_29070_44	SARG|ZP_04631861	25.7	382	392	543	9.02e-17	80.9
k141_29070_44	SARG|ZP_04615639	24.6	382	392	543	1.20e-16	80.5
k141_29070_44	SARG|ZP_04635128	25.6	379	392	543	1.20e-16	80.5
k141_29070_44	SARG|YP_001007250	25.2	389	392	563	1.25e-16	80.5
k141_29070_44	SARG|ZP_04638974	25.3	388	392	563	1.66e-16	80.1
k141_29070_44	SARG|ZP_04630103	25.7	381	392	543	2.87e-16	79.3
k141_29070_44	SARG|ZP_04623897	25.4	382	392	543	2.87e-16	79.3
k141_29070_44	SARG|gi|318604694|emb|CBY26192.1|	25.3	379	392	540	1.62e-15	77.0
k141_29070_44	SARG|gi|544012122|gb|ERK10884.1|	25.1	390	392	541	2.89e-15	76.3
k141_29070_44	SARG|AAC60780	25.1	287	392	563	1.67e-13	70.9
k141_29070_46	CARD|gb|AAD51347.1|ARO:3003067|smeS	29.3	270	475	467	6.33e-34	132
k141_29070_46	CARD|gb|CYF42523.1|ARO:3004047|kdpD	25.9	228	475	885	1.42e-16	81.6
k141_29070_47	megares|MEG_4078|Drugs|Multi-drug_resistance|Multi-drug_RND_efflux_regulator|MTRAD_1	46.7	227	233	228	1.52e-65	201
k141_29070_47	NCBI|WP_006285581.1|1|1|vanR-F|vanR-F|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-F|AMR|glycopeptide	43.6	225	233	231	8.78e-63	194
k141_29070_47	NCBI|WP_063856726.1|1|1|vanR-M|vanR-M|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-M|AMR|glycopeptide	42.7	225	233	232	9.06e-63	194
k141_29070_47	CARD|gb|ATC67679.1|ARO:3000838|arlR	41.3	223	233	219	1.34e-56	178
k141_29070_47	NCBI|WP_011461303.1|1|1|vanR-I|vanR-I|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-I|AMR|glycopeptide	38.3	227	233	232	1.40e-56	179
k141_29070_47	megares|MEG_7482|Drugs|Glycopeptide|VanL-type_regulator|VANRI_1	38.3	227	233	232	1.40e-56	179
k141_29070_47	NCBI|WP_063856727.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.8	230	233	232	1.59e-55	176
k141_29070_47	NCBI|WP_016295750.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.8	230	233	232	2.25e-55	176
k141_29070_47	NCBI|WP_021418928.1|1|1|vanR-G|vanR-G|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G|AMR|glycopeptide	40.9	232	233	235	2.46e-55	176
k141_29070_47	megares|MEG_7449|Drugs|Glycopeptide|VanA-type_regulator|VANRA_1	38.9	229	233	231	4.37e-55	175
k141_29070_47	NCBI|WP_063856716.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	38.9	229	233	231	4.37e-55	175
k141_29070_47	NCBI|WP_063856722.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	38.7	230	233	232	4.50e-55	175
k141_29070_47	NCBI|WP_023042613.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.4	230	233	232	9.01e-55	174
k141_29070_47	NCBI|WP_003126775.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	39.0	228	233	231	1.24e-54	174
k141_29070_47	NCBI|WP_063856721.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.9	228	233	231	3.50e-54	172
k141_29070_47	NCBI|AXB64454.1|1|1|vanR-Cd|vanR-Cd|re-structuring_of_the_cell_wall|1|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-G-Cd|AMR|glycopeptide	40.9	230	233	233	3.72e-54	172
k141_29070_47	NCBI|WP_023043165.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.8	230	233	232	4.09e-53	170
k141_29070_47	NCBI|WP_063856715.1|1|1|vanR-D|vanR-D|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-D|AMR|glycopeptide	37.4	230	233	232	5.78e-53	169
k141_29070_47	NCBI|WP_222891057.1|1|1|vanR-P|vanR-P|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-P|AMR|glycopeptide	38.0	234	233	239	2.01e-52	168
k141_29070_47	NCBI|WP_063856720.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	228	233	231	2.25e-52	168
k141_29070_47	NCBI|WP_001280781.1|1|1|vanR-A|vanR-A|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-A|AMR|glycopeptide	39.0	228	233	231	8.99e-52	166
k141_29070_47	NCBI|WP_005228837.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	233	231	8.99e-52	166
k141_29070_47	NCBI|WP_063856725.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	233	231	3.59e-51	165
k141_29070_47	NCBI|WP_034872470.1|1|1|vanR-C|vanR-C|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-C|AMR|glycopeptide	37.3	228	233	231	5.08e-51	164
k141_29070_47	CARD|gb|AAG05188.1|ARO:3005068|ParR	38.5	226	233	235	3.22e-50	162
k141_29070_53	CARD|gb|AAC73788.1|ARO:3003841|kdpE	33.3	129	147	225	3.51e-23	89.7
k141_29070_53	megares|MEG_3448|Drugs|Aminoglycosides|Aminoglycoside_efflux_pumps|KDPE_1	33.3	126	147	225	1.37e-22	88.2
k141_29070_53	NCBI|WP_063856723.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	115	147	219	9.98e-21	83.2
k141_29070_53	NCBI|WP_002317273.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	115	147	219	9.98e-21	83.2
k141_29070_53	NCBI|WP_063856719.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	115	147	220	1.02e-20	83.2
k141_29070_53	NCBI|WP_032489743.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	115	147	220	1.43e-20	82.8
k141_29070_53	NCBI|WP_002368697.1|1|1|vanR-B|vanR-B|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-B|AMR|glycopeptide	35.7	115	147	220	5.52e-20	81.3
k141_29070_53	SARG|ZP_02848503	36.5	115	147	221	4.25e-19	79.0
k141_29070_53	CARD|gb|AAG06465.1|ARO:3005063|cprR	35.2	122	147	223	4.83e-17	73.6
k141_29070_53	NCBI|WP_063856729.1|1|1|vanR-O|vanR-O|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-O|AMR|glycopeptide	31.8	129	147	233	3.04e-13	63.5
k141_29070_53	NCBI|WP_011029105.1|1|1|vanR-Sc|vanR-Sc|re-structuring_of_the_cell_wall|2|VANCOMYCIN|GLYCOPEPTIDE|glycopeptide_resistance_response_regulator_transcription_factor_VanR-Sc|AMR|glycopeptide	31.8	129	147	231	4.12e-13	63.2
k141_62145_9	SARG|gi|487407385|ref|WP_001675419.1|	28.9	253	267	648	1.61e-20	89.7
k141_62145_9	SARG|gi|746482713|ref|WP_039520502.1|	28.9	253	267	648	1.61e-20	89.7
k141_62145_9	SARG|gi|487661511|ref|WP_001751648.1|	28.9	253	267	648	1.61e-20	89.7
k141_62145_9	SARG|YP_002214869	28.9	253	267	648	1.61e-20	89.7
k141_62145_9	SARG|YP_002044935	28.9	253	267	648	2.18e-20	89.4
k141_62145_9	SARG|gi|835666879|ref|WP_047606339.1|	28.9	253	267	648	2.18e-20	89.4
k141_62145_9	SARG|gi|555254264|ref|WP_023237471.1|	28.9	253	267	648	2.18e-20	89.4
k141_62145_9	SARG|gi|959101689|ref|WP_058107049.1|	28.9	253	267	648	2.18e-20	89.4
k141_62145_9	SARG|gi|923061916|ref|WP_053445667.1|	28.9	253	267	648	2.18e-20	89.4
k141_62145_9	SARG|gi|446048017|ref|WP_000125872.1|	28.9	253	267	648	7.29e-20	87.8
k141_62145_9	SARG|gi|1004393797|ref|WP_061537938.1|	28.9	253	267	648	7.29e-20	87.8
k141_62145_9	SARG|gi|446048019|ref|WP_000125874.1|	28.9	253	267	648	7.29e-20	87.8
k141_62145_9	SARG|gi|960315461|ref|WP_058222782.1|	28.9	253	267	648	7.29e-20	87.8
k141_62145_9	SARG|ZP_02685546	28.9	253	267	648	7.29e-20	87.8
k141_62145_9	SARG|YP_002225954	28.9	253	267	648	7.29e-20	87.8
k141_62145_9	SARG|YP_002242988	28.9	253	267	648	7.29e-20	87.8
k141_62145_9	SARG|gi|502669352|ref|WP_012905216.1|	28.3	237	267	648	3.30e-19	85.9
k141_62145_9	SARG|gi|1004367277|ref|WP_061537620.1|	28.5	253	267	648	3.30e-19	85.9
k141_62145_9	SARG|gi|803568669|ref|WP_046077412.1|	29.4	238	267	648	1.10e-18	84.3
k141_62145_9	SARG|gi|446110352|ref|WP_000188207.1|	29.4	238	267	648	1.10e-18	84.3
k141_62145_9	SARG|YP_002382193	29.4	238	267	648	1.10e-18	84.3
k141_62145_9	SARG|gi|803575554|ref|WP_046081557.1|	29.4	238	267	648	1.10e-18	84.3
k141_62145_9	SARG|gi|446110351|ref|WP_000188206.1|	29.4	238	267	648	1.10e-18	84.3
k141_62145_9	SARG|gi|1035670474|ref|WP_064517458.1|	28.3	237	267	648	4.07e-17	79.7
k141_62145_9	SARG|gi|1035717981|ref|WP_064557480.1|	28.3	237	267	648	4.07e-17	79.7
